Characterisation of bone marrow progenitor cells in disease by Gowers, Kate Hayley Christine
 ~ 1 ~ 
 
 
 
 
 
 
 
Characterisation of bone marrow 
progenitor cells in disease 
 
A thesis submitted for the degree of      
Doctor of Philosophy  
 
Imperial College London 
Leukocyte Biology 
 
 
Kate Hayley Christine Gowers 
2012 
 ~ 2 ~ 
 
Acknowledgements 
I would like to thank my supervisor Prof. Sara Rankin for giving me the opportunity to 
do my PhD in her lab, and for the helpful discussions, support and enthusiasm she has 
provided throughout. I would also like to thank Dr. Carla Jones for sharing her 
knowledge and experience with me, as well as for her patience and encouragement 
throughout my time in the lab. Thanks also to Dr. P. Turowski for his help and advice. 
  
I owe a huge thank you to my family, particularly my mum, dad and sister Sally; they 
have provided unfailing support and encouragement when I needed it most, as well as 
always taking an interest in my research, and for that I’m extremely grateful. I would 
also like to thank all of my friends for their interest and support throughout, 
particularly my housemates Katherine and Andy.  
 
Finally I would like to thank past and present members of the Rankin lab for their 
advice and support, as well as making my time in the lab so enjoyable. Special thanks go 
to Tariq for his support, encouragement and for never failing to make me laugh even on 
the worst of days, to Moira for her patience and generosity in sharing her knowledge 
and time, to Andia for her endless positivity, and to Jill for sharing her experience and 
skills.  
 
This work would not have been possible without funding from the MRC. 
 ~ 3 ~ 
 
Declaration of originality 
To the best of my knowledge no work presented in this thesis has been previously 
published or submitted for a degree at Imperial College London, or any other university. 
Information obtained from another person or from published work has been 
acknowledged in the text and the source included in the list of references. 
 
 
 
 
 
 
 
 
 
 
 
 
 ~ 4 ~ 
 
Abstract 
The bone marrow serves as a reservoir for leukocytes and stem cells, from where cells 
can be mobilised into the circulation and can be recruited to sites of inflammation. 
Mobilisation of cells out of the bone marrow is dependent on their migration across the 
bone marrow sinusoidal endothelium, which is thought to be structurally and 
functionally different to endothelial cells from other vascular beds. In order to 
characterise the bone marrow endothelium and to study the molecular mechanisms 
involved in the mobilisation of cells, a protocol to isolate bone marrow endothelial cells 
and to grow them in vitro was developed. The bone marrow contains a number of 
distinct progenitor cell populations, including endothelial progenitor cells (EPCs) and 
mesenchymal stem cells (MSCs). Whether these populations of stem cells are recruited 
from the bone marrow to the lungs was investigated in two contrasting models of lung 
disease: the house dust mite (HDM) model of allergic airways disease and the bleomycin 
model of pulmonary fibrosis. In the HDM model increased recruitment of EPCs to the 
inflamed lungs was associated with increased peribronchial angiogenesis, and reduced 
EPC numbers in the bone marrow. Blocking VEGF inhibited EPC recruitment to the 
inflamed lungs and reduced the associated peribronchial angiogenesis. In this model, no 
recruitment of MSCs to the inflamed lungs was observed. However, in the bleomycin 
model, a significant elevation in MSC numbers was observed in the circulation, lung 
tissue and BAL fluid. Experiments to block the recruitment of MSCs to the lungs in 
response to bleomycin injury were performed, along with investigations into the 
recruitment of exogenously administered MSCs to the injured lungs. A population of 
MSCs residing in the naïve lungs was identified, which are phenotypically similar to 
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bone marrow MSCs, but can be distinguished by their size and expression of specific cell 
surface antigens. 
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1.1 The bone marrow 
The bone marrow is the primary site of haematopoiesis during adult life, providing the 
microenvironment for the maintenance, proliferation and differentiation of 
haematopoietic stem cells into all cells of the erythroid and myeloid lineages, although 
T-lymphocytes continue to mature in the thymus. In addition, the bone marrow also 
serves as a reservoir for mature granulocytes and stem cells, which can be rapidly 
mobilised into the blood in response to inflammatory mediators. 
 
1.1.1 The structure of the bone marrow 
The bone marrow consists of two major compartments: the vascular compartment, 
comprising the venous and arterial vessels, and the haematopoietic compartment, 
comprising the extravascular haematopoietic cords [1, 2]. The major blood supply to the 
bone marrow comes from the nutrient artery, which branches into smaller central 
arteries and then further into radial arteries which run towards the periphery of the 
marrow [3]. Once at the periphery, these radial branches form capillaries which join to 
form venous vessels, or sinuses, which form a complex anastomosing network of 
sinusoids. These sinusoids connect with the central sinus from where blood leaves the 
bone marrow to join with the systemic circulation. The haematopoietic cords lie 
between the vascular sinuses and are made up of structural elements as well as 
haematopoietic cells of various lineages and stages of maturation. The structural 
elements, or stroma, consist of fibroblasts, macrophages, adipocytes and their 
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extracellular matrix components, which provide the growth and differentiation factors 
needed for haematopoiesis [4].  
 
1.1.2 The blood-bone marrow barrier 
The vascular sinuses are the main sites of bidirectional exchange of blood-borne factors 
and cells between the blood and the haematopoietic compartment of the bone marrow. 
The sinus wall has a trilaminar structure, comprising a continuous layer of endothelial 
cells, which lie on a discontinuous layer of adventitial reticular cells and basement 
membrane [5-7]. The basement membrane is absent along large stretches of the 
endothelium and the adventitial reticular cells are subject to significant morphological 
changes, therefore the sinuses are effectively lined only with endothelial cells. Despite 
the lack of permanent pores within the sinusoidal endothelium, sites of endothelial 
thinning, so called diaphragmed fenestrae, have been identified which confer a degree 
of permeability to the endothelium, most likely for the passage of blood-borne 
molecules [5, 8].  
 
1.2 Endothelial cells  
The lumen of the entire vascular system is lined by a monolayer of endothelial cells, 
which play an important role in a variety of processes, including tissue homeostasis, 
blood-tissue exchange and blood cell migration. Although endothelial cells are found 
throughout the body, there is a high degree of heterogeneity amongst endothelial cells 
from different tissues [9], with variations in morphology and expression of surface 
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markers, such as chemokine receptors, adhesion molecules and glycoproteins [10]. This 
is likely to be related to their characteristic biological functions, although at present this 
heterogeneity is poorly understood.  
 
1.2.1 The bone marrow sinusoidal endothelium 
The bone marrow sinusoidal endothelium is an example of a specialised endothelium, 
exhibiting the unique ability to regulate leukocyte and stem cell release from the bone 
marrow [11].  The bone marrow sinusoidal endothelium has been poorly characterised 
to date and many of the mechanisms by which it regulates the selective release of cells 
remain to be elucidated. Previous studies have shown vascular cell adhesion molecule 1 
(VCAM-1), E-selectin and P-selectin, adhesion molecules usually only expressed on 
endothelial cells under inflammatory conditions, to be constitutively expressed on 
murine bone marrow sinusoidal endothelium [12-14], suggesting a possible role for 
these molecules in the trafficking of cells between the bone marrow and the blood. 
Indeed, it has previously been shown that these molecules are important for the homing 
of haematopoietic progenitor cells (HPCs) back to the bone marrow [12, 15, 16], and 
importantly, very late antigen-4 (VLA-4), the integrin that binds VCAM-1, has been 
shown to be critical for neutrophil mobilisation from the bone marrow [17]. It has 
recently been reported that the bone marrow sinusoidal endothelium selectively 
expresses vascular endothelial growth factor receptor 3 (VEGFR3), an antigen that has 
been reported to distinguish sinusoidal endothelial cells from vascular endothelial cells 
[18]. Studies using in vivo imaging of the bone marrow vasculature in flat bones have 
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shown that it is comprised of discrete functional domains that express specific adhesion 
molecules and chemokines, such as E-selectin and CXCL12, which define sites at which 
haematopoietic stem cells (HSCs) and lymphocytes, as well as malignant cells in the 
context of leukaemia, home to the bone marrow [19]. Indeed, it has been suggested that 
CXCL12 is constitutively expressed on the bone marrow endothelium, while it is not 
produced by lung endothelial cells, which contributes to the selective homing of HSCs to 
the bone marrow [20]. In another study, Dar et al. demonstrated that the bone marrow 
endothelium acts as a delivery system for ‘information transfer’ between the blood 
circulation and the marrow compartment, by binding, internalising and transcytosing 
stromal cell-derived factor-1 (SDF-1), or CXCL12, from the blood into the bone marrow 
[21]. The authors postulate that this redistribution of SDF-1 across the bone marrow 
endothelium enables communication between the bone marrow and distant organs to 
enhance homing of haematopoietic stem and progenitor cells to the bone marrow, both 
in homeostasis and in stress situations [21]. 
 
1.3 Cell egress from the bone marrow 
The mobilisation of progenitor cells and mature leukocytes from the bone marrow into 
the circulation is dependent on their migration across the sinusoidal endothelium [11], 
a process which is thought to occur by a transcellular route, with cells moving through 
tight-fitting migration pores in the endothelial cell [11, 22]. Egress of a mature 
leukocyte involves the leukocyte making contact with the endothelial cell, setting in 
motion a series of events that causes the formation of a transient pore in the cytoplasm 
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of the endothelial cell. The leukocyte pushes through this pore before it closes behind 
the egressing cell [4]. This process occurs under homeostatic conditions when it is 
predominantly mature leukocytes [4] that leave the bone marrow, and during specific 
disease states, when subpopulations of bone marrow cells are rapidly mobilised into the 
circulation in response to various blood-borne stimulants [17, 23-26]. 
 
It has been shown that at sites of inflammation, stromal cells underlying the 
endothelium can stimulate or modulate the inflammatory response of the endothelium 
[27-29]. For example, fibroblasts isolated from the chronically inflamed synovium of 
patients with rheumatoid arthritis have been shown to promote leukocyte recruitment 
to otherwise naïve human umbilical vein endothelial cells (HUVECs) [28]. It is therefore 
possible that this stromal modulation of endothelial responses could apply to the bone 
marrow and therefore, the bone marrow stromal microenvironment may be important 
in regulating cell egress. 
 
1.4 Bone marrow stem and progenitor cells 
Stem cells are undifferentiated cells which have the capacity to continuously divide and 
produce more stem cells of the same type or to differentiate into a defined set of 
progeny. Stem cells are usually divided into two sub-types: embryonic stem cells, which 
are isolated from the blastocyst and have the capacity to differentiate into cells of all 
lineages, and adult stem cells, which reside in adult tissues and are more lineage-
restricted. In addition, progenitor cells are undifferentiated cells which have the 
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capacity to differentiate into specialised cells; however, unlike stem cells they do not 
show unlimited self-renewal and can only differentiate into a restricted number of cell 
types.  In this respect progenitor cells are termed unipotent or oligopotent and share 
similarities with adult stem cells. Both stem and progenitor cells play an essential role 
in the daily processes of repair and renewal that take place within the body, as well as 
following injury. Stem and progenitor cells have been identified as rare populations of 
cells within most tissues, including the skin, lungs, intestinal epithelium and probably 
most notably, in the bone marrow. To date, the most well characterised populations of 
adult stem and progenitor cells are those found in the bone marrow (Figure 1.1). 
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1.4.1 Haematopoietic stem cells 
Haematopoietic stem cells (HSCs) are the most well characterised population of stem 
cells within the bone marrow and have been extensively studied in terms of their 
characteristics and function, since their discovery by Till and McCulloch in 1961 [30]. 
Figure 1.1 Populations of progenitor cells in the bone marrow and the cells they give rise to 
The bone marrow contains a number of populations of stem and progenitor cells. The main subpopulations 
are: haematopoietic stem cells (HSCs) which give rise to all red and white blood cells, endothelial progenitor 
cells (EPCs) which enhance angiogenesis by integrating into blood vessels in vivo, as well as producing pro-
angiogenic factors, and finally the mesenchymal stem cells (MSCs) which exhibit trilineage differentiation into 
adipocytes, osteoblasts and chondrocytes, as well as having the capacity to modulate the immune response 
through secretion of a range of soluble factors. 
 ~ 26 ~ 
 
HSCs can self-renew, as well as give rise to haematopoietic progenitor cells (HPCs), 
which can differentiate into all cells of the innate and adaptive immune system, as well 
as red blood cells and platelets. In the bone marrow HSCs are mostly localised within 
their niche but can be mobilised in response to various factors. It is thought that the 
bone marrow contains two types of HSCs; long-term HSCs (LT-HSCs), which are able to 
self-renew and persist throughout the lifetime of the organism, sustaining the HSC pool, 
and short-term HSCs (ST-HSCs) which undergo proliferation and terminal 
differentiation into functional haematopoietic cells [31]. HSCs and HPCs (HSPCs) can be 
identified by surface markers, and transplanted in vivo without the need to culture the 
cells first [32, 33]. HSCs can be prospectively identified by their low staining with vital 
dyes, such as Hoechst 33342, termed side population, their lack of lineage markers and 
their expression of various other haematopoietic stem cell markers [34, 35].  
 
1.4.2 Endothelial progenitor cells (EPCs) 
An important subset of progenitor cells, which reside in the bone marrow, and are 
mobilised into the blood under homeostatic and inflammatory conditions, are the 
endothelial progenitor cells, or EPCs. EPCs home to newly forming blood vessels and 
enhance angiogenesis when recruited to ischemic tissue, through direct integration into 
vessels or by stimulating pre-existing endothelial cells in a paracrine manner [36]. 
These cells were originally identified by Asahara et al. in 1997, after observing that 
purified CD34+ cells can differentiate in culture into cells of an endothelial phenotype, 
which express various endothelial markers and incorporate into vessels at sites of 
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ischemia [37].  These cells were originally defined as being positive for HSC markers, 
such as CD34, and in addition, positive for endothelial markers, such as CD31 [37].  
Since CD34 is also expressed by mature endothelial cells, EPCs have also been defined 
as positive for CD133, a more primitive HSC marker which is not expressed on mature 
endothelial cells, as well as VEGF receptor 2 (VEGFR2), to distinguish them from 
endothelial cells shed from the vessel wall [38]. The search for the phenotypic definition 
of an EPC has caused controversy, with some believing that these cells express 
haematopoietic markers, while others believe they do not [39]. In 2000, Lin et al. 
described a population of cells in peripheral blood which formed colonies in culture 
within 9 days, and another population that were derived from the bone marrow which 
formed colonies after 28 days in culture, were highly proliferative and expressed 
endothelial but not haematopoietic markers [40, 41]. Following on from this, it has 
historically been thought that there are two subsets of EPCs: early and late outgrowth 
cells, which are likely to have different roles in neoangiogenesis [42].   
 
1.4.2.1 Early outgrowth EPCs 
Early outgrowth EPCs (EOG EPCs), giving rise to colonies in vitro that appear after 5 
days, are thought to be derived from a common monocytic lineage, expressing proteins 
including CD11b, CD14, CD31 and VE-cadherin, staining for lectin and taking up Ac-LDL 
(Figure 1.2). Early outgrowth EPCs are thought to contribute to vascular remodelling by 
their secretion of growth factors, such as vascular endothelial growth factor-A (VEGF-
A), hepatocyte growth factor (HGF), granulocyte-colony stimulating factor (G-CSF) and 
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granulocyte macrophage-colony stimulating factor (GM-CSF), thereby promoting 
angiogenesis in a paracrine manner [43]. Indeed, in vivo administration of these cells 
has been shown to promote angiogenesis in animal models of ischemia [44, 45]. 
Although the consensus is that EOG EPCs are pro-angiogenic, there has been no 
conclusive evidence that they incorporate into vessels in vivo or that they are clonogenic 
at a single cell level and it is now generally accepted that early outgrowth EPCs do not 
represent true endothelial progenitor cells, but rather are of a monocytic lineage. It has 
been suggested that it would be more appropriate to rename these cells ‘circulating 
angiogenic cells’ [43]. 
   
1.4.2.2 Late outgrowth EPCs 
Late outgrowth EPCs (LOG EPCs), on the other hand, form colonies after 21 days in 
culture and are derived from an endothelial lineage, showing classical endothelial 
characteristics and expression of endothelial markers, such as VEGFR2, CD31 and VE-
cadherin, staining for lectin and taking up Ac-LDL. Importantly, these cells lack the 
expression of monocytic and haematopoietic markers seen on EOG EPCs (Figure 1.2). 
These cells have been shown to be highly proliferative and capable of forming tubes in 
vitro [40]. Furthermore, LOG EPCs form perfused vessels in vivo when implanted into 
immunodeficient mice [46, 47]. LOG EPCs are thought to represent true endothelial 
progenitor cells, contributing to vascular remodelling by their incorporation into 
vessels in vivo and differentiation into mature endothelial cells, although studies into 
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their ability to repair and regenerate the vascular system in animal models have been 
limited due to the lack of specific markers to identify these cells [48, 49]. 
 
 
 
 
 
 
 
 
 
Figure 1.2 Characteristics and properties of early outgrowth and late outgrowth endothelial progenitor 
cells 
Endothelial progenitor cells (EPCs) can be subdivided into two populations: early outgrowth EPCs and late 
outgrowth EPCs. Early outgrowth EPCs appear in culture after about 5 days and exhibit a spindle-shaped 
morphology. They are characterised by expression of haematopoietic markers such as CD11b and CD14, and 
endothelial markers such as CD31, VE-cadherin, GS-lectin and taking up Ac-LDL. In addition they have been 
shown to secrete pro-angiogenic factors such as VEGF-A, HGF, G-CSF and GM-CSF. In contrast, late outgrowth 
EPCs appear in culture after 14-21 days and exhibit cobblestone morphology. They are characterised by the 
lack of expression of haematopoietic markers such as CD45 and CD14, while showing expression of 
endothelial markers such as CD31, VE-cadherin, VEGFR2, GS-lectin and taking up Ac-LDL. In addition they 
have also been shown to integrate into vessels in vitro and in vivo. 
 ~ 30 ~ 
 
1.4.2.3 EPCs in angiogenesis 
There still exists some controversy over how much EPCs actually contribute to 
angiogenesis though this is largely due to the limited characterisation of putative EPCs 
in the various studies, combined with the use of different isolation methodologies and 
the lack of specific markers to prospectively isolate EPCs.  This has resulted in the 
investigation of different populations of cells which make varying contributions to the 
vasculature [50].  
 
Both EOG and LOG populations of EPCs have been shown to contribute to 
neoangiogenesis in a hind limb ischemia murine model [42, 45] and interestingly, 
administration of a mixture of the two cell types augmented the effects of either 
population alone, suggesting a synergistic mechanism of action [51]. Only LOG EPCs 
have been shown to form de novo blood vessels when implanted in vivo [46, 47], 
although it is possible that EOG EPCs are involved in the regulation of angiogenesis [52]. 
 
Due to their pro-angiogenic capacity, it has been suggested that EPCs could be utilised in 
vascular engineering strategies. Indeed, two independent studies have shown that when 
seeded with keratinocytes onto either acellular human cadaveric skin or onto a tissue 
engineered skin substitute, functional endothelial vessels were observed within the skin 
substitutes [53, 54]. 
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1.4.2.4 EPCs in disease 
EPCs have been implicated in disease pathology since they were originally discovered in 
1997 and have been suggested to be involved in both pro-angiogenic and anti-
angiogenic pathologies [39]. Clinical studies have been conducted in a range of disease 
areas including cardiovascular disease, oncology, metabolic syndrome and pulmonary 
disease but in the majority of these studies it is in fact EOG EPCs that have been 
measured and therefore these results must be treated with caution [39]. 
 
Cardiovascular disease (CVD) is a multifactorial disease and it is likely that endothelial 
cells play a crucial role in its development. Indeed, one theory suggests that endothelial 
damage can set in motion a series of events that leads to the formation of 
atherosclerotic plaques and the eventual occlusion of the blood vessel. EPCs, which are 
thought to play a role in the resolution of endothelial injury, are thought to be important 
in the development of this disease, although their exact role is yet to be established. 
Indeed numbers of circulating EOG EPCs in patients have been shown to correlate with 
complications in CVD and also diabetes [44]. A number of clinical studies have 
suggested that levels of circulating EPCs are decreased in patients with CVD [55-58]. In 
addition, a reduced number of circulating EPCs has been suggested as an indicator of 
increased risk of CVD [59]. Contrary to this, other studies have suggested that EPC 
numbers are in fact increased in the circulation after ischemic stroke [60] or in patients 
with severe heart failure [61]. Furthermore, one study reported increased numbers of 
EPCs in the circulation of patients with chronic heart failure that exercised compared to 
those that did not [62]. EPCs have also been studied in oncology patients and in one 
 ~ 32 ~ 
 
study were shown to be elevated in patients with ovarian cancer compared to healthy 
controls, with higher levels of these cells in patients, after tumour excision, correlating 
with poor survival rate [63]. In chronic obstructive pulmonary disorder (COPD), EPCs 
have been suggested to be reduced in number in the circulation compared to healthy 
controls [64], although they have been reported to increase again during exacerbations 
of the disease, which the authors hypothesise may be related to an increase in VEGF-A 
levels in the plasma [65]. 
 
EPCs have also been studied in the context of asthma and one study has shown that 
there are elevated levels of EPCs (EOG EPCs) in the blood of asthmatic patients 
compared to normal controls [66]. Previous studies have also shown an increased 
recruitment of these cells to the inflamed lungs in the ovalbumin (OVA) mouse model of 
allergic airways disease: one study showed an increased recruitment of EOG EPCs to the 
lungs following allergen challenge [66], while previous work in our laboratory 
demonstrated that LOG EPCs are recruited to the lungs after allergen challenge [67]. 
EPCs have been shown to express CXCR2 [68] and this recruitment of EPCs to the 
inflamed lungs in the OVA model of allergic airways disease was shown to be dependent 
on the CXCL1/2-CXCR2 chemokine axis [67]. Indeed, increased production of CXCL1 and 
CXCL2 was observed in the lungs following allergen challenge and if CXCR2 was blocked 
with an antibody, the numbers of EPCs in the lungs of OVA sensitised mice were 
reduced back to basal levels [67]. 
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In a recent study, Asosingh et al. demonstrated that the secretome of EOG EPCs could be 
modulated by the inflammatory environment [69].  They used the OVA model of allergic 
airways disease to show that EOG EPCs from challenged mice not only contained higher 
levels of CCL11 (eotaxin) than those from unchallenged mice, but that they secreted 
more of this chemokine when in contact with activated lung endothelium from 
sensitised and challenged mice [69]. In addition, another group has found that chronic 
hypoxia in a model of pulmonary hypertension has a profound effect on the 
functionality of EOG EPCs, resulting in cells with an impaired ability to sustain 
angiogenesis [70]. These data suggest that the function of EOG EPCs may be dependent 
on the microenvironment and the particular disease context. 
 
1.4.3 Mesenchymal stem cells   
In addition to HSCs and EPCs, another population of stem cells, the mesenchymal stem 
cells (MSCs), has been identified in the bone marrow. MSCs were first identified over 40 
years ago by Friedenstein, as stromal cells from the bone marrow that adhere to plastic, 
exhibiting a fibroblast-like appearance and forming colonies in vitro, as well as showing 
trilineage differentiation into adipocytes, chondrocytes and osteoblasts in vitro and in 
vivo [71].  It has since been suggested that MSCs can also differentiate into a number of 
other cell types including cardiomyocytes, neurons, endothelial cells and muscle cells 
(Figure 1.3) [72-75]. In addition, there is also some evidence to suggest MSCs have the 
capacity to differentiate into epithelial cells [76-78]. Due to their reported capacity for 
self-renewal and their mesenchymal multipotency, Caplan named these multipotent 
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stromal cells ‘mesenchymal stem cells’ [79]. MSCs were initially identified in bone 
marrow, but have since been isolated from several other tissues, including muscle [80], 
umbilical cord [81], amniotic fluid [82], lungs [83]  and adipose tissue [84].  MSCs 
constitute a rare population in all of these sources, comprising about 0.001-0.01% of 
human bone marrow [74].  
 
1.4.3.1 Characterisation of MSCs 
As research into MSCs has increased over the years, characterisation criteria have been 
developed in order to standardise the definition of an MSC. In 2006, the Mesenchymal 
and Tissue Stem Cell Therapy Committee of the International Society of Cellular 
Therapy (ISCT) established a minimal set of criteria that a human multipotent stromal 
cell must meet to be classified as an MSC: MSC populations must be plastic-adherent, 
they must differentiate into osteoblasts, chondrocytes and adipocytes in vitro, and 
finally they must express the MSC markers CD105, CD90, and CD73, while they must be 
negative for the haematopoietic markers CD45, CD34, CD14 or CD11b, CD79α or CD19, 
and HLA-DR (Figure 1.3) [85]. In addition, MSCs have also been shown to express CD13, 
CD29, CD44 and CD166. Murine MSCs additionally express stem cell antigen-1 (Sca-1) 
and platelet-derived growth factor-α (PDGFRα), while to date no human homologue of 
Sca-1 has been identified. On the other hand, Stro-1 has been shown to be expressed on 
human MSCs, while it is absent from murine MSCs. Variable levels of expression of these 
markers have been observed and this is likely the result of isolating MSCs from different 
tissue sources and from the use of varied culture conditions. 
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Currently, most studies are carried out on MSCs grown in vitro, which are generally 
considered to be a heterogeneous population of plastic-adherent cells that contain 
within their number a subset of true stem cells.  As a result of the lack of a single marker 
to identify MSCs and the fact that what is known about these cells is based on their 
characterisation in vitro, it has been very difficult to study the properties and function of 
these cells in vivo.   
 
In a recent report, Morikawa et al. demonstrated that MSCs from adult mouse bone 
marrow can be identified and isolated as CD45- Ter119- Sca-1+ PDGFRα+ (termed PαS 
cells).  This subpopulation of MSCs was shown to be significantly enriched for colony-
forming units with trilineage differentiation potential and was shown to integrate into 
both the bone marrow and adipose tissue when systemically transplanted [86].  These 
cells were also shown to have the capacity to differentiate in vitro into cells of a neural 
crest lineage, including glial cells and α smooth muscle actin (αSMA)-positive smooth 
muscle cells [87]. PαS cells were found in the bone marrow of multiple different mouse 
strains investigated, including Balb/c and C57BL/6 mice. In this study, MSCs were 
shown to be located predominantly in the arterial perivascular space, adjacent to 
vascular smooth muscle cells (vSMCs) [86].  
 
In recent years it has been suggested that MSCs may have a perivascular origin and may 
be related to pericytes, which are closely associated with endothelial cells in small 
vessels. Indeed it is possible that pericytes are derived from MSCs, although much work 
still remains to be done before any firm conclusions can be made [80].  
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1.4.2.2 Immunomodulatory properties and tissue repair 
Originally, MSCs were thought to hold great therapeutic potential for tissue repair due 
to their differentiation capacity. Indeed in 2008, chondrocytes differentiated from bone 
Figure 1.3 Characteristics and differentiation potential of mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are characterised as being plastic-adherent, lacking expression of the 
haematopoietic markers CD45, CD11b and CD34, while expressing markers such as CD73, CD90 and CD105. 
Historically, MSCs have been shown to possess trilineage differentiation potential, differentiating into 
adipocytes, osteoblasts and chondrocytes. More recently, MSCs have also been reported to differentiate into 
cardiomyocytes, neurons, endothelial cells, epithelial cells and muscle cells. MSCs secrete a range of soluble 
factors, including factors which can modulate the immune response, such as TGF-β, IL-10, NO, PGE2, IDO and 
iNOS. In addition, MSCs have been shown to secrete reparative factors, such as VEGF, HGF, bFGF, EGF, PDGF, 
IGF-1 and angiopoietin-1.  
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marrow-derived human MSCs were grown on a decellularised trachea, which was 
successfully transplanted into a patient and served as a functional airway [88]. While 
there is still considerable activity in this area, especially for repairing cartilage and 
bone, in recent years, the focus of studies into the properties of MSCs has moved away 
from their multipotentiality and has instead been redirected towards their capacity to 
promote tissue repair through their paracrine actions and to modulate immune 
responses in vitro and in vivo (Figure 1.4). This interest has followed on from the 
observation by Bartholomew et al. that bone marrow-derived baboon MSCs could 
suppress T cell proliferation in vitro and when transplanted in vivo could prevent the 
rejection of allogeneic skin grafts [89]. It is thought that when tissue damage occurs, 
MSCs are recruited to the site of damage where they have been shown to have a strong 
capacity to promote repair [90]. Although the exact mechanisms by which MSCs 
promote tissue repair remain unclear, it is currently believed that MSCs act in a 
paracrine way through the secretion of immunomodulators and growth factors. Indeed 
it has been shown that MSC-conditioned medium could mimic some of the reparative 
effects of MSCs in wound healing and after myocardial infarction (MI) [91-93]. MSCs 
have been shown to produce a range of soluble factors including transforming growth 
factor-β (TGF-β), interleukin-10 (IL-10), nitric oxide (NO), prostaglandin E2 (PGE2), 
hepatocyte growth factor (HGF), indoleamine 2,3-dioxygenase (IDO), epidermal growth 
factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), 
VEGF, SDF-1, insulin-like growth factor-1 (IGF-1) and angiopoietin-1 (Ang-1) (Figure 
1.3) [90]. The production of many of these soluble factors has been shown to be 
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stimulated by the inflammatory milieu, in particular by interferon-γ (IFN-γ) [94], 
tumour necrosis factor-α (TNF-α), lipopolysaccharide (LPS) or hypoxia [95].  
 
1.4.3.3 Innate immunity 
Although the effect of MSCs on the adaptive immune response was initially the main 
focus of research into the immunomodulatory role of MSCs, in more recent years, this 
interest has expanded to include the capacity of these cells to regulate the innate 
immune response (Figure 1.4). Human MSCs have been shown in vitro to inhibit the 
maturation of monocytes and CD34+ HPCs into dendritic cells (DCs) [96-98]. In addition, 
it has been reported that human MSCs induce downregulation of the expression of co-
stimulatory molecules (CD80 and CD86), CD83 and CD11c on DCs and their production 
of interleukin-12 (IL-12), thereby impairing their antigen-presentation function and 
inducing a tolerogenic DC phenotype [96]. 
 
In addition, human MSCs can inhibit the proliferation, IFN-γ production and cytotoxic 
activity of both resting and, to a lesser extent, pre-activated natural killer (NK) cells in 
vitro [99-102]. However, MSCs have been shown to be killed by pre-activated NK cells in 
vitro, although this effect could be partially abrogated by the incubation of MSCs with 
IFN-γ [99]. This suggests that the inflammatory milieu is important in determining the 
interplay between MSCs and NK cells, although the importance of these results in vivo 
remains to be established. Human MSCs have also been shown to regulate the 
neutrophilic response, by reducing their respiratory burst and by promoting the 
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survival of resting and interleukin-8 (IL-8) activated neutrophils in vitro [103]. This 
effect is dependent on interleukin-6 (IL-6) production by MSCs [103]. It has also been 
suggested that LPS-activated human MSCs attract neutrophils and increase their pro-
inflammatory activity [104]. 
 
Bone marrow-derived MSCs have been shown to recruit monocytes and macrophages 
into inflamed tissues, a process dependent on their production of CCL3, CXCL12 and 
CCL12 [91]. In vitro, co-culture of either human or murine MSCs with monocytes 
induces the formation of M2-polarised macrophages, which produce high levels of IL-10 
and phagocytose apoptotic cells [105-107], giving them an important role in the 
resolution of inflammation. It has been suggested that this effect is cell-contact-
dependent, as well as being dependent on the release of MSC-derived IDO and PGE2 
[105, 107, 108]. The importance of the interplay between MSCs and macrophages was 
demonstrated in a model of sepsis, in which murine MSCs were shown to have a 
protective effect, which was dependent on IL-10 production by macrophages [108]. In 
addition, in an endotoxin-induced model of lung injury, administration of murine bone 
marrow-derived MSCs increased the production of IL-10 by alveolar macrophages 
[109]. 
 
1.4.3.4 Adaptive immunity 
MSCs have been shown to regulate the adaptive immune response in a number of ways 
(Figure 1.4). Several studies have demonstrated the ability of human, murine and 
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baboon MSCs to suppress the proliferation of T cells [89, 102, 110, 111] by inhibiting 
the expression of cyclin D2 in activated T cells, thereby causing cell cycle arrest [111]. 
This anti-proliferative effect in humans is thought to be dependent on MSC production 
of IDO, NO and PGE2 [102, 112, 113].  In addition to suppressing T cell proliferation, 
murine MSCs have been shown to reduce the cytotoxicity of CD8+ cytotoxic T cells [114]. 
Importantly, it has also been demonstrated that MSCs reduce IFN-γ-induced T cell 
production both in vitro and in vivo [115] and increase production of anti-inflammatory 
interleukin-4 (IL-4) by T helper 2 (Th2) cells [102]. Indeed, recent studies in animal 
models suggest that a shift towards Th1 or Th2 dominance in a disease state could be 
rectified by the administration of MSCs [116-119]. Furthermore, human MSCs have 
been reported to promote the generation of T regulatory (TReg)  cells, which are an 
immunosuppressive subpopulation of T cells [102, 120]. In a recent in vivo study, it was 
shown that murine MSCs induce T cell apoptosis through the FAS ligand-dependent 
pathway, which results in the expansion of TReg cells, promoting immune tolerance 
[121]. 
 
In addition, there is evidence that human MSCs inhibit the proliferation of other cells, 
such as natural killer T (NKT) cells in response to interleukin-2 (IL-2) [99], γδ T cells 
[122] and B cells [112, 123], and may inhibit B cell differentiation and modulate the 
expression of chemokine receptors on the surface of B cells, affecting their chemotactic 
ability [123]. It has also been suggested that human MSCs change the profile and 
function of antigen presenting cells (APCs).  One example of this is the failure of 
monocytes to differentiate into dendritic cells in response to GM-CSF and IL-4 in the 
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presence of MSCs, and the impaired ability of these monocytes to stimulate the T cell 
response [98]. 
 
 
 
 
 
 
 
 
 
Figure 1.4 Immunomodulatory properties of mesenchymal stem cells 
Mesenchymal stem cells (MSCs) have been shown to modulate the immune response both in vitro and in vivo 
in a number of ways. MSCs have been shown to promote the generation of T regulatory cells, as well as 
supporting the M2-polarisation of macrophages, shifting the inflammatory response to a more regulatory 
phenotype. In addition, MSCs have also been shown to have the capacity to suppress various branches of the 
immune response: MSCs can inhibit T and B cell proliferation, as well as the cytotoxicity of CD8
+
 T cells, the 
neutrophilic respiratory burst and the maturation of monocytes into dendritic cells. In addition MSCs have 
been shown to suppress dendritic cell function and the cytotoxicity of NK cells.  
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1.4.3.5 Immunosuppression 
Although there is a growing body of data giving insights into the immunosuppressive 
activities of MSCs, the mechanisms are still only partially understood. It has been 
suggested that immunosuppression by MSCs is not intrinsic and that the environmental 
conditions to which both human and murine MSCs are exposed can modulate their anti-
proliferative properties, possibly through the secretion of immunomodulators, as has 
been shown to be the case for MSCs stimulated with TNFα and IFN-γ [124, 125]. Indeed 
it has been shown that NO and IDO are only produced by MSCs in response to IFN-γ 
production by other cells [125, 126]. In addition, murine MSCs can be stimulated to 
produce T-cell attractive chemokines and inducible nitric oxide synthase (iNOS), which 
generates NO, through stimulation with IFN-γ in combination with the pro-
inflammatory cytokines TNF-α or interleukin-1α (IL-1α) or interleukin-1β (IL-1β) [94, 
127]. The dependence on IFN-γ for the immunosuppressive activity of MSCs was 
demonstrated in a study using IFN-γ receptor 1 (IFNγR1)-deficient mice, in which no 
immunosuppressive effect of MSCs was observed [127]. Indeed it is now generally 
accepted that MSCs need to be ‘immuno-licenced’ by stimulation with IFN-γ for them to 
be immunosuppressive. It is worth noting that there appears to be species variation in 
the mechanisms of immunosuppression by MSCs. Ren et al. demonstrated that while 
human MSCs mediate their immunosuppression through IDO and produce very low 
levels of iNOS, murine MSCs mediate their effects through NO, and produce very low 
levels of IDO [94]. Furthermore, while human MSCs only require stimulation with IFN-γ 
to elicit their immunosuppressive effects, mouse MSCs require co-stimulation with 
either TNF-α or interleukin-1α (IL-1α) in combination with IFN-γ [94]. 
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1.4.3.6 Migration 
Although there has been no definitive demonstration of MSCs being mobilised from the 
bone marrow into the circulation and recruited into damaged tissues, exogenously 
administered culture-expanded MSCs have been shown to migrate into injured tissue in 
vivo [128-131]. In the majority of these studies MSCs were administered by intravenous 
injection, which resulted in the entrapment of a large proportion of these cells in the 
lungs [128, 132, 133] and their subsequent distribution to other tissues, including the 
spleen, kidneys and liver [133].  
 
The mechanism by which MSCs migrate into tissues is currently unclear but it is likely 
that chemokines and their receptors are involved since they are known to be important 
in leukocyte migration. Indeed, MSCs have been shown to express a range of chemokine 
receptors, although there appear to be differences in the chemokine receptor 
expression profile of human and mouse MSCs [134, 135] (Table 1.1). It also remains to 
be established how MSCs transmigrate across the endothelial barrier into the tissue but 
it seems likely that this occurs by an active process similar to leukocyte transmigration. 
In support of this, in vitro experiments have shown that VLA-4 and P-selectin ligands 
expressed on MSCs can bind VCAM-1 and P-selectin on HUVECs, causing the arrest and 
adhesion of MSCs to endothelial cells [136].  Furthermore, in a recent study, human 
MSCs were shown to actively transmigrate across TNF-α-stimulated endothelial cells in 
a manner dependent on VCAM-1 and G-protein coupled receptor (GPCR) signalling 
[137]. Evidence of paracellular and transcellular migration was observed in this study, 
with MSC transmigration occurring over a matter of hours rather than minutes as is the 
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case with leukocyte transmigration [137]. It has also been suggested that 
metalloproteinase-2 (MMP-2), membrane type1-metalloproteinase (MT1-MMP) and 
tissue inhibitor metalloproteinase-2 (TIMP-2), which are expressed by MSCs, facilitate 
MSC transmigration [138, 139]. Interestingly, the pro-inflammatory cytokines TGF-β, IL-
1β and TNF-α have been shown to increase the expression of MMP-2, MT1-MMP and 
TIMP-2 on human MSCs [138]. In addition, TNF-α and IL-1β-primed cells have been 
shown to express higher levels of CCR2, CCR3 and CCR4, as well as demonstrating 
greater chemotaxis to their cognate ligands [140]. These data suggest that these 
molecules may be involved in the migration of MSCs into injured tissues and that this 
migration may be affected by the inflammatory milieu, although this remains to be 
investigated in vivo.   
 
 
Human MSCs Mouse MSCs 
CCR1            CXCR1 
CCR2            CXCR2 
CCR3            CXCR3 
CCR4            CXCR4 +/- 
CCR7            CXCR6 
CCR8            CX
3
CR1 
CCR9 
CCR10 
CCR3           CXCR4 
CCR5           CXCR5 
CCR7 
 
Table 1.1 Chemokine receptors shown to be expressed by human and mouse MSCs  
From Fox, JM., et al. 2007, Br J Haematol [135]; Chamberlain, G., et al. 2008, PLoS ONE [134]. 
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1.4.3.7 Therapeutic potential 
Given their multipotentiality and immunoregulatory properties, MSCs are considered to 
possess potent regenerative and reparative potential and have been shown to be 
efficacious in a number of animal models including myocardial infarction [141], 
bleomycin-induced fibrosis [129, 142-144] and allergic airways disease [116, 117].  In 
the bleomycin model of pulmonary fibrosis, systemically administered MSCs have been 
shown to reduce inflammation and fibrosis and were shown to be preferentially 
localised to areas of injury [129, 143]. Furthermore Ortiz et al. showed a 23-fold 
increase in engraftment of donor-derived MSCs into the bleomycin-injured lungs 
compared to the lungs of control mice [129]. Following on from this, Ortiz et al. 
suggested that the protective effect observed upon administration of MSCs in the 
bleomycin model was the result of a reduction in pro-inflammatory cytokines, such as 
TNF-α and IL-1 in the lungs [142]. In addition, MSCs have also been shown to support 
angiogenesis in a model of hind limb ischemia [145], producing pro-angiogenic factors 
such as basic FGF (bFGF), VEGF, placental growth factor (PlGF) and monocyte 
chemotactic protein-1 (MCP-1), which promote survival of existing endothelial cells and 
formation of tubular structures in vitro [145, 146]. Following on from this, MSCs are 
being evaluated in an increasing number of clinical trials, currently standing at over 250 
registered on www.clinicaltrials.gov, using both allogeneic and autologous therapy 
(Figure 1.5). These include trials to promote bone regeneration, to improve graft-
versus-host disease (GvHD), autoimmune diseases, cardiac disease and ischemic 
disorders to name but a few [141, 147-149]. Early results for clinical trials using MSCs 
to enhance repair in cardiac disease suggest modest improvement following MSC 
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therapy [150]. It is important to note that in a number of these studies, both human and 
murine, engraftment of MSCs into tissue has been very low or only transient [151-154]. 
Despite this, reparative effects of administration of MSCs have still been observed in 
these studies and therefore it seems likely that it is soluble factors secreted by MSCs 
that are critical for their therapeutic effects. Indeed, MSC-conditioned medium has also 
been shown to improve repair after MI [92, 93] and to enhance wound healing [91]. 
 
 
 
 
 
 
 
Figure 1.5 Current clinical trials registered using mesenchymal stem cells  
MSCs are currently being evaluated in a wide range of clinical trials, currently standing at over 250 
registered on www.clinialtrials.gov. Data as of August 2012 from www.clinicaltrials.gov. 
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In addition, MSCs are being used as ‘Trojan horses’, utilising their capacity to home to 
sites of injury to deliver specific molecules to diseased areas, such as IL-10 in a model of 
ischemia-reperfusion after lung transplantation and TNF-related apoptosis-inducing 
ligand in lung cancer [155, 156]. 
 
1.4.4 Fibrocytes 
Another subset of progenitor cells known to reside in the bone marrow, are the 
fibroblast progenitor cells, called fibrocytes. These cells were only identified relatively 
recently, and much still remains unknown about their characteristics and function. The 
term ‘fibrocyte’ was first used in 1994, to describe a population of cells with features of 
both leukocytes and fibroblasts, which accumulate at the site of tissue injury [157]. 
These cells were shown to uniquely express markers of fibroblasts, such as vimentin 
and collagen, as well as the leukocyte marker CD45, monocytic markers including 
CD11b and the HSC and endothelial marker, CD34 [157]. More recent studies suggest 
that fibrocytes originate from CD14+ peripheral blood mononuclear cells [158-160] and 
most likely represent an intermediate cell type in the differentiation process from 
monocytic precursor to fibroblast and myofibroblast within the tissue [161, 162].   It 
has been suggested that these cells play a pivotal role in wound healing [157, 158, 162, 
163], while they have also been reported to contribute to the pathogenic fibrosis 
associated with pulmonary fibrosis [164-166] and to airway remodelling in asthma 
[167]. Although the exact role of fibrocytes is still unknown, it is thought that fibrocytes 
are recruited to sites of injury to promote tissue repair, where they produce 
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extracellular matrix components and are believed to differentiate into myofibroblasts 
[166]. It has been suggested that excessive injury may cause an aberrant response in 
fibrocytes which promotes pathological fibrosis instead of constructive tissue repair 
[168].  
 
Fibrocytes were initially identified as a blood-borne cell population and their tissue 
origin has proved a controversial topic. However, a number of studies have since 
provided convincing evidence that these cells originate from the bone marrow [163, 
169-171]. Since the original studies on these cells, their surface expression has been 
explored further and fibrocytes have been shown to express a number of CCR and CXC 
chemokine receptors, including CCR2, CCR3, CCR5, CCR7 and CXCR4 [158, 170], which 
are likely to be important in the accumulation of these cells in tissues during injury. 
Indeed CCR2 has been shown to be critical for the recruitment of lung fibrocytes into 
areas of injury in a model of FITC-induced pulmonary fibrosis [170], while CXCR4 and 
CCR7 have been shown to be involved in the recruitment of bone marrow-derived 
fibrocytes into the lungs in a murine model of pulmonary fibrosis [164].  
 
1.4.5 Epithelial progenitor cells 
There is evidence to suggest that a population of bone marrow-derived cells can 
contribute to tissue repair by incorporating and differentiating into the lung airway 
epithelium in response to bleomycin- or LPS-induced injury or sex-mismatched tracheal 
transplantation [76, 172-176]. Indeed, a population of cells was identified in the bone 
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marrow expressing the haematopoietic markers CD45 and CD34, along with the MSC 
markers CD73, CD90 and CD105. Importantly, this population was also shown to 
express CCSP, the Clara cell secretory protein, usually only expressed by epithelial cells 
[172]. Wong et al. showed that this population of bone marrow cells was capable of in 
vitro differentiation into epithelial cells, and notably showed that following 
naphthalene-induced lung injury, an increased number of these cells could be detected 
in the bone marrow and circulation and that exogenously administered bone marrow 
CCSP+ cells were capable of homing to the injured lungs and of repopulating the airway 
epithelium [172] . In another study, prominin-1+ progenitor cells in the lungs, which 
were shown to differentiate into alveolar type II epithelial cells and to protect against 
bleomycin-induced lung fibrosis, were shown to be of bone marrow origin [173]. 
Furthermore, in human sex-mismatched transplantations, recipient airway epithelial 
cells have been identified following lung transplantation [177], along with donor-
derived airway epithelium following bone marrow transplantation [178]. This concept 
however, is still controversial, with other studies suggesting that there is in fact no 
contribution of bone marrow stem cells to the lung epithelium [179]. Indeed recent 
studies suggest that the techniques used to determine engraftment may have 
overestimated its occurrence [179, 180]. Further studies will be necessary to determine 
whether a population of epithelial progenitor cells exists in the bone marrow and 
whether these cells are capable of reconstituting airway epithelium.  
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1.5 The Bone Marrow Niche 
For many years it has been known that HSCs in the bone marrow are associated with 
the bone and that this cell-cell contact is important in regulating self-renewal and 
preventing differentiation of HSCs in vivo; this bone marrow microenvironment was 
termed the ‘stem-cell niche’ [181]. More recently it has been demonstrated that two 
bone marrow stem cell niches exist: the endosteal niche near the internal surface of the 
bone where quiescent HSCs are maintained, and the vascular niche near the sinusoids, 
where dividing HSCs can be found (Figure 1.6) [35].  
 
MSCs have been shown to support haematopoiesis [182, 183] and to be a critical 
component of the bone marrow niche. In 2010, nestin-positive MSCs were identified 
throughout the bone marrow, spatially associated with HSCs and sympathetic nerve 
fibres, and were shown to retain HSCs, as well as being important in the homing of HSCs 
back to the bone marrow (Figure 1.6) [184]. In addition, CXCL12-abundant reticular 
(CAR) cells, also found in close proximity to HSCs and tightly associated with the 
sinusoids, have also been suggested to promote HSC self-renewal [185]. Furthermore, 
monocytes and macrophages have been shown to be involved in regulating the HSC 
niche, with macrophage depletion leading to decreased HSC self-renewal and increased 
mobilisation from the bone marrow [186, 187]. In one study, CD169+ macrophages 
were shown to modulate nestin-positive bone marrow MSCs, by promoting expression 
of HSC-retention factors, such as CXCL12, angiopoietin-1, stem cell factor (SCF) and 
VCAM-1 [187]. 
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Figure 1.6 Cellular components of the bone marrow niche  
Two niches are thought to exist within the bone marrow: the vascular niche and the endosteal niche.  The 
vascular niche comprises the sinusoids, surrounded by nestin
+
 MSCs and CXCL12-abundant reticular (CAR) 
cells, and is where dividing haematopoietic stem cells (HSCs) reside. The endosteal niche, located close to the 
bone, also includes osteoclasts and osteoblasts and has been shown to be where quiescent HSCs reside within 
the bone marrow. (Adapted from Ehninger, A. & Trumpp, A., 2011, JEM, [188]). 
 
 
 
 
1.6 Selective mobilisation of cells from the bone marrow    
It is well known that blood-borne factors, including cytokines, chemokines, growth 
factors and complement components, stimulate the mobilisation of leukocytes and 
progenitor cells from the bone marrow into the blood [23-25, 189]. In the case of 
chemokines, this process is thought to occur by the establishment of a chemotactic 
gradient across the sinusoidal endothelium which stimulates cells to move from the 
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haematopoietic compartment, into the vasculature, from where they enter the systemic 
circulation. 
 
The chemokine CXCL12 is constitutively produced in the bone marrow and its 
interaction with CXCR4 has been shown to be important in maintaining HSC quiescence 
[185] and retaining HSCs within the bone marrow [190]. G-CSF, which has been used for 
many years to mobilise HSPCs for bone marrow transplants, has been shown to disrupt 
this CXCL12/CXCR4 retention axis by reducing expression of CXCR4 on HSPCs and by 
lowering the concentration of CXCL12 in the bone marrow [190]. Furthermore, a 
combination of chronic G-CSF treatment and acute administration of a CXCR4 
antagonist enhances mobilisation of HSPCs from the bone marrow still further [191, 
192] and has been shown to be efficacious, compared to G-CSF treatment alone, in 
clinical trials for peripheral blood HSPC transplantation [193]. In addition, 
administration of a CXCR4 antagonist has been reported to increase numbers of EPCs in 
the circulation [194]. In 2008, it was reported that circulating HSPCs exhibit circadian 
fluctuations in antiphase with levels of CXCL12 in the bone marrow, which is regulated 
by the sympathetic nervous system. The authors postulate that this may promote the 
regeneration of the stem cell niche under steady state conditions [195]. 
 
Previous work in the laboratory has shown cytokine conditioning of the bone marrow 
to dramatically affect the profile of progenitor cells and leukocytes mobilised in 
response to disruption of the CXCR4/CXCL12 retention axis, using the CXCR4 antagonist 
AMD3100 [196]. VEGF pre-treatment of the bone marrow resulted in enhanced 
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mobilisation of EPCs in response to CXCR4 antagonism, while inhibiting egress of HPCs 
and neutrophils. Unlike G-CSF, VEGF did not disrupt the CXCR4/CXCL12 axis, but 
signalled through VEGFR1 on HPCs to stimulate their entry into the cell cycle, thereby 
reducing their migratory capacity, and through VEGFR2 on EPCs to stimulate their 
mobilisation from the bone marrow in response to CXCR4 antagonism [196]. 
Importantly, this treatment regime mobilised large numbers of MSCs from the bone 
marrow, which was not seen with any other treatment combination tested. Further 
investigation of this mobilisation has shown VEGF to be acting through VEGFR2 and this 
mobilisation of MSCs to be dependent on membrane metalloproteinase (MMP) activity 
(Hahnel, M., personal communication).  More recently, it has also been suggested that 
pre-treatment with IGF-1 in combination with AMD3100 mobilises MSCs from the bone 
marrow into the blood [197]. This demonstrates that distinct factors and mechanisms 
regulate the mobilisation of subsets of progenitor cells and leukocytes from the bone 
marrow. This may be important in regulating progenitor cell mobilisation and 
recruitment in inflammatory disease, with levels of cytokines and growth factors in the 
plasma possibly impacting on the bone marrow to cause subsets of cells to be mobilised; 
although the mechanisms involved in regulating progenitor cell release in inflammation 
remain to be elucidated. 
 
1.7 Bone marrow stem cells and lung disease 
Chronic inflammatory lung diseases are associated with tissue damage, repair and 
remodelling and it is evident that bone marrow derived-stem and progenitor cells play a 
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role in these processes. As described above, studies are currently being carried out to 
investigate the effect of exogenously administered bone marrow stem cells on chronic 
inflammatory lung diseases; however the role of endogenous populations of bone 
marrow stem and progenitor cells in lung diseases still remains largely unclear.  
 
 1.7.1 Allergic airways disease 
Asthma is an example of a chronic inflammatory disease induced by allergen exposure. 
It is characterised by airway hyperreactivity, airway wall thickening and Th2-polarised 
airway inflammation, with a notable infiltration of eosinophils into the lungs, which 
eventually leads to structural changes of the lungs, including increased angiogenesis 
[198, 199]. This disease has a high prevalence amongst adults and children and to date 
the mechanisms of initiation and progression of this disease are poorly understood, 
with a number of treatment options available, but currently no cure.  
 
It is well established that asthma is associated with an eosinophilia in the bone marrow, 
blood and lungs [200-202], along with increased numbers of eosinophil progenitor cells 
in the circulation [201]. The cytokine IL-5 has been shown to drive eosinopoeisis in the 
bone marrow and, in combination with eotaxin, mobilisation of mature eosinophils into 
the blood [24, 203, 204]. In the OVA model of allergic airways disease, an increase in 
CD45+ CD34+ IL-5R+ eosinophil committed progenitor cells were observed in the lungs 
after allergen exposure [205]. These results suggest that HPCs, specifically eosinophil 
progenitors, are mobilised from the bone marrow and recruited to the lungs in response 
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to allergen challenge [200]. In addition, studies have shown elevated levels of EPCs in 
the circulation of asthmatic patients and in the murine OVA model of allergic airways 
disease, which correlates with an increased number of blood vessels present in the 
lungs [66, 67]. However, these studies did not elucidate the mechanisms or factors 
involved in regulating EPC mobilisation from the bone marrow into the circulation, from 
where they could be recruited to the inflamed lungs, or whether there was an associated 
increase in the number of EPCs residing in the bone marrow. To date endogenous MSCs 
have not been studied in asthma.  
 
1.7.2 Pulmonary fibrosis  
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease, 
associated with high rates of mortality and ineffective treatment options. The disease is 
characterised by alveolar epithelial cell damage, resulting in a ‘honeycomb’ appearance 
in the lung tissue, increased fibroblast proliferation and extracellular matrix deposition, 
resulting in the development of fibroblastic foci [206, 207]. This reduces the elasticity of 
the lungs and the area available for gas exchange, resulting in impaired lung function. 
To date the natural history of this disease in humans remains unclear and has proved 
difficult to study since patients often present at an advanced stage, therefore much still 
remains unknown about the cause and development of IPF [206, 207]. 
 
The bleomycin model of pulmonary fibrosis is commonly used to recapitulate this 
disease in mice, and has been well-characterised to date. A single dose of the 
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chemotherapy drug bleomycin, given intratracheally causes alveolar epithelial damage 
resulting in the development of lung fibrosis in rodents.  Initial damage results in an 
infiltration of inflammatory cells into the lungs and airways within the first seven days 
[208], after which time the cells are cleared and fibroblast hyperplasia and extracellular 
matrix deposition can be observed by day 14 [209], with maximal fibrosis seen between 
days 21 and 28 [209]. After this period, there is some discrepancy over the continued 
response to bleomycin. Initial studies suggested that the fibrotic response progresses 
over 60-90 days, while other studies suggest a self-limiting response which initiates 
resolution 28 days after administration of bleomycin [206].  The development of 
fibrosis in response to bleomycin in mice is dependent on strain, with C57BL/6 mice 
exhibiting a significantly higher level of susceptibility than Balb/c mice. This is likely the 
result of a strain difference in levels of expression of bleomycin-hydrolase, a bleomycin-
inactivating enzyme [209]. 
 
Administration of bleomycin has been shown to be associated with an increased release 
of certain chemokines within the lungs, including CCL2, CCL3, CCL12, CCL17, CXCL10 
and CXCL12, and importantly, the development of fibrosis has been shown to be 
dependent on this chemokine production, as well as on the recruitment of inflammatory 
cells and fibrocytes [164, 206, 210-214]. CXCL2 has also been shown to be elevated in 
the lungs following bleomycin injury and is thought to be involved in the vascular 
remodelling observed in this model [215]. TGF-β1 and TNF-α have also been shown to 
be critical in the development of bleomycin-induced fibrosis [216, 217]. To date there 
has been very limited investigation of HSCs, EPCs and MSCs in the bleomycin model.  
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1.8 Lung Stem cells  
The lungs, although not traditionally thought of as a major source of progenitor cells, 
have been shown to harbour a number of progenitor cells and have a substantial 
regenerative capacity, which can be activated following exposure to injurious stimuli. 
The identification, characterisation and function of these progenitor cells and the 
lineage of mature cells that they give rise to have been subjects of extensive research in 
recent years but remain a somewhat contentious topic. This is largely due to the 
absence of markers that are uniquely expressed by lung stem cells. Indeed, isolation of 
these cell populations has relied on the identification of various cell surface antigens, 
such as Sca-1 and CD34 [218-222], or on exhibition of a side population phenotype 
[221, 223]. To date, progenitor cells of the proximal and distal epithelium have been 
identified in the murine adult lungs [224-226], along with putative mesenchymal 
progenitor cells [219-221, 227, 228] and are thought to play a role in epithelial 
maintenance and repair. 
 
There are thought to be two populations of progenitor cells in the adult mouse lungs 
that contribute to epithelial repair in the bronchiolar airways: the transit-amplifying 
cell, or Clara cell, and the much rarer bronchioalveolar stem cell (BASC) [229, 230].  
Clara cells are thought to act as differentiated cells during homeostasis, but can 
proliferate and generate differentiated ciliated cells in response to injury.  BASCs, also 
known as variant Clara cells or bronchiolar stem cells, are thought to be located at the 
bronchoalveolar duct junction and have been characterised as being naphthalene-
resistant, and expressing the airway marker Clara cell secretory protein (CCSP), along 
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with the alveolar marker pro-surfactant protein C (pro-SPC) [218, 226, 231]. 
Importantly, BASCs have also been characterised as being negative for haematopoietic 
markers such as CD45, as well as endothelial markers such as CD31, while being 
positive for the stem cell antigen Sca-1 [218, 222]. The level of expression of Sca-1 and 
whether or not these cells are positive for CD34 varies between studies [232]. Teisanu 
and colleagues identified these cells as being Sca-1low CD34neg and further characterised 
them as exhibiting low autofluorescent properties, and being positive for EpCAM, an 
epithelial cell marker [222]. In contrast, Kim and colleagues showed an enrichment of 
BASCs in the Sca-1pos CD34pos fraction of the CD45neg CD31neg population of cells [218].  
These discrepancies may be the result of technical differences in methodologies, 
including sources of antibodies and fluorophores, as well as flow cytometers [232]. Kim 
et al. demonstrated that these cells were multipotent, producing Clara and alveolar 
type-II cells and that BASCs are resistant to damage and could be induced to proliferate 
following bronchiolar and alveolar injury [218]. Zacharek et al. went on to further 
define BASCs as CD45neg CD31neg Sca-1low EpCAMpos CD24low [233]. Further to this, 
several groups have identified possibly overlapping populations of progenitor cells in 
the mouse lungs which they propose as epithelial progenitor cells: CD45neg CD31neg 
CD34neg Sca-1low EpCAMpos Autofluorescencelow [234] and CD45neg CD31neg Sca-1low 
EpCAMhigh CD49fpos CD104pos CD24low [220]. The lineage specificity of these cell 
populations however remains to be fully established [235]. Following on from this, a 
recent study showed that Linneg EpCAMpos airway epithelial progenitor cells are region 
specific and that they respond differently to bleomycin-induced lung injury, with a 30% 
increase in colony-forming ability in the EpCAMpos CD24low SFTPC-GFPhi (the gene for 
 ~ 59 ~ 
 
SPC) population compared with the control group 20 days after bleomycin injury, 
compared to no change, or a reduction of other subpopulations of EpCAMpos cells [236]. 
In another recent study, Chapman et al. identified a population of alveolar epithelial 
cells expressing the β4 integrin which could grow clonally, differentiate into SPC-
positive epithelial cells in vitro and in vivo, and were shown to expand in the bleomycin-
injured lungs [237]. In addition, p63pos Krt5pos Krt14pos basal cells, which reside in the 
trachea and proximal bronchial airways and are thought to be absent from the distal 
lungs, have been shown to differentiate into the alveolar lineage and to contribute to 
epithelial regeneration after H1N1 influenza infection [238]. These studies support the 
idea of a hierarchy of epithelial cells within the lungs. 
 
There is also a growing appreciation that endogenous progenitor cell populations of 
other cell lineages also reside in the adult lungs. Several papers have identified 
progenitor cell populations which share characteristics with MSCs in both the human 
and murine lungs [219, 221, 239, 240]. Recent papers have suggested that the Sca-1pos 
fraction of cells in the murine lungs may in fact be a mixture of epithelial progenitor and 
mesenchymal progenitor cells [219, 220, 232, 234]. Summer et al. identified a rare 
population of mesenchymal progenitor cells within the CD45neg CD31neg side population 
of the adult lungs, which showed mesenchymal cell differentiation and expressed 
markers such as Sca-1, VCAM-1 and CD44 [221]. Subsequently, McQualter and 
colleagues suggested that the CD45neg CD31neg Sca-1pos CD34pos population of the lungs 
contains predominantly mesenchymal progenitor cells, but also some epithelial 
progenitor cells [219]. In this study, CD31neg Sca-1pos cells were localised in the 
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parenchyma of the distal lungs, and no Sca-1-positivity was observed on epithelial cells 
[219]. In another study lung MSCs were suggested to have a perivascular localisation 
[241], while another suggested them to localised to the alveolar microenvironment 
[242]. Lung-resident MSCs have only been minimally studied to date and the effect of 
inflammation and injury on this population of cells is still unclear. One study suggests 
that lung-resident MSCs may be reduced in response to bleomycin-induced lung injury 
but the cells were in fact very poorly characterised in this study and therefore much 
work still remains to be done to determine whether this is indeed the case [243]. 
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Figure 1.7 Localisation of lung epithelial and mesenchymal cell lineages in the bronchiolar and alveolar 
airways of the distal adult murine lungs  
The bronchioles of the distal adult murine lungs are lined by a range of epithelial cells, including ciliated cells, 
goblet cells and Clara cells. Clara cells are thought to act as differentiated cells during homeostasis but 
generate differentiated ciliated cells in response to injury. The alveoli are lined by alveolar type I and alveolar 
type II cells. Around the airways lie the structural cells such as myofibroblasts and smooth muscle cells and 
blood vessels are found in close association with the airways. In addition there are thought to be populations 
of region specific epithelial progenitor cells within the adult murine lungs.  Putative alveolar and bronchiolar 
stem cells have been suggested to reside within the bronchioles and alveoli, with their putative niche 
suggested to be found at the bronchoalveolar duct junction; although identification of the characteristics and 
properties of these populations of cells is still an area of much research, in particular with respect to their 
relationship to each other. Mesenchymal stem cells (MSCs) have also been isolated from the lungs and are 
thought to be associated with the vasculature, although this remains to be conclusively established. 
(Adapted from McQualter, JL., 2012, Stem Cells).  
 
Alveolus 
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In 2010, McQualter et al. highlighted EpCAM expression on Sca-1pos non-endothelial, 
non-haematopoietic cells as being important in distinguishing between epithelial and 
mesenchymal progenitor cells, suggesting that epithelial progenitor cells are enriched 
within the CD45neg CD31neg Sca-1low EpCAMhigh CD49fpos CD104pos CD24low fraction of the 
lungs, while MSCs could be found within the CD45neg CD31neg Sca-1high EpCAMneg fraction 
[220].  The authors demonstrated that the lungs contain a population of epithelial 
progenitor cells which give rise to airway and alveolar epithelial cell lineages in vitro 
and that the proliferation and differentiation of these cells could be regulated by FGF-10 
and HGF produced by murine lung MSCs [220].  
 
Interestingly, a recent study in the human lungs has identified a population of c-kitpos 
cells which show clonogenicity, self-renewal and multipotentiality both in vitro and in 
vivo [244]. In a murine model of lung injury, human c-kitpos cells were shown to 
participate in regeneration of the affected tissue and to give rise to all cells which 
comprise the architecture of the lungs, suggesting for the first time the existence of a 
true resident lung stem cell. Whether this cell population exists in mice and what its 
relationship is to previously identified lung progenitor cells remains to be elucidated 
[244]. 
 
1.9 Hypothesis and aims 
Bone marrow-derived stem cells contribute to the pathogenesis of inflammatory lung 
diseases. 
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Aims: 
 To develop an in vitro model system to dissect the molecular mechanisms regulating 
stem cell mobilisation from the bone marrow 
 To conduct a detailed comparison of bone marrow and lung MSCs to establish a way 
to distinguish between these populations 
 To investigate changes in bone marrow, blood and lung stem cell populations 
associated with a number of inflammatory lung diseases 
  To investigate the trafficking of MSCs into tissue in response to injury 
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CHAPTER 2 
Materials and Methods 
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2.1 Materials 
General laboratory reagents were purchased from Invitrogen (Paisley, UK), or Sigma 
(Poole, UK). Flow cytometry antibodies were purchased as stated in the appendix 
(Appendix Table 9.1). 
 
2.2 Animals 
Female BALB/c or C57BL/6 mice were purchased from Harlan laboratories (Harlan, 
UK).  Mice were used between the ages of 8-14 weeks unless otherwise stated. Where 
mentioned 8-14 week old B6.129S4-Pdgfratm11(EGFP)Sor/J (PDGFRα-GFP) (Jackson, 
USA) mice were used in some studies. Animals were treated according to UK Home 
Office guidelines for animal welfare, based on the Animals (Scientific Procedures) Act of 
1986.  
 
2.3 Animal models 
2.3.1 HDM model of allergic airways disease 
15 µg HDM (Dermatophagoides pteronyssinus in phosphate-buffered saline [PBS]) 
(Greer Laboratories, USA) or, for control mice PBS (Invitrogen, UK), was administered 
intranasally in a 15 μl volume 3 times a week to female Balb/c mice under isofluorane 
anaesthesia, for up to 5 weeks in these studies. Mice were killed 24 hours after the last 
HDM challenge.   
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2.3.2 Bleomycin model of pulmonary fibrosis 
Female C57BL/6 mice weighing between 18-25 g were anaesthetised using isofluorane 
gas. 1.25–2.5 U/kg bleomycin (Sigma Aldrich, UK) was given in a 40 μl volume 
intratracheally. Briefly, mice were suspended by their teeth from surgical thread, and 
intubated using a gavage needle attached to a Hamilton syringe. Mice were allowed to 
recover and subsequently monitored and weighed daily.  Any animal that lost 20% or 
more of its body weight was culled immediately.  
 
2.3.3 Mobilisation studies in response to AMD3100 
For mobilisation studies, 5 mg/kg AMD3100 (Sigma) was injected intraperitoneally 1 
hour before animals were culled. 
 
2.3.4 BrdU assay 
C57BL/6 mice were intratracheally injected with either bleomycin or PBS as previously 
described. Mice were subsequently injected intraperitoneally with 1 mg 5-bromo-2'-
deoxyuridine (BrdU) (BD Biosciences, UK) 24 hours before they were culled.  
 
2.3.5 CXCR3 blocking experiments 
C57BL/6 mice were administered bleomycin or PBS intratracheally as described above. 
1 and 4 days later, mice were injected intraperitoneally with 100 µg of either anti-
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CXCR3 (Clone CXCR3-173) (Biolegend, USA) or an IgG control antibody (Clone HTK888) 
(Biolegend). Mice were culled 3 days later.  
 
2.3.6 VEGF blocking experiments 
Female Balb/c mice were given 15 µg HDM intranasally 3 times a week for 1, 3 and 5 
weeks. In blocking experiments, 3 mg/ml SU5416 (Tocris Bioscience, UK) was given 
intraperitoneally 20 minutes prior to each challenge.  
 
2.3.7 Injection of PαS cells in vivo 
Female C57BL/6 mice were administered bleomycin or PBS intratracheally as described 
above. 3 days later, mice were intravenously injected with 106 DiD-labelled PαS cells (as 
described below) or PBS as a control. Mice were culled 4 days later. 
 
2.4 Tissue harvest and preparation 
2.4.1 Harvest of circulating cells 
Mice were anaesthetised with pentobarbital until unresponsive to stimuli, before a 
cardiac puncture was performed using a 1 ml syringe and a 26 gauge needle, pre-coated 
with and containing 100 µl sodium citrate (Sigma). Blood was centrifuged at 1200 rpm 
for 10 minutes with the brake and acceleration turned to low, and the plasma carefully 
removed and stored at -20⁰C for short-term storage and -80⁰C for long-term storage. 
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Cells were then resuspended in 5 ml lysis buffer (8.29 g/L NH4Cl, 1 g/L KHCO3, 0.0372 
g/L Na2EDTA) and incubated at room temperature for 5 minutes. 10 ml of 10% RPMI 
(Invitrogen) was then added to each tube and cells were centrifuged at 1200 rpm for 5 
minutes. Cells were then washed again as described, before cells were resuspended in 
0.5 ml RPMI (Invitrogen) containing 10% fetal calf serum (FCS) (10% RPMI) ready for 
further analysis. 
 
2.4.2 Harvest of murine bone marrow 
Femurs, and where necessary tibias and iliac crests, were isolated from both mouse 
hind limbs. The bones were cleaned and the bone marrow flushed out with 2 ml of 10% 
RPMI per bone, using a 23 gauge needle and syringe.  The cells were resuspended and 
counted using methylene blue solution.  
 
2.4.3 Bronchoalveolar Lavage (BAL) 
After mice were terminally anaesthetised, an incision was made in the trachea and a 
cannula inserted. Lungs were washed with three lots of 0.4 ml PBS and the lavage fluid 
centrifuged at 1200 rpm for 5 minutes. The supernatant was then divided in half into 
two labelled eppendorfs and frozen at -20⁰C for short-term storage and -80⁰C for long-
term storage. The cell pellet was resuspended in 0.5 ml 10% RPMI and counted using 
methylene blue solution. 
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2.4.4 Preparation of lung digest 
Mice underwent bronchoalveolar lavage before lungs were perfused through the heart 
with 1ml of PBS to remove any residual blood within the lung vasculature. The large 
lobe of the lungs was excised and chopped into small pieces in 1 ml of 10% RPMI. To 
this 4 ml of digest buffer was added, which comprised RPMI without serum, 150 µg/ml 
collagenase IV (Sigma) and 25 µg/ml DNase (Roche, UK).  Lungs were incubated at 37°C 
for 1 hour, whilst shaking, and then immediately placed on ice.  Lung suspensions were 
homogenised using the end of a syringe and then filtered through a 100 µm pore filter 
to create a single cell suspension. Cells were washed twice in 10% RPMI, before being 
resuspended in 2 ml 10% RPMI ready for quantifying cell number and further analysis. 
 
2.4.5 Preparation of spleen 
Spleens were homogenised using the end of a syringe and filtered through a 100 μm 
pore filter in 10% RPMI to create a single cell suspension ready for quantification of cell 
number and further analysis. 
 
2.4.6 Preparation of lungs for EPC assay 
Mice were lavaged and whole lungs excised. Lungs were then prepared as described 
above. After digestion, lung cell suspensions were gently loaded in 2 ml of 10% RPMI 
onto a discontinuous Percoll (Sigma) gradient (75%/60%/45%). Gradients were 
centrifuged at 2000 rpm, at 21⁰C, for 40 minutes, with brake and acceleration set to 0. 
The middle layer of cells (between the 75% and 60% gradients) was carefully taken and 
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washed twice in 10% RPMI. Cells were then enumerated using methylene blue solution, 
ready for plating. 
 
2.4.7 Preparation of lungs for histology 
Lungs were treated as described above. Following perfusion, the top left-hand lobe was 
excised and placed in 10% neutral-buffered formalin at 4°C for 24 hours before being 
processed for wax embedding and cut into 3-4 µm sections. If necessary, sections were 
then stained with either haematoxylin and eosin to look at lung morphology and 
inflammatory infiltrate, or picrosirius red to look at collagen deposition. Sections were 
cut and staining was performed by Lorraine Lawrence (Leukocyte Biology, Imperial 
College London) according to well established protocols. For frozen sections, mice were 
perfused with 50% OCT/PBS through the trachea until the lungs were fully inflated. 
Lungs were then excised and placed on a pre-frozen layer of OCT, before being fully 
embedded in OCT, on dry ice. Lungs were then stored at -80°C until needed.  
 
2.4.8 Lung homogenate 
The lower left-hand lobes of the lungs were excised following perfusion of the lungs, 
and immediately flash frozen in liquid nitrogen, from where they were stored at -20°C 
for short-term storage, and -80°C for longer-term storage. Lungs were weighed and 
homogenised in HBSS (Invitrogen) containing protease inhibitors to a concentration of 
50 mg/ml. The homogenate was then centrifuged at 1600 rpm for 20 minutes, at 4°C. 
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The supernatant was then removed and divided between 2 labelled eppendorfs to avoid 
subsequent cycles of freeze-thawing. Homogenised lungs were then stored at -80°C. 
 
2.5 Cell culture 
2.5.1 Endothelial progenitor cell assay 
1 x 106 cells were added to EPC colony medium (EBM-2 medium (Lonza, USA) + 
supplements: additional VEGF-A165 (50 ng/ml) (Peprotech, UK) and 17% FCS) on 
fibronectin-coated 6-well plates (10 µg/ml) (Sigma).  Plates were incubated at 37°C, 5% 
CO2 for 7 days before medium was changed.  “Early outgrowth colonies”, spindle shaped 
in appearance, were enumerated after 7 days in culture, while “late outgrowth 
colonies”, exhibiting a cobblestone appearance, were incubated for a further 14 days 
before enumeration of EPC colonies.  Colonies of 20 cells or more were scored using an 
inverted microscope. 
 
2.5.2 Haematopoietic progenitor cell assay 
1 x 105 bone marrow cells were added to Methocult medium (StemCell Technologies) in 
35 mm dishes, and were incubated at 37°C, 5% CO2 for 12 days before enumeration of 
HPC colonies.  Colonies of 50 cells or more were counted. 
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2.5.3 Mesenchymal stem cell assay  
5 x 105 bone marrow cells were added to Mesencult medium (StemCell Technologies, 
France) in 35 mm dishes.  Dishes were incubated at 37°C, 5% CO2 for 7 days, before 
medium was changed.  Dishes were incubated for a further 14 days before MSC colonies 
were enumerated. Colonies of 20 cells or more were counted. 
 
2.5.4 Culture of PαS cells 
Bone marrow cells were harvested as described above. Cells were then resuspended in 
12 ml 10% DMEM (Invitrogen) (supplemented with 10% FCS, 1 U/ml heparin (Sigma), 
5 ng/ml bFGF (Peprotech) and 1% Penicillin/streptomycin (Invitrogen)) and plated 
into a T75 flask (4 femurs and 4 iliac crests per flask). Cells were incubated at 37°C, 5% 
CO2 and were passaged after 7 days. To passage cells, medium was removed, cells were 
rinsed once in sterile PBS, and 3 ml trypsin was added. Flasks were placed at 37°C for 5 
minutes before flasks were gently agitated and the detached cells were collected. Cells 
were washed in 10% DMEM and were then either split into new flasks for further 
culture, or used for subsequent studies. 
 
2.5.5 Differentiation assay 
For osteogenic and adipogenic differentiation, bone marrow PαS cells were plated into a 
6 well plate. 3 ml of differentiation medium was added to each well; adipogenic medium 
(0.5 μM dexamethasone (Sigma), 0.5 μM isobutyl-methylxanthine (Sigma), 50 μM 
indomethacin (Sigma) in DMEM + 10% FCS) was added to differentiate cells into 
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adipocytes, and osteogenic medium (10 nM dexamethasone, 10 mM β-
glycerolphosphate (Sigma), 82 μg/ml ascorbic acid-2-phosphate (Sigma) in DMEM + 
10% FCS) was added to differentiate cells into osteocytes. For chondrogenic 
differentiation, 2 x 105 cells were pelleted into 15 ml Falcon tubes. 1 ml of chondrogenic 
medium (10 ng/ml TGF-β1 (R&D Systems, UK), 100 nM dexamethasone, 50 μg/ml 
ascorbic acid-2-phosphate, 100 μg/mL sodium pyruvate Sigma), 40 μg/mL L-proline 
(Sigma), 1X ITS+3 (Sigma), 1.25 mg/ml BSA (Sigma) in serum-free DMEM)  was gently 
added. Cells were incubated at 37°C, 5% CO2 for 3 weeks and medium was changed 
every 2-3 days. 
 
2.5.6 Preparation of PαS cells for injection in vivo 
 PαS cells were trypsinised as described above. They were then resuspended in RPMI 
without serum at a concentration of 106 cells/ml. 2.5 µl DiD (Invitrogen) was added per 
1ml of cells and this was incubated at 37°C for 20 minutes, in the dark. Cells were then 
washed twice, once with RPMI and once with sterile PBS. Cells were then resuspended 
in sterile PBS for injection.  
 
2.6 Flow Cytometry 
2.6.1 Flow cytometric analysis of cell surface markers 
All staining was performed at 4°C and in the dark unless otherwise stated.  Cells were 
resuspended in FACS buffer (1x PBS, 1% bovine serum albumin (BSA), and 0.1% sodium 
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azide).  Cells were incubated with mouse serum (1:10 dilution) (Sigma) at 4⁰C, for 20 
minutes to block Fc receptors.  Specific antibodies conjugated to an appropriate 
fluorophore were then added to the cells and the cells were incubated for 20 minutes.  
Cells were washed 3 times in FACS buffer and finally fixed in BDFix (BD Biosciences) for 
20 minutes at room temperature.  After a final wash, cells were resuspended in FACS 
buffer and either run on a FACS Aria or Fortessa II (BD Biosciences), and analysed using 
FlowJo software (version 7.6.5, Tree Star, USA). Isotype controls and FMO (fluorescence 
minus one) were used to set gates for analysis and in overton subtractions to calculate 
the percentage of a particular population that was positive for an antigen. 
 
2.6.2 Intracellular flow cytometric analysis 
For intracellular staining, cells were stained as described above to detect the desired 
extracellular antigens before being fixed in BDFix overnight at 4oC, after which time, 
they were resuspended in permeabilisation buffer (ebioscience, UK) containing the 
specific antibody conjugated to the appropriate fluorophore.  Cells were incubated for 
20 minutes before being washed and run on the FACS Aria or the Fortessa II, and then 
analysed using FlowJo software.   
 
2.6.3 Flow cytometric analysis using unconjugated fluorophores 
On some occasions a conjugated antibody was not available, therefore it was necessary 
to use unconjugated antibodies, as in the case of NG2. In these instances, cells were 
blocked as described above, before being incubated with the primary antibody for 20 
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minutes at 4⁰C in the dark. Cells were then washed 3 times, before the secondary 
antibodies were added for 20 minutes at 4⁰C in the dark. Cells were washed another 3 
times after this, before they were incubated with conjugated antibodies. Cells were then 
treated as described above. 
 
2.6.4 Flow cytometric analysis of BrdU incorporation 
For flow cytometric detection of BrdU incorporation the FITC-conjugated BD 
Pharmingen BrdU Flow Kit was used (BD Biosciences). Cells were stained as per the 
manufacturer’s instructions. Briefly, cells were stained for detection of cell surface 
markers before being fixed in BDFix overnight at 4oC. The following day, cells were 
washed in FACS buffer ready for detection of BrdU incorporation. Cells were 
resuspended in BD Cytofix/Cytoperm Buffer and incubated for 15 minutes on ice. Cells 
were then washed in 1X BD Perm/Wash before being resuspended in BD Cytoperm 
Permeabilization Buffer Plus and incubated for 10 minutes on ice. The cells were 
washed again in 1X BD Perm/Wash Buffer and re-fixed in BD Cytofix/Cytoperm Buffer 
for 5 minutes on ice before being washed again in 1X BD Perm/Wash. Cells were then 
incubated in 300 µg/ml DNase for 1 hour at 37oC to expose incorporated BrdU. Cells 
were washed again in 1X BD Perm/Wash Buffer and resuspended in 50 µL of BD 
Perm/Wash Buffer containing diluted FITC-conjugated anti-BrdU for 20 minutes at 
room temperature. Cells were finally washed in 1X BD Perm/Wash Buffer and run on 
the Fortessa II, and analysed using FlowJo software.  
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2.7 Immunofluorescent staining 
2.7.1 Endothelial cell immunostaining 
Isolated endothelial cells were grown on chamber slides in the appropriate cell culture 
conditions.  Cells were analysed for uptake of acetylated low-density lipoprotein 
(AcLDL) (Invitrogen) and were stained with Griffonia simplicifolia lectin (GS-lectin) 
(Invitrogen). 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchorate (Dil)-
labelled AcLDL was added to EGM2-MV medium (5 µg/ml) (Lonza) and incubated at 
37°C for 4 hours.  Cells were washed with PBS and fixed with 2% paraformaldehyde, 
before they were incubated with Alexa488-conjugated GS-lectin (10 µg/ml in PBS) for 1 
hour. 
 
2.7.2 Immunofluorescent staining of lungs 
6 μm thick sections were cut from frozen lung blocks from PDGFRα-GFP mice. Sections 
were fixed for 10 minutes at room temperature in 1% paraformaldehyde, before being 
washed twice in PBS. Sections were then blocked for 2 hours at room temperature in 
the dark, in PBS/5% normal donkey serum/0.2% BSA/0.3% Triton-X (Sigma). Primary 
antibodies were then added and sections were incubated overnight at room 
temperature in the dark: rabbit α-mouse EpCAM (1:200) (Abcam, UK) and APC-labelled 
Sca-1 (1:100) (ebioscience). Sections were washed for 1 hour in PBS and secondary 
antibodies added: donkey α-rabbit Alexa546 (1:400) (Invitrogen). Sections were 
incubated for 2 hours at room temperature in the dark before being washed for 1 hour 
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in PBS. Sections were mounted in DAPI-Vectashield (Dako). Sections were imaged on a 
Zeiss LSM-510 with the help of Dr. J. Johnson.  
 
2.8 Staining of differentiated culture expanded PαS cells 
For adipogenic differentiation, cells were fixed with 4% paraformaldehyde for 1 hour at 
room temperature, before being incubated in Oil Red O (Sigma) consisting of 3 parts Oil 
Red O solution (3.75% in isopropanol) and 2 parts distilled H2O at room temperature 
for a further 10 minutes. The cells were then rinsed in distilled water and 
photographed.  For osteogenic differentiation, cells were rinsed with PBS and then 
incubated in a 2% solution of Alizarin Red S (Sigma) for 5 minutes at room temperature. 
Cells were then rinsed in distilled water and photographed. For chondrogenic 
differentiation, cell pellets were fixed in 4% paraformaldehyde for 10 minutes at room 
temperature and washed in 1x PBS. Pellets were then embedded in OCT medium and 
frozen. 7 μm sections were cut and stained with 1% toluidine blue for 10 minutes at 
room temperature. Sections were washed dH2O before being mounted and imaged. 
 
2.9 Quantification of vessels in the lungs 
Lung sections cut from paraffin-embedded lungs were dewaxed in 3 changes of 
histoclear, each for 5 minutes, before being rehydrated through 100%, 90% and 75% 
alcohol to water for 30 seconds at each stage. Slides were then incubated in PBS for 5 
minutes at room temperature. Antigen retrieval was then performed by incubating lung 
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sections with proteinase K (1:1000 dilution) for 10 minutes at 37⁰C. Following this, 
slides were washed twice in PBS before being incubated in 30% H2O2 (Sigma) in 
methanol for 30 minutes at room temperature to remove endogenous peroxidase 
activity. Slides were then washed twice with PBS for 5 minutes each wash. Avidin 
(Vector Labs) binding complex was then added for 15 minutes at room temperature, 
after which time sections were washed twice in PBS for 5 minutes each time, before the 
biotin binding complex was added and sections incubated for a further 15 minutes at 
room temperature, and sections were again washed twice in PBS for 5 minutes each 
wash. Sections were then incubated with 10% donkey serum for 20 minutes at room 
temperature to block non-specific binding. The donkey serum was then removed and 
either rabbit anti-human von Willebrand Factor (vWF), which has been shown to cross-
react with murine vWF [245] (1:200, Dako) or the equivalent concentration of isotype 
control antibody was added and the sections incubated for 1 hour at room temperature. 
Slides were then washed twice for 5 minutes each in 0.1% PBS/Tween (Sigma) and then 
incubated with biotinylated anti-rabbit (1:250) for 45 minutes at room temperature. 
Again, slides were washed twice in PBS/Tween as before. Sections were then incubated 
with the streptavidin complex (Santa Cruz, USA) for 45 minutes at room temperature 
before being washed in PBS/Tween as before. Finally sections were incubated with 3,3'-
Diaminobenzidine (DAB) substrate to develop the staining until a brown colour was 
visible. Slides were then fixed in water for 10 minutes, before being stained in 
haematoxylin for 30 seconds and then washed with water. Sections were then 
dehydrated in ethanol and histoclear in the reverse of what was done previously. 
Following this, slides were mounted with histomount solution. vWF+ peribronchial 
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vessels were then enumerated either per mm2 or per airway in a minimum of four 
airways per section. For this, medium size airways were selected, approximately 30 μm 
in diameter, and vessels up to 10 μm away from the airway were counted.  
 
2.10 Quantification of collagen deposition 
Collagen content in the lungs was measured using a Sircol Assay (Biocolor, UK), as per 
the manufacturer’s guidelines. Briefly, lung homogenates were incubated with Sircol 
Dye Reagent, before being washed with Acid-Salt Wash Reagent and finally incubated 
with Alkali Reagent to dissolve all of the bound dye. Absorbance was read on a Tecan 
Sunrise microplate reader set to 555 nm.  
 
2.11 Measurement of VEGF concentration in the lungs 
VEGF concentrations were measured in homogenised lung samples using paired 
antibodies in a sandwich ELISA according to the manufacturer’s protocol (R&D Systems, 
UK). 
 
2.12 Statistical analysis 
Data are expressed as the mean ± SEM.  Data were analysed using the Mann-Whitney U 
test or Kruskal-Wallis.  All statistical analyses were carried out using GraphPad Prism 
software (version 4.3, GraphPad, USA).  P values <0.05 were considered to be significant 
(* denotes P<0.05, ** denotes P<0.01, *** denoted P<0.001). 
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CHAPTER 3 
Molecular and functional characterisation of 
bone marrow sinusoidal endothelial cells 
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3.1 Introduction 
The bone marrow serves as a reservoir for leukocytes and stem cells, from where cells 
can be mobilised into the circulation to carry out their desired roles. This mobilisation 
of stem cells and mature leukocytes is dependent on their migration across the 
sinusoidal endothelium [11]. As previously described, this process is thought to take 
place via a transcellular route [11, 22], and happens under homeostasis [4], but 
importantly in inflammatory disease, when subpopulations of leukocytes and stem cells 
are rapidly mobilised into the circulation in response to inflammatory stimuli [17, 23-
26]. Throughout the body there are a number of vascular beds with different specialised 
functions, and the bone marrow sinusoidal endothelium is an example of one of these. It 
exhibits the unique ability to regulate the release of leukocytes and stem cells into the 
circulation, but to date it has been very poorly characterised and the mechanisms by 
which it regulates this release remain unclear.  
 
Given the unique function of the bone marrow sinusoidal endothelium, it is reasonable 
to hypothesise that it is structurally and functionally different to endothelia from other 
vascular beds. Indeed a number of studies have suggested this to be the case. 
Interestingly, VCAM-1, E-selectin and P-selectin, which are usually only expressed on 
endothelial cells under inflammatory conditions, have been shown to be constitutively 
expressed on the bone marrow sinusoidal endothelium [12-14]. Further to this it has 
recently been shown that VEGFR3 is expressed on bone marrow sinusoidal endothelial 
cells and is absent from the bone marrow vascular endothelium [18]. These differences 
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in expression of cell surface antigens suggest that the bone marrow sinusoidal 
endothelium is functionally different to endothelia from other sources; however the 
molecular mechanisms underlying bone marrow endothelial transcellular migration 
have not yet been explored in great detail.  
 
The unique and important function of the bone marrow in controlling the mobilisation 
of cells into the circulation both in homeostasis and under inflammatory conditions 
makes it interesting to investigate how the bone marrow sinusoidal endothelium differs 
from other endothelial beds. Not only this, but it is also possible that the bone marrow 
endothelium is fundamentally changed by the cytokine milieu in inflammatory disease 
and that the mechanisms by which it controls the release of cells are changed. It has 
been suggested that the bone marrow endothelium is altered in a murine model of 
diabetes, with mice showing decreased numbers of endothelial cells, a decreased 
capacity of these cells to migrate and form networks, as well as increased permeability 
and adhesiveness to mononuclear cells [246]. This would be likely to affect the 
mobilisation of certain cell types, but it remains to be established as to whether this is 
also the case in other inflammatory diseases.  
 
The molecular mechanisms which regulate the migration of leukocytes from the blood 
into inflamed tissues have been extensively studied using in vitro models of 
transmigration [247, 248]. However, to date the molecular mechanisms which regulate 
transcellular migration and cell egress from the bone marrow have been poorly 
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characterised. The aim of this work was therefore to phenotypically characterise the 
bone marrow sinusoidal endothelium in terms of the expression of cell surface markers, 
and importantly to functionally characterise these endothelial cells in terms of 
migration of cells across an endothelial monolayer, by setting up an in vitro system to 
study transmigration. In these studies endothelial monolayers from other tissues, such 
as the brain and lungs, would be used as a comparison, to increase our understanding of 
how bone marrow endothelial cells differ to endothelial cells from other vascular beds, 
and to provide further insights into which features of the bone marrow endothelium are 
important in regulating stem cell and leukocyte transmigration. Further to this, such 
studies would also be valuable in allowing the phenotypic and functional 
characterisation of bone marrow endothelial cells from specific inflammatory diseases 
to be carried out which would increase our understanding of the changes that occur to 
these cells in an inflammatory disease setting and how this might affect the mobilisation 
of cells from the bone marrow into the circulation. 
 
Endothelial cells have been successfully isolated from a variety of organs, including skin, 
brain and liver. However, at the onset of this project no successful isolation protocol had 
been established to isolate murine bone marrow sinusoidal endothelial cells. In order to 
investigate the structure and function of bone marrow endothelial cells (BMECs) it was 
necessary to grow these cells in culture as a monolayer of cells, representative of the 
bone marrow endothelium in vivo.  The initial aim of this project was therefore to 
establish a protocol to isolate murine BMECs. This would generate a useful tool to 
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characterise the bone marrow sinusoidal endothelium both in terms of structure and 
function as described above.  
 
3.2  Aims 
 To develop a protocol to isolate bone marrow sinusoidal endothelial cells 
 To optimise cell culture conditions to grow and expand bone marrow sinusoidal 
endothelial cells in vitro 
 To develop protocols to isolate brain and lung endothelial cells to use as a 
comparison to bone marrow endothelial cells 
 To characterise the bone marrow sinusoidal endothelium in vitro in terms of 
expression of cell surface markers and compare it to endothelial cells from brain 
and lungs 
 To investigate the functionality of the bone marrow sinusoidal endothelium by 
studying neutrophil and stem cell transmigration across a bone marrow 
endothelial cell monolayer in response to chemokines and cytokines 
 To characterise and investigate the functionality of the bone marrow sinusoidal 
endothelium in inflammatory disease 
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3.3 Results 
3.3.1 Isolation and culture of bone marrow endothelial cells 
Optimisation of a technique to isolate BMECs was initially carried out in collaboration 
with Dr. P. Turowski at University College London, who has expertise in isolating 
endothelial cells and has established a protocol for the isolation and culture of rat brain 
microvascular endothelial cells [249].  Isolation of endothelial cells in general is thought 
to be much more challenging when dealing with mouse cells compared to rat, and 
therefore the first step in the optimisation process was to isolate BMECs from rat, by 
modifying the protocol used in Dr. Turowski’s laboratory.  Various different methods 
were compared (Figure 3.1), but the optimal protocol consisted of a 30 minute digestion 
step with 1 mg/ml collagenase/dispase to separate the cells, followed by purification on 
a BSA column, and further digestion for 1 hour.  Cells were then further purified on a 
pre-equilibrated 50% Percoll gradient before plating on fibronectin/collagen IV coated 
dishes in EGM2-MV medium; culture conditions that have been shown to be optimal for 
growing rat brain endothelial cells.  Isolated BMECs showed characteristic cobblestone 
morphology (Figure 3.2A).  However, the yield of endothelial cells was very low, with 
the majority of the cells exhibiting a stromal morphology (Figure 3.2B). 
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Figure 3.1 Optimisation a protocol to isolate murine bone marrow endothelial cells 
Diagram showing the different methods used to optimise a protocol to isolate murine bone marrow 
endothelial cells. Endothelial media tried: EGM2 (Lonza) or EGM2-MV (Lonza) ± murine recombinant VEGF-
A165 (0.05 µg/ml), ± heparin (1 ng/ml) or DMEM + 1% penicillin/streptomycin, 1% endothelial cell growth 
factor, 1% heparin, 20% FCS. 
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Although the yield of BMECs from rat was low we proceeded to modify this protocol to 
isolate cells from mouse.  The main objective was to minimise cell loss during 
purification and the protocol was therefore simplified by removing the BSA column.  
The first successful BMEC preparation was obtained from mice that had been pre-
treated with VEGF-A165 for 4 days (Figure 3.2C).  The protocol consisted of a 30 minute 
digestion step with collagenase (250 μg/ml) and DNase I (125 μg/ml), before cells were 
separated on a discontinuous Percoll gradient (70%/60%/40%).  Cells were isolated 
from the middle layer, plated on fibronectin-coated plates, and grown in EGM2-MV 
medium.  These cells had cobblestone morphology, and grew as a ‘lawn’ of cells. The 
yield of cells obtained was quite low, with only about 1-3 million mononuclear cells 
obtained per mouse, which was only enough to plate into one well of a 6-well plate. 
Cells failed to grow after re-plating in order to expand these cells. Flow cytometry was 
used to attempt to verify that these cells were endothelial, using antibodies to detect 
CD45neg CD31pos VEGFR2pos GS-lectinpos cells, however, this was not successful, and 
given the low yield of cells, a further attempt was not possible. 
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Figure 3.2 Isolation of bone marrow endothelial cells 
Bone marrow endothelial cells obtained using two different isolation protocols. Endothelial cells isolated 
from rat bone marrow, grown on collagen IV/fibronectin-coated plates, in EGM2-MV medium. 20x 
magnification (A). Contaminating cells in endothelial culture from rat bone marrow preparation. 40x 
magnification (B).  Endothelial cells isolated from the bone marrow of mice pre-treated with 2.5 µg VEGF-
A165/mouse, given intraperitoneally for 4 days, bone marrow collected on day 5. Cells grown on 
fibronectin-coated plates, in EGM2-MV medium. 20x magnification (C).   
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After further optimisation of the isolation protocol and the culture conditions, BMECs 
were successfully isolated from naïve mice (Figure 3.3).  Critically, endothelial medium 
was supplemented with murine recombinant VEGF-A165 (0.05 µg/ml) and heparin (1 
ng/ml).  These cells had cobblestone morphology (Figure 3.3A) and showed 
characteristic endothelial staining; stained with GS-lectin and took up labelled Ac-LDL, a 
functional characteristic of endothelial cells (Figure 3.3B). In this endothelial cell 
preparation there was, however, still a large population of cells with stromal 
morphology, which would need to be reduced in order to achieve a pure culture of 
BMECs.  
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3.3.2 Optimised protocol for isolating bone marrow endothelial cells 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Murine bone marrow endothelial cells obtained from optimised isolation protocol 
Endothelial cells isolated from mouse bone marrow, grown on fibronectin-coated plates, in EGM2-MV medium, 
supplemented with mouse recombinant VEGF-A165 (0.05 µg/ml) and heparin (1 ng/ml) (A). Endothelial cells 
isolated from mouse bone marrow, stained with GS-lectin-Alexa488 and Dil AcLDL, 200x magnification (B). 
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During the course of this project, Oikawa et al. reported a method to successfully isolate 
endothelial cells from the murine bone marrow [246]. Using this method, the optimised 
protocol described above was further modified to try to improve the yield and purity of 
the cells obtained. In this protocol femurs were flushed and bone marrow suspensions 
were homogenised but not digested. The resulting bone marrow cell suspension was 
then depleted for haematopoietic cells, using magnetic beads against the CD45 antigen. 
Cells were then plated on 0.1% gelatin-coated plates and grown in DMEM supplemented 
with 20% serum and acetyl-Ser-Asp-Lys-Pro (AcSDKP), which is a breakdown product 
of thymosin β4 and has been reported to enhance endothelial cell proliferation in vitro 
[250, 251] (Figure 3.4A). Isolated cells showed cobblestone morphology typical of 
endothelial cells and formed a lawn of cells rather than colonies (Figure 3.5B), 
suggesting that they were mature endothelial cells rather than progenitors. This cell 
culture was stained with an antibody to vWF, a known endothelial marker, and 
enumeration of vWF-positive cells showed this culture to be about 85% pure for 
endothelial cells (Figure 3.4C). 
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Figure 3.4 Optimised protocol for isolating murine bone marrow endothelial cells 
Schematic of the protocol established to isolate endothelial cells from murine bone marrow (A). Image of 
endothelial cells isolated from mouse bone marrow, grown on gelatin-coated plates, in DMEM, 
supplemented with AcSDKP (1 nM) and 20% FCS. 20x magnification, insert 40x magnification (B). Endothelial 
cells isolated from mouse bone marrow, stained for vWF. 40x magnification (C). 
 
85% vWF+ 
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3.2.2 Culture of brain and lung endothelial cells 
In order to determine whether BMECs are in fact structurally and functionally different 
to endothelial cells from other vascular beds, endothelial cells needed to be isolated 
from other organs as a comparison.  Brain endothelial cells were chosen to use as an 
effective protocol to isolate murine brain microvascular endothelial cells has already 
been established in Dr. Turowski’s laboratory (Figure 3.5).  The isolation protocol 
works on the basis that ‘vessel fragments’ are generated during the preparation and 
then purified, from which brain endothelial cells spread (Figure 3.6A).  
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Figure 3.5 Optimisation of a protocol to isolate murine endothelial cells from brain and lungs 
Diagram showing developed protocols for isolating murine endothelial cells from brain and lungs. 
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The brain microvascular endothelium, the main component of the blood brain barrier, is 
unique in itself, exhibiting the selective ability to restrict the movement of cells and 
molecules from the circulation into the cerebrospinal fluid.  For this reason, an 
endothelium that is thought to be more representative of endothelial cells in general, 
lung endothelium, was chosen in addition to brain endothelium as a comparison to 
BMECs.  Optimisation of a protocol to isolate murine lung endothelial cells was carried 
out in collaboration with Dr. Turowski.  Lung endothelial cells were obtained using the 
protocol developed so far (Figure 3.5) and these cells showed endothelial 
characteristics; cobblestone morphology, staining with GS-lectin and taking up labelled 
Ac-LDL (Figure 3.6B and 3.6C).  However, the yield of lung endothelial cells obtained 
was low, with only half a million cells isolated from 1 mouse, and there were still a large 
number of cells of stromal morphology present in the culture. Therefore further 
optimisation of this protocol would be necessary if these cells were to be used as a 
comparison to bone marrow endothelial cells.  
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Figure 3.6 Isolation of murine brain and lung endothelial cells 
Endothelial cells isolated from the murine blood brain barrier, grown on collagen I-coated plates, in 
EGM2 medium. Arrow shows vessel fragment with endothelial cells spreading out from it. 5x 
magnification (A). Endothelial cells isolated from mouse lung, grown on fibronectin-coated plates, in 
EGM2-MV medium, supplemented with mouse recombinant VEGF-A165 (0.05 µg/ml) and heparin (1 
ng/ml). 10x magnification (B). Endothelial cells isolated from mouse lung, stained with GS-lectin-
Alexa488 and Dil AcLDL, 20x magnification (C). 
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3.4 Discussion 
To date very little is known about the structure and function of the bone marrow 
sinusoidal endothelium but given its unique role in selectively regulating the 
mobilisation of cells from the bone marrow into the circulation, and their homing back 
again, it seems likely that it has specific characteristics, which make it distinct from 
endothelial cells from other vascular beds and give it its unique function.  To investigate 
whether this is indeed the case, it would be necessary to develop a technique to isolate 
endothelial cells from murine bone marrow in order to grow them in culture so that 
they could be characterised in terms of their structure and function.  However, at the 
onset of this project, no reproducible protocol had been established to isolate 
endothelial cells from murine bone marrow and to grow them in culture.   
 
Various isolation methods were compared in this study (Figure 3.1).  The initial aim of 
this project was to isolate endothelial cells from mouse, as this is the system that would 
enable the most effective studies to be carried out, due to the availability of knockout 
mice and mouse reagents, such as antibodies and cytokines.  Therefore, having 
established some basic principles for isolating BMECs from rat, this protocol was 
refined to isolate endothelial cells from mouse.  The first BMECs that were successfully 
isolated were from mice pre-treated with VEGF-A165 for 4 days (Figure 3.2B).  When the 
same isolation protocol was carried out using naïve mice, no BMECs were successfully 
isolated, suggesting that the VEGF-A165 pre-treatment was enhancing endothelial cell 
isolation.  The effect of VEGF-A165 pre-treatment on the bone marrow endothelium has 
 ~ 98 ~ 
 
not previously been studied, although previous work in the laboratory has shown that it 
enhances the mobilisation of EPCs and MSCs, whilst blocking the mobilisation of 
neutrophils, from the bone marrow when administered in combination with a CXCR4 
antagonist, AMD3100 [196].  VEGF-A165 is a well-known growth and survival factor for 
endothelial cells [252, 253] and it is possible that VEGF-A165 acts on the endothelium 
itself, enabling endothelial cells to be isolated or enhancing their growth in culture, 
possibly by stimulating proliferation.  From these results it is not possible to conclude 
the effect of VEGF-A165 pre-treatment on the endothelium, and further analysis of these 
isolated cells would be necessary to gain a better understanding. It is worth noting that 
this isolation protocol was attempted a number of times and the results were quite 
variable in terms of recovered yield and growth in culture, suggesting that this 
technique needs further optimisation. 
 
Having further optimised the isolation protocol, critically by adding heparin to the 
medium, BMECs were successfully isolated from naïve mice.  Heparin has been shown 
to stimulate endothelial cell proliferation [254], therefore, it is possible that it acts by 
enhancing the growth of the isolated endothelial cells in culture. Again this isolation 
protocol was not very reproducible and it was not possible to expand the cells, 
therefore further optimisation of this protocol was necessary. 
 
In 2009, Oikawa et al. [246] published data using endothelial cells isolated from murine 
bone marrow. In this method they supplemented their growth medium with AcSDKP, 
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which is a peptide generated in the breakdown of thymosin β4 and has been shown to 
enhance the proliferation and survival of endothelial cells [250, 251]. The protocol for 
isolating endothelial cells from the bone marrow that had been optimised up to this 
point was then further modified using the method from Oikawa et al. [246] to try to 
improve the yield, purity and reproducibility. The results of this isolation were very 
promising, with cells exhibiting cobblestone morphology and 85% of them staining 
positive for vWF, a marker of endothelial cells (Figure 3.4). Unfortunately, on 
attempting to expand the cells for further analysis, cells failed to grow and eventually 
died. Furthermore, on attempting the isolation protocol again, a successful culture was 
not generated as in the previous attempt. It is interesting to note, that nothing further 
has been published using this method since the original paper in 2009 and in a personal 
communication with P. Madeddu, he stated that his protocol was very variable. 
 
Although, an endothelial cell culture was generated from murine bone marrow and 
shown to be 85% pure for endothelial cells, there were still significant limitations with 
this project which made it prudent not to continue with it, particularly given time 
constraints. Probably the biggest limitation was the lack of reproducibility of any of the 
protocols attempted. Although the final established protocol was certainly an 
improvement on previous methods, it still did not result in the generation of a pure 
endothelial culture every time it was attempted. This would be problematic if trying to 
isolate endothelial cells to use in experiments, and would limit the usefulness of this 
technique. In addition to this, the yield of cells generated was still very low, and 
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attempts to expand the cells were unsuccessful, which again raises the question of how 
useful this technique would be in an experimental setting. Notably, the low yield of cells 
isolated and the inability to expand them hampered the ability to thoroughly 
characterise these cells and to confirm that they were in fact endothelial cells. 
 
The initial aim of this project was to establish a protocol for isolating sinusoidal 
endothelial cells from the bone marrow. However, it is likely that the optimised culture 
generated (Figure 3.4) contained vascular endothelial cells as well as sinusoidal ones. In 
a recent paper it was shown that VEGFR3 expression is specific to sinusoidal and not 
vascular endothelial cells [18].  The endothelial culture isolated was fluorescently 
stained for VEGFR3 to establish the percentage of sinusoidal endothelial cells present, 
however this staining was unsuccessful. It is possible that this antigen, in combination 
with other endothelial markers, could be used in future to isolate bone marrow 
sinusoidal endothelial cells by fluorescence-activated cell sorting (FACS), however given 
how sensitive these cells appear to be, it is unlikely that a technique as harsh as FACS 
would be appropriate.   
 
As well as contamination with vascular endothelial cells, it is also likely that the 
endothelial culture generated (Figure 3.4) also contained a contamination of EPCs. 
Although cells grew as a ‘lawn’ of cells rather than as colonies, suggesting that the 
majority of cells were mature endothelial cells rather than EPCs, it is highly likely that 
some EPCs were present given that they would be contained in the non-haematopoietic 
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fraction of the bone marrow and would be likely to thrive in the endothelial medium 
used. Again, the limited yield of cells isolated hampered the ability to analyse these cells 
to establish the degree of contamination by EPCs. 
 
Even though a good culture of brain microvascular endothelial cells could be 
reproducibly generated, the yield and purity of lung endothelial cells isolated needed 
further optimisation and more extensive characterisation. However, given time 
constraints this was not possible during the course of this project. 
 
In this work, the final protocol optimised to isolate endothelial cells from murine bone 
marrow generated encouraging results, with cells exhibiting cobblestone morphology 
and 85% of them staining positive for vWF, suggesting them to be endothelial. However, 
given the limitations described above, particularly the lack of robust reproducibility of 
the protocol and the low yield of cells generated, it was decided not to continue with 
this project.  
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4.1 Introduction 
Until recently, mesenchymal stem cells (MSCs) have been isolated from various tissues 
and studied based on their capacity to adhere to plastic surfaces. It is now generally 
accepted that this method produces a heterogeneous population of cells, of mixed 
morphology and stages of commitment, within which the putative mesenchymal stem 
cell lies. Methods of isolation and expansion are not standardised between labs and 
consequently there has been a lack of a unifying definition to identify murine MSCs. In 
vitro manipulation of MSCs may alter their properties and profile, with different studies 
showing MSCs to express a different profile of surface markers and growth factor 
receptors. It is therefore possible that some of the characteristics that are associated 
with this progenitor cell type may in fact be an artefact of culturing these cells. 
Importantly, the reliance on characterisation of cultured cells has also severely limited 
the study of the properties and function of these cells in vivo. In contrast, HSCs, which 
can be isolated based on their expression of certain surface markers, have been 
extensively studied in vivo, and their biology is consequently well understood.  
 
Stem cell antigen-1 or Sca-1, has long been used as a stem cell marker but has been 
shown to be expressed by all populations of stem cells, including HSCs, MSCs and EPCs. 
In 2009, Morikawa et al. set out to determine a pattern of antigen expression that would 
allow for the prospective identification of bone marrow MSCs in vivo [86]. A population 
of cells was reported which was negative for the haematopoietic markers CD45 and 
Ter119, positive for Sca-1 and also for Platelet-derived growth factor receptor α 
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(PDGFRα). Of the CD45- and Ter119-negative cells, they observed four distinct 
subpopulations based on expression of Sca-1 and PDGFRα.  Interestingly, they found 
that in a traditional CFU-F assay, the PDGFRα+ Sca-1+ (PαS cell) subpopulation formed 
the highest number of colonies with mesenchymal morphology, compared with the 
other subpopulations, which formed a lower frequency of colonies and showed different 
morphologies. They also demonstrated that it was the PαS cell population which had the 
highest proliferative capacity and showed the most robust differentiation into 
adipocytes, chondrocytes and osteocytes. In addition, PαS cells were transplanted in 
vivo and were shown to repopulate haematopoietic niche components, including 
perivascular reticular cells and osteoblasts, as well as adipocytes in adipose tissue [86]. 
Importantly, this study highlighted a specific cell population with MSC-like 
characteristics, which can be identified by their expression of cell surface markers, 
therefore enabling the properties and function of MSCs to be studied in vivo. It is 
possible that PαS cells represent the true mesenchymal stem cells, while the other 
subpopulations represent progenitor cells. 
 
MSCs were first isolated from the bone marrow but have since been identified, by 
plastic adherence and colony formation, in a range of tissues within the body, including 
muscle, adipose tissue, lungs, kidney, liver and spleen and are thought to be found in 
close association with the vasculature [83, 255]. MSCs isolated from different tissues 
have been shown to exhibit similar morphology, along with expression of characteristic 
MSC markers. However, their differentiation potential appears to differ depending on 
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their tissue of origin, for example muscle-derived MSCs show poor osteogenic 
differentiation, while lung-derived MSCs show greatest propensity for chondrogenic 
differentiation and require a longer induction period for adipogenic differentiation than 
bone marrow MSCs [83, 256, 257]. Studies comparing MSCs derived from different 
tissues were carried out on culture expanded cells, which, although informative, may be 
affected by culture-induced changes to cells and gives limited information about the 
properties and function of these cells in vivo [83, 256, 258]. Bone marrow MSCs have 
been suggested to support haematopoiesis [182, 183], however it is currently unclear 
what the role of endogenous tissue-resident MSCs are and whether MSCs from different 
tissues have different properties and functions in vivo.  This has important implications 
for stem cell therapies as many studies are using MSCs derived from adipose tissue, as 
well as other sources.  
 
Recent studies examining stem cell populations in the lungs have used Sca-1 to identify 
progenitor cells. While recently Sca-1pos EpCAMpos cells have been suggested to 
represent epithelial progenitor cells in the lungs [220, 222, 234], no specific markers 
have been shown to definitively identify lung MSCs. Despite this, MSCs have previously 
been described in the murine lungs and different groups have identified lung MSCs 
using different combinations of markers. For example, in one study, a population of 
mesenchymal progenitor cells were identified within the CD45neg CD31neg side 
population (SP) of the lungs, expressing the MSC markers Sca-1, VCAM-1 and CD44 
[221]. In another study, MSCs were identified in the lungs as CD45neg CD31neg Sca-1pos 
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CD34pos and were localised to the parenchyma of the distal lungs [219]. To date lung 
MSCs have only been minimally studied and it is currently unclear whether lung and 
bone marrow MSCs are distinct. In a recent study McQualter et al. showed that the Sca-
1-positive population in the lungs constituted a mixture of bronchioalveolar stem cells 
(BASCs) and mesenchymal stem cells, which could be resolved based on their 
expression of EpCAM and their level of Sca-1 expression: MSCs were suggested to be 
positive for Sca-1, but negative for EpCAM, while epithelial progenitor cells were said to 
show low expression of Sca-1, but express EpCAM [220]. While BASCs were shown to be 
localised to the bronchoalveolar duct junction (BADJ) [218], it is still unclear where 
MSCs are localised in the lungs.  One recent study suggested lung MSCs had a 
perivascular localisation, however the markers they used to identify these cells were 
those used to identify pericytes rather than MSCs [241]. There have been only a limited 
number of studies investigating differences between bone marrow and lung MSCs, and 
much still remains unknown. One study suggested that the two populations were 
similar in terms of phenotype and immunomodulatory properties, however, lung MSCs 
showed a greater propensity for epithelial polarisation after in vitro treatment with 
retinoic acid [241]. 
 
It is well known that exogenously administered MSCs can migrate into tissues from the 
circulation, and although the mechanisms by which this process occurs remain unclear, 
it is likely that chemokines and their receptors are involved, as they are known to be 
important in directing cell recruitment. Indeed it has been shown that chemokines are 
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involved in the migration of a number of other subsets of bone marrow progenitor cells: 
CXCL12 and its receptor CXCR4 have been shown to be involved in the migration of 
HSCs and EPCs [190, 259, 260], as well as the chemokines CXCL1 and CXCL2 and their 
receptor CXCR2 in the migration of EPCs into tissue in response to allergen [67].  
 
I sought to further characterise the bone marrow PαS cells identified by Morikawa et al. 
with respect to their chemokine receptor expression and to investigate whether I could 
identify a population of mesenchymal stem cells in the lungs based on the profile of 
markers proposed by Morikawa et al. [86]. Furthermore, I sought to investigate 
whether lung MSCs could be distinguished from bone marrow MSCs in terms of cell 
surface expression and chemokine receptor expression. 
 
4.2 Aims 
 To establish whether a population of PαS cells can be identified in the murine 
lungs 
 To characterise and compare PαS cells from the bone marrow and lung in terms 
of expression of cell surface markers, in particular characteristic MSC markers 
 To investigate the differentiation potential of bone marrow and lung PαS cells 
 To analyse the chemokine receptors expressed on the cell surface of PαS cells 
from the bone marrow and lungs 
 To examine the localisation of PαS cells in the lungs 
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 To investigate how the PαS cell population in the bone marrow and lungs 
changes with age 
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4.3 Results 
4.3.1 PαS cells can be identified in the lungs as well as in the bone marrow 
Morikawa et al. identified a population of cells in the bone marrow which were negative 
for the haematopoietic markers CD45 and Ter119, and positive for Sca-1 and PDGFRα 
[86]. In the work presented here, the same population of cells was detected in the bone 
marrow by flow cytometry (Figure 4.1A). These cells constitute a very small percentage 
of the bone marrow, only 0.1% (Figure 4.1E). In the lungs a similar population of cells 
was detected, but with a subpopulation expressing higher levels of Sca-1 (Figure 4.1C) 
and PDGFRα (Figure 4.1D) than those in the bone marrow. The proportion of PαS cells 
in the lungs is much greater than in the bone marrow, with these cells constituting 
about 5% of all lung cells (Figure 4.1E).  
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Figure 4.1 Comparison of CD45
neg 
Ter119
neg
 PDGFRα
pos
 Sca-1
pos
 cells in the bone marrow and lungs 
Bone marrow (A) and lung (B) cells from C57BL/6 mice were stained with antibodies to identify PαS cells 
and analysed by flow cytometry. Live cells were gated by FSC/SSC, of which CD45/Ter119-negative cells 
were selected. This population was analysed for expression of Sca-1 and PDGFRα based on isotype controls. 
Sca-1 (C) and PDGFRα (D) expression levels on PαS cells were compared for bone marrow and lungs. Mean 
fluorescent intensity (MFI) shown. CD45
neg
 Ter119
neg
 PDGFRα
pos
 Sca-1
pos
 percentage of live cells was 
calculated for the bone marrow and lung. Bars represent mean ± SEM. * p < 0.05, n=4 (E). 
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In the bone marrow, the size of PαS cells was small in comparison to bone marrow 
leukocytes, with low granularity (Figure 4.2A and 4.2B). In contrast, although still 
relatively small in size in comparison to leukocytes, the PαS cells in the lungs were 
larger than those in the bone marrow and showed greater flow cytometric side scatter, 
indicating a greater degree of granularity than bone marrow PαS cells (Figure 4.2A and 
4.2B).   
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Figure 4.2 Analysis of the size of PαS cells in the bone marrow and lungs 
Bone marrow and lung cells from C57BL/6 mice were stained with antibodies to identify PαS cells and 
analysed by flow cytometry. PαS cells (green) were back-gated onto the total lung and bone marrow FSC/SSC 
scatters showing CD45
neg 
Ter119
neg
 cells (orange) and total cells (red) (A). Histograms of the FSC and SSC of 
lung (red) and BM (black) PαS cells were overlaid for comparison (B).  
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4.3.2 Cell surface antigen expression profile of PαS cells in the bone marrow and 
lungs 
In the laboratory we can culture bone marrow PαS cells by selecting cells using plastic 
adherence and culturing cells in medium supplemented with basic fibroblast growth 
factor (bFGF). At passage 2 approximately 65% of the resulting cells are negative for 
CD45 and of those, almost all are positive for PDGFRα and Sca-1 (Figure 4.3A). Passage 
2 bone marrow PαS cells were larger in size and exhibited a greater degree of flow 
cytometric side scatter, indicating that they are more granular than freshly isolated 
bone marrow PαS cells (Figure 4.2 and 4.3B). Passage 2 bone marrow PαS cells were 
analysed by flow cytometry for expression of characteristic MSC markers. Cultured 
MSCs showed robust expression of CD29, CD90 and CD105, while lacking expression of 
c-kit (Figure 4.3C). 
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4.3 Characterisation of passage 2 bone marrow PαS cells in culture 
PαS cells were isolated from C57BL/6 mice by plastic adherence, and grown in medium supplemented with 
10% FBS, 1 U/ml heparin and 5 ng/ml bFGF. Passage 2 cells were stained with antibodies to identify PαS 
cells and analysed by flow cytometry (A). PαS cells were back-gated to show FSC/SSC, along with histograms 
to show FSC and SSC to indicate their size and granularity (B). Expression of MSC markers was analysed on 
the PαS cell population. Percentages, calculated by Overton Subtraction, represent the percentage of cells 
positive for that particular marker (C). 
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Given that the phenotype of MSCs may be changed on culturing these cells, freshly 
isolated PαS cells from the bone marrow and lungs were analysed in terms of 
expression of characteristic MSC markers to identify any differences in expression 
profiles. Data are presented as histograms showing the percentage of the PαS cell 
population expressing a particular antigen and in addition, in a table showing mean 
fluorescent intensity (MFI) for that antigen. Cell surface expression was investigated on 
PαS cells from both Balb/c (Figure 4.4) and C57BL/6 (Figure 4.5) mice for comparison. 
In Balb/c mice, both bone marrow and lung PαS cells exhibited robust expression of 
CD29 and CD44, with a lower percentage expressing CD73, CD90 and CD105 and a small 
proportion expressing CD13 (Figure 4.4A and 4.4C). Significant differences in 
expression levels between bone marrow and lungs were noted with respect to CD90 
and CD105 (Figure 4.4B and 4.4C). A similar pattern of expression was observed when 
PαS cells in the bone marrow and lungs were examined in C57BL/6 mice, with no 
statistical differences in levels of expression between strains. The only notable 
statistically significant difference between bone marrow and lung PαS cells in the 
C57BL/6 strain of mice was with respect to levels of expression of CD73 (Figure 4.5A 
and 4.5C). It is worth noting that in both strains of mice a proportion of bone marrow 
PαS cells lacked expression of MSC-markers or expressed them at low levels (Figure 4.4 
and 4.5). Furthermore, culture expanded bone marrow PαS cells expressed higher levels 
of CD29, CD90, and CD105 (Figure 4.3C), indicating that the expression of MSC markers 
changes in culture. 
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Figure 4.4 Characterisation of the cell surface antigen expression of PαS cells in the bone marrow and 
lungs of Balb/c mice (Part 1) 
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Figure 4.4 Characterisation of the cell surface antigen expression of PαS cells in the bone marrow and 
lungs of Balb/c mice (Part 2) 
Bone marrow (A) and lung (B) cells from Balb/c mice were stained with antibodies to identify PαS cells in 
combination with antibodies to cell surface antigens of interest. Staining was analysed by flow cytometry. 
The CD45
neg
 Ter119
neg
 CD31
neg
 PDGFRα
pos
 Sca-1
pos 
population was selected and expression of antigens on 
this population analysed. Percentages, calculated by Overton Subtraction, represent the percentage of 
CD45
neg
 Ter119
neg
 CD31
neg 
PDGFRα
pos
 Sca-1
pos
 cells positive for that marker. Percentages and MFI are shown 
for each antigen investigated (C). Data represents mean of 5 independent experiments ± SEM. * p < 0.05, 
comparing % expression between bone marrow and lung, and MFI between bone marrow and lung. n=3-5. 
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Freshly isolated PαS cells from the bone marrow and lungs were also examined for 
expression of c-kit, which has been shown to be expressed on HSPCs [261] and a 
recently identified multipotent stem cell population in the human lungs [244]. PαS cells 
from the bone marrow and lungs of both strains of mice were positive for c-kit and 
expressed it at high levels (Figure 4.4 and 4.5). Notably culture expanded bone marrow 
PαS cells were negative for this antigen (Figure 4.3C), again indicating that phenotypic 
changes occur on culturing these cells. In addition, freshly isolated bone marrow and 
lung PαS cells were examined for expression of integrin β3, which has been correlated 
with side population phenotype [262], a common characteristic of stem and progenitor 
cells [223, 263]. Less than half of PαS cells from both the bone marrow and lungs 
showed expression of integrin β3 (Figure 4.4 and 4.5), from which it could be inferred 
that only a small percentage possess a SP phenotype; although this would need to be 
confirmed by Hoechst staining. Finally, VEGFR1 and VEGFR2 expression was examined 
on freshly isolated bone marrow and lung PαS cells as these have been previously 
shown in the laboratory to be expressed on cultured MSCs and work following on from 
this has implicated VEGFR2 in the mobilisation of MSCs from the bone marrow (M. 
Hahnel, personal communication). PαS cells from both tissues and strains of mice 
showed expression of VEGFR1 and VEGFR2, with notably higher expression of VEGFR2 
on lung PαS cells, and with a statistically significant difference in the C57BL/6 strain 
(Figure 4.4 and 4.5). No statistically significant differences were observed between the 
two different strains of mice investigated (Figure 4.4 and 4.5).  
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This work has shown PαS cells from the bone marrow and lungs of Balb/c and C57BL/6 
mice to express a similar profile of cell surface antigens. Although, there are some 
differences in levels of expression between the two strains of mice, this was not 
statistically significant and therefore the antigen expression profile can be considered 
comparable and not strain specific. 
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Figure 4.5 Characterisation of the cell surface antigen expression of PαS cells in the bone marrow and lungs 
of C57BL/6 mice (Part 1) 
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Figure 4.5 Characterisation of the cell surface antigen expression of PαS cells in the bone marrow and lungs 
of C57BL/6 mice (Part 2) 
Bone marrow (A) and lung (B) cells from C57BL/6 mice were stained with antibodies to identify PαS cells in 
combination with antibodies to cell surface antigens of interested. Staining was analysed by flow cytometry. 
The CD45
neg
 Ter119
neg
 CD31
neg
 PDGFRα
pos
 Sca-1
pos 
population was selected and expression of antigens on this 
population analysed. Percentages, calculated by Overton Subtraction, represent the percentage of CD45
neg
 
Ter119
neg
 CD31
neg 
PDGFRα
pos
 Sca-1
pos
 cells positive for that marker. Percentages and MFI are shown for each 
antigen investigated (C). Data represents mean of 5 independent experiments ± SEM. * p < 0.05; ** p < 0.01, 
comparing % expression between bone marrow and lung, and MFI between bone marrow and lung. n=3-5. 
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4.3.3  Discrepancies in reactivity with different fluorescent antibodies 
Variability between studies can come from differences in the methodology used by 
different groups. The literature on lung progenitor cells is controversial with respect to 
whether these cells express CD34 [218, 219, 222, 232]. I examined CD34 expression on 
bone marrow and lung PαS cells using two alternatively conjugated versions of the 
same clone. The work presented here has highlighted the variability of staining which 
exists with commercially available antibodies. Variation in staining was apparent both 
in terms of the percentage of PαS cells which were positive for CD34 and the levels of 
expression of CD34, even when comparing alternatively conjugated versions of the 
same antibody clone (Figure 4.6). When using a phycoerythrin conjugated CD34 
antibody, 7% of bone marrow PαS cells and 24% of lung PαS cells stained positive for 
CD34 (Figure 4.6A). In contrast, when using the same antibody clone, RAM34, but 
conjugated to AlexaFluor700 and from a different company, staining showed higher 
intensity, with 80% of bone marrow PαS cells and 63% of lung PαS cells appearing 
positive for CD34 and expressing it at higher levels (Figure 4.6B). These discrepancies 
in staining with different fluorescently conjugated versions of the same antibody make 
it impossible to conclude whether PαS cells in the bone marrow and lungs are positive 
for CD34. 
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Figure 4.6 Discrepancies in CD34 antibody reactivity  
Bone marrow and lung cells from C57BL/6 mice were stained with antibodies to identify PαS cells in 
combination with 2 different fluorescently conjugated versions of the RAM34 clone of CD34 antibody: 
CD34-PE (BD Pharmingen) (A) and CD34-AF700 (ebioscience) (B). The CD45
neg
 Ter119
neg
 CD31
neg
 PDGFRα
pos
 
Sca-1
pos 
population was selected and expression of CD34 on this population analysed by flow cytometry. 
Percentages represent the percentage of CD45
neg
 Ter119
neg
 CD31
neg 
PDGFRα
pos
 Sca-1
pos
 cells positive for 
CD34. Percentages and MFI are shown for each CD34 antibody. Data represents mean of 3 independent 
experiments ± SEM, n=3. 
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4.3.4 PαS cells are distinct from endothelial cells and pericytes 
Analysis of the cell surface expression profiles of PαS cells isolated from the bone 
marrow and lungs has shown results consistent with cells of a mesenchymal phenotype. 
However, there are other subsets of cells in both the bone marrow and lungs which 
share expression of some of these markers, such as endothelial cells and pericytes and 
therefore it was important to confirm that the PαS cell population being studied really 
did represent MSCs and not another cell type. 
 
PECAM-1, or CD31, was used to exclude the possibility that cells of an endothelial 
lineage might be contained within the PαS cell population. Only 3% and 5% of PαS cells 
from the bone marrow and lungs, respectively, were positive for CD31 (Figure 4.7A). 
Analysis of total bone marrow and lung cells was conducted to confirm the antibody 
was working, with 5% and 14% of bone marrow and lung cells, respectively, staining 
positive for CD31 (Figure 4.7B). 
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Figure 4.7 CD31 and NG2 expression on PαS cells in the bone marrow and lungs 
Bone marrow and lung cells from C57BL/6 mice were stained with antibodies to identify PαS cells in 
combination with antibodies to NG2 and CD31, and analysed by flow cytometry. The CD45
neg
 Ter119
neg
 
CD31
neg
 PDGFRα
pos
 Sca-1
pos 
population was selected and expression of antigens on this population analysed. 
Percentages represent the percentage of CD45
neg
 Ter119
neg
 CD31
neg 
PDGFRα
pos
 Sca-1
pos
 cells positive for that 
antigen (A). Total bone marrow and lung cells were analysed for expression of CD31 and NG2 to confirm 
antibody staining was working. Percentages represent the percentage of total cells positive for that antigen 
(B). Data represents mean of 3 independent experiments ± SEM, n=3. 
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In recent years it has been postulated that MSCs may have a perivascular origin and that 
they may be related in some way to pericytes [80]. In order to address whether PαS 
cells from the bone marrow and lungs were in fact pericytes, an antibody against 
Neuron glial antigen-2 (NG2), a known marker of pericytes, was used. Less than 2% of 
bone marrow and lung PαS cells stained positive for NG2 (2% and 1%, respectively) 
(Figure 4.7A). In order to confirm that the NG2 antibody was working, total bone 
marrow and lung cells were analysed for expression of NG2, with 2% and 6% of total 
bone marrow and lung cells, respectively, staining positive for NG2, confirming the 
reactivity of this antibody (Figure 4.7B). 
 
4.3.5 Differentiation of PαS cells from the bone marrow and lungs 
In order to further confirm that the PαS cells being investigated in the bone marrow and 
lungs were indeed MSCs, adipogenic, osteogenic and chondrogenic differentiation of 
these cells was necessary. As mentioned above, it is possible to grow bone marrow PαS 
cells in culture in medium supplemented with bFGF (Figure 4.3A). This however, was 
not possible with lung PαS cells as the high levels of contaminating cells in the lungs 
outgrew the PαS cells. As an alternative method of isolation, fluorescence activated cell 
sorting (FACS) was used to purify PαS cells from the lungs prior to tissue culture. 
However, this proved unsuccessful as the yield of cells obtained was very low and cells 
failed to expand in culture. Due to time restrictions, other methods of isolation were not 
attempted and consequently the differentiation potential of lung PαS cells could not be 
determined.  
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Passage 2 bone marrow PαS cells were grown for 3 weeks in conditions to induce 
osteogenic, adipogenic and chondrogenic differentiation. Differentiation was assessed 
by staining with Oil Red O, Alizarin Red S and Toluidine Blue, respectively (Figure 4.8A).  
Results show differentiation of bone marrow PαS cells into all 3 cell lineages, confirming 
their MSC differentiation potential.  
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Figure 4.8 Differentiation of passage 2 bone marrow PαS cells in culture 
Passage 2 bone marrow PαS cells were grown in conditions to induce adipogenic (A), osteogenic (B) and 
chondrogenic (C) differentiation. Cells are stained with Oil Red O to identify lipid vesicles in adipocytes (red) 
(A), Alizarin Red S to identify calcium deposits from osteocytes (red) (B) and Toluidine Blue to identify 
cartilaginous extracellular matrix from chondrocytes (purple) (C). For adipogenic and osteogenic 
differentiation, the top image was taken at 10x magnification and the bottom image at 20x magnification. For 
chondrogenic differentiation, the top image was taken at 40x magnification and the bottom image was taken 
at 100x magnification. 
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4.3.6 Chemokine receptor expression profile of PαS cells in the bone marrow 
and lungs 
Given the importance of chemokines and their receptors in directing cell trafficking, 
chemokine receptor expression on freshly isolated PαS cells from the bone marrow and 
lungs of Balb/c and C57BL/6 mice was investigated. Chemokine receptors investigated 
were those that have been shown previously in the laboratory to be highly expressed on 
cultured murine bone marrow MSCs: CXCR3, CXCR6, CCR9 & CCR10 (M. Hahnel, 
personal communication) and those that are known to be involved in the mobilisation 
or recruitment of other progenitor cell subsets: CXCR2 & CXCR4 [67, 259]. Data are 
presented as histograms showing the percentage of the PαS cell population expressing 
each chemokine receptor and in a table showing MFI for that chemokine receptor. 
Freshly isolated PαS cells from both the lungs and bone marrow consistently expressed 
CXCR3, CCR9 and CCR10 at high levels (Figure 4.9 and 4.10). Expression of CXCR4 was 
significantly lower on lung PαS cells compared with bone marrow PαS cells in both 
strains of mice, in addition to a notable significant difference in expression of CXCR6 in 
C57BL/6 mice. Again, there was no statistical significance between the two strains of 
mice (Figure 4.9 and 4.10). 
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Figure 4.9 Characterisation of chemokine receptor expression on PαS cells in the bone marrow and lungs 
of Balb/c mice 
Bone marrow (A) and lung (B) cells from Balb/c mice were stained with antibodies to identify PαS cells in 
combination with antibodies to chemokine receptors of interest. Cells were analysed by flow cytometry. 
The CD45
neg
 Ter119
neg
 CD31
neg
 PDGFRα
pos
 Sca-1
pos 
population was selected and expression of chemokine 
receptors on this population analysed. Percentages, calculated by Overton Subtraction, represent the 
percentage of CD45
neg
 Ter119
neg
 CD31
neg 
PDGFRα
pos
 Sca-1
pos
 cells positive for chemokine receptor. 
Percentages and MFI are shown for each antigen investigated (C). Data represents mean of 5 independent 
experiments ± SEM. * p < 0.05, comparing % expression between bone marrow and lung, and MFI between 
bone marrow and lung.  n=3-5. 
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Figure 4.10 Characterisation of chemokine receptor expression on PαS cells in the bone marrow and lungs 
of C57BL/6 mice 
Bone marrow (A) and lung (B) cells from C57BL/6 mice were stained with antibodies to identify PαS cells in 
combination with antibodies to chemokine receptors of interest. Cells were analysed by flow cytometry. 
The CD45
neg
 Ter119
neg
 CD31
neg
 PDGFRα
pos
 Sca-1
pos 
population was selected and expression of chemokine 
receptors on this population analysed. Percentages, calculated by Overton Subtraction, represent the 
percentage of CD45
neg
 Ter119
neg
 CD31
neg 
PDGFRα
pos
 Sca-1
pos
 cells positive for chemokine receptor. 
Percentages and MFI are shown for each antigen investigated (C). Data represents mean of 5 independent 
experiments ± SEM. * p < 0.05, comparing % expression between bone marrow and lung, and MFI between 
bone marrow and lung.  n=3-5. 
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4.3.7 Differences between PαS cells in the bone marrow and lungs 
The expression profile of cell surface markers and chemokine receptors appears to be 
very similar between PαS cells from the bone marrow and those from the lungs. 
However, one striking difference that could be observed was with respect to expression 
of epithelial cell adhesion molecule (EpCAM), or CD326, a pan-epithelial differentiation 
antigen. Only about 1.5% of bone marrow PαS cells were positive for EpCAM, while 70% 
of lung PαS cells were shown to express EpCAM, and at high levels (Figure 4.11A).  
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Figure 4.11 EpCAM expression in the bone marrow and lungs 
Bone marrow and lung cells from C57BL/6 mice were stained with antibodies to identify PαS cells in 
combination with an antibody to EpCAM, and cells were analysed by flow cytometry. The CD45
neg
 Ter119
neg
 
CD31
neg
 PDGFRα
pos
 Sca-1
pos 
population was selected and the percentage of EpCAM-positive and -negative 
cells calculated. Percentages represent the percentage of CD45
neg
 Ter119
neg
 CD31
neg 
PDGFRα
pos
 Sca-1
pos
 cells 
positive for EpCAM (A). The PαS cell population of the lung was subdivided into Sca
low
 and Sca
high
 and 
EpCAM expression was analysed on these subpopulations. Percentages represent the percentage of CD45
neg
 
Ter119
neg
 CD31
neg 
PDGFRα
pos
 Sca-1
high 
or Sca-1
low
 cells positive for EpCAM. MFI for EpCAM expression on the 
lung Sca
low
 and Sca
high 
populations of PαS cells is shown (Sca
low
 in pink, Sca-1
high
 blue) (B). In addition the 
CD45
neg
 Ter119
neg
 CD31
neg
 Sca-1
pos 
cell population of the lung was subdivided into Sca
low
 and Sca
high
 and 
EpCAM expression was analysed on these subpopulations. Percentages represent the percentage of CD45
neg
 
Ter119
neg
 CD31
neg 
Sca-1
high 
or Sca-1
low
 cells positive for EpCAM. MFI for EpCAM expression on the lung Sca
low
 
and Sca
high 
populations of CD45
neg
 Ter119
neg
 CD31
neg
 cells is shown (Sca
low
 in pink, Sca-1
high
 blue) (C). *** p < 
0.001, n=8 of 2 independent experiments. 
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EpCAM expression was analysed on the Sca-1low and Sca-1high populations of PαS cells to 
investigate whether Sca-1 levels could distinguish between the EpCAM-positive and -
negative populations, as has been suggested in the literature to be the case for the 
CD45neg CD31neg population in the lungs [220]. Although the Sca-1high population did 
appear to express higher levels of EpCAM than the Sca-1low population, fewer of these 
cells were actually positive for EpCAM (Figure 4.11B). Further, in order to compare 
these results to the previous studies discussed, the total CD45neg Ter119neg CD31neg Sca-
1pos population was analysed for differences in EpCAM expression on the Sca-1low and 
Sca-1high populations (Figure 4.11C). Again, although the Sca-1high population expressed 
higher levels of EpCAM than the Sca-1low population, fewer of these cells were positive 
for EpCAM (Figure 4.11C). In the work presented here, it would appear that EpCAM 
expression cannot be completely resolved based on levels of expression of Sca-1. 
 
4.3.8 Localisation of EpCAM-positive and -negative PαS cells in the lung tissue 
In order to gain a better understanding of what the function of these EpCAM-positive 
and -negative PαS cells in the lungs might be, it was important to visualise where they 
were localised within the lung tissue. In preliminary experiments, lung sections from 
PDGFRα-GFP reporter mice were stained with antibodies to Sca-1 and EpCAM to 
visualise PDGFRαpos Sca-1pos EpCAMneg and PDGFRαpos Sca-1pos EpCAMpos cells. While 
PDGFRα- positive and EpCAM-positive cells were clearly visible, the staining for Sca-1 
was very diffuse and difficult to localise to a particular cell. This therefore precluded the 
quantification of the localisation of EpCAM-positive and -negative PDGFRαpos Sca-1pos 
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cells. From the PDGFRα and EpCAM staining however, it was possible to conclude that 
the majority of PDGFRαpos cells were EpCAMpos, which is consistent with data obtained 
from flow cytometric analysis. Different areas of the lungs were examined and EpCAMpos 
PDGFRαpos and EpCAMneg  PDGFRαpos cells were detected in all parts of the lungs: the 
lung parenchyma, between an airway and a vessel and at the bronchiolar junction. 
Further investigation and optimisation of Sca-1 staining will be required in the future to 
quantify the localisation of PαS cells.  
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Figure 4.12 Localisation of EpCAM-positive and -negative PαS cells in the lung tissue (Part 1) 
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Figure 4.12 Localisation of EpCAM-positive and -negative PαS cells in the lung tissue (Part 2) 
Frozen sections from PDGFRα-GFP reporter mice were stained with antibodies to Sca-1 (Blue) and EpCAM 
(Red). PDGFRα (Green) and DAPI (White) are also shown. Areas containing a bronchiolar junction, an airway 
& vessel and the parenchyma were imaged at 40x (A) and the area within the white box magnified at 80x 
(B). Single colours shown at 80x magnification: PDGFRα (C), EpCAM (D), and Sca-1 (E). Isotype control 
antibodies are shown at 40x (F) and 80x magnification (G) in both PDGFRα-GFP
pos
 and PDGFRα-GFP
neg 
mice 
for comparison. 
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4.3.9 Changes in PαS cell numbers in the bone marrow and lungs with age 
There is evidence to suggest that the frequency of HSCs within the bone marrow 
compartment increases with age, while their homing efficiency and engraftment 
potential decreases [264-266]. In contrast, very little work has been carried out to study 
whether MSCs change with age, however it has been suggested that human bone 
marrow MSCs decrease in number with age [267]. In order to address this question, PαS 
cells were examined in the bone marrow and lungs of 2.5 week old neonatal mice, and 
34 week old middle-aged mice (Figure 4.13). The percentage of PαS cells in both the 
bone marrow and lungs were shown to be significantly lower in the older mice 
compared with the 2.5 week old mice (Figure 4.13C). Expressing PαS cells per mg of 
tissue to account for differences in size between the older and younger mice, there was 
a trend towards a decrease in number of PαS cells in the bone marrow and a significant 
decrease in number of PαS cells in the lungs of the 34 week old mice compared with the 
2.5 week old mice (Figure 4.13A and 4.13B). It is worth noting that the percentage of 
PαS cells in the 34 week old mice was comparable to 8-10 week old mice in both the 
bone marrow and lungs (Figure 4.13C). 
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Figure 4.13 Changes in PαS cell numbers in the bone marrow and lungs with age 
Bone marrow and lungs were isolated from 2.5 week old and 34 week old Balb/c mice and analysed by flow 
cytometry for PαS cells. PαS cells per mg of femur (A) and lung (B) were calculated. Percentages of PαS cells 
were compared to the PαS cell percentage of the bone marrow and lungs of 8-10 week old Balb/c mice 
from a separate experiment (C). Bars represent mean ±SEM. n=4-5, * p < 0.05. 
  
 
 
 ~ 140 ~ 
 
4.4 Discussion 
As a prelude to experiments aimed to examine changes in lung and bone marrow MSC 
populations with disease, it was first important to fully characterise MSC populations in 
the lungs and bone marrow of naïve mice. Two different strains of mice were compared 
such that disease models could be performed in either strain. For all studies I focussed 
on analysis of CD45neg Ter119neg CD31neg PDGFRαpos Sca-1pos (PαS) cells as it has 
recently been shown by Morikawa et al. that this population of cells in the bone marrow 
are enriched for cells with phenotypic and functional characteristics of MSCs [86].  
 
In the work presented here a PαS cell population was identified in the murine lungs in 
addition to in the bone marrow (Figure 4.1), with the lungs containing a significantly 
higher percentage of PαS cells (5%) than the bone marrow (0.1%). One classic 
characteristic of stem cells is their small size [268, 269]. I have shown here that relative 
to other leukocytes in the bone marrow, PαS cells are small (Figure 4.2). In terms of 
morphology, the PαS cells in the lungs are larger and more granular than those in the 
bone marrow (Figure 4.2). This may reflect differences between the cell populations 
from the different tissues. The greater granularity of lung PαS cells may indicate that 
they are producing more molecules to be secreted, such as cytokines and growth factors 
than those in the bone marrow; however, this is just conjecture at this stage. Notably, 
culture expanded MSCs are larger and more granular than PαS cells from either the 
bone marrow and lungs, indicating that, in culture, MSCs change in terms of size and 
morphology (Figure 4.3B).  
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Bone marrow culture expanded PαS cells were first characterised for expression of 
characteristic MSC markers. As previously reported, culture expanded MSCs were 
shown to robustly express CD29, CD90 and CD105, while lacking expression of c-kit 
(Figure 4.3C). In contrast, when freshly isolated bone marrow PαS cells were examined, 
while robust expression of CD29 and CD44 was evident, levels of CD90 and CD105 were 
significantly lower, suggesting that, in culture, MSCs change phenotypically (Figure 4.4 
and 4.5). Indeed, it is notable that in the literature there is a great variation in 
expression of specific antigens, particularly by murine MSCs, and it is likely that this 
may be due to differences in isolation techniques and culture conditions. It is also worth 
noting that these MSC markers were identified on cells grown in vitro and therefore do 
not necessarily represent the phenotype of MSCs in vivo. Analysis of freshly isolated PαS 
cell populations in the bone marrow and lungs showed them to be largely similar in 
terms of expression of characteristic markers of MSCs, with only statistically significant 
differences in expression levels with respect to CD105 and CD90 in Balb/c mice and 
CD73 in C57BL/6 mice (Figure 4.4 and 4.5). These data are consistent with the findings 
of Morikawa et al. [86] and the idea that these populations of cells represent MSCs.  
 
The side population phenotype (SP) has historically been used to identify HSCs with 
long-term multilineage reconstitution capacity [270]. It has since been suggested that 
the SP phenotype is a property that is common to all tissue-specific stem cells and in 
recent years it has been used to isolate cells with stem cell-like properties from a variety 
of different tissues [223, 263].  Cells with a SP phenotype have the ability to efflux 
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Hoechst 33342, a DNA-binding dye, via their ATP-binding cassette transporter G2 
(ABCG2) [271]. However, Morikawa et al. reported that freshly isolated PαS cells from 
the bone marrow do not possess the SP phenotype [86]. Since the SP phenotype is 
thought to correlate with the possession of stem cell-like properties it was important to 
compare this property in freshly isolated bone marrow and lung PαS cells. In a recent 
study, it was demonstrated that expression of integrin β3 is correlated with the 
possession of the SP phenotype by quiescent HSCs [262]. Since we do not have access to 
the ultra-violet laser necessary to measure SP properties by Hoechst 33342 efflux, I 
examined expression of integrin β3. Just under half of PαS cells from both the bone 
marrow and lungs were shown to express integrin β3 (Figure 4.4 and 4.5), which 
suggests that they may possess a SP phenotype [262]. However, since the efflux of 
Hoechst 33342 was not directly analysed, the side population capacity of these cells can 
only be inferred.  
 
CD117, or c-kit, the receptor for stem cell factor (SCF), has been shown to be expressed 
on HSPCs in the bone marrow [261], and more recently has been used to identify a rare 
cell population in the human lungs which has the capacity to give rise to all lung cell 
lineages [244].  MSCs are not thought to express this antigen, and indeed culture 
expanded bone marrow MSCs were negative for c-kit (Figure 4.3C). Surprisingly, the 
majority of freshly isolated PαS cells in both the bone marrow and lungs were positive 
for c-kit (Figure 4.4 and 4.5).  This is contrary to what was observed in the study by 
Morikawa et al. [86] in which very little expression of c-kit was observed and possibly 
 ~ 143 ~ 
 
reflects differences in antibody clones. It is possible that MSCs express c-kit in vivo but 
that this antigen is lost on expansion ex vivo, hence why its expression has not been 
reported before now.  
 
It is generally thought that mobilisation of MSCs from the bone marrow is part of their 
physiological role in tissue regeneration and therefore it is important to study the 
process by which this mobilisation occurs. Previous work suggests that VEGF is 
important in the mobilisation of MSCs from the bone marrow into the circulation [196]. 
The expression of VEGF receptors on PαS cells from the bone marrow and lungs was 
therefore investigated. Freshly isolated PαS cells from the bone marrow and lungs 
showed robust expression of VEGFR1 and lower expression of VEGFR2 (Figure 4.4 and 
4.5). This suggests that within the PαS cell population there are still further 
subpopulations of cells, and perhaps it is the VEGFR2pos subpopulation that can be 
mobilised from the bone marrow in response to pre-treatment with VEGF. This 
demonstrates that there might be different subpopulations of MSCs with different 
characteristics and physiological roles. Furthermore, PαS cells isolated from the lungs 
showed higher levels of expression of VEGFR2 than those in the bone marrow, pointing 
towards functional differences between these tissue populations (Figure 4.4 and 4.5).  
 
It is important to note that there were no statistically significant differences in the 
profile of cell surface antigens expressed by bone marrow and lung PαS cells between 
Balb/c and C57BL/6 strains of mice, which shows that these results are not strain 
 ~ 144 ~ 
 
specific, and suggests that they are likely to hold true for other strains of mice. This is 
important for future studies comparing MSCs in different disease models as either 
strain could be used (Figure 4.4 and 4.5). 
 
Historically MSCs have been thought of as being negative for CD34, while this antigen 
has been used to enrich other progenitor cell populations, such as HSCs and progenitor 
cells in the lungs [218, 219, 222, 272]. The work presented here has shed doubt on the 
reliability of using CD34 to identify populations of cells given the variability of staining 
that exists between alternatively conjugated versions of the same clone of CD34 
antibody (Figure 4.6). Interestingly, there is much debate in the literature regarding 
whether the Sca-1pos population of lung progenitor cells express CD34 [218, 219, 222], 
but careful analysis of these studies shows that different CD34 antibodies, conjugated to 
a range of fluorophores, purchased from different companies were used. The results 
presented here reflect similar findings in the literature with respect to lung stem cells 
and likely accounts for the variability in CD34 staining levels seen in these different 
studies [232].  In light of this and the data presented here, it is impossible to conclude 
from flow cytometric analysis whether PαS cells from the lungs and bone marrow 
express CD34, and it would be prudent to avoid relying on CD34 as an antigen to 
identify any population of cells. Data would need to be confirmed by other means, for 
example by examining levels of mRNA for CD34.  
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In recent years there has been much debate about the true identity of MSCs, particularly 
with respect to their relationship to fibrocytes [273] and pericytes [80, 274], which 
have been shown to possess some MSC-like properties. Although it is thought that 
fibrocytes are a mesenchymal progenitor cell, possessing the capacity to differentiate 
into cells of a mesenchymal lineage,  such as adipocytes [275], it is important to note 
that they are distinct from the MSCs investigated in this study, which are CD45-, while 
fibrocytes are positive for CD45 [157]. MSCs have also been shown to share 
morphology, expression of surface antigens (CD44, CD90, CD73, CD13 and CD105) and 
trilineage differentiation potential with pericytes [80]. Furthermore, tissue resident 
MSCs have been postulated to be in close association with the vasculature, adding 
further weight to the idea that they may in fact be pericytes [83, 255]. However, it 
remains contentious as to whether MSCs are derived from vascular pericytes. Indeed 
bone marrow and lung PαS cells investigated in this study were shown to lack 
expression of NG2, a defining marker of pericytes, demonstrating them to represent a 
population of cells distinct from pericytes (Figure 4.7). This does not however, exclude 
the possibility that MSCs may be ancestrally related to pericytes. Preliminary studies 
examining the localisation of PαS cells suggested them to be localised not only close to 
blood vessels but also in large numbers near the airways and in the lung parenchyma 
(Figure 4.12), again suggesting them to be distinct from pericytes. However, further 
optimisation of the immunofluorescent staining of PαS cells in the lungs will be 
necessary before any firm conclusions can be drawn from this data. In addition, bone 
marrow and lung PαS cells were also shown to lack expression of CD31, a marker of 
endothelial cells, demonstrating them to be distinct from endothelial cells (Figure 4.7).  
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To establish for certain that the PαS cells I was investigating in the bone marrow and 
lungs were indeed MSCs, it was necessary to confirm that they could differentiate into 
osteocytes, adipocytes and chondrocytes, the three cell lineages that define MSC 
differentiation [85]. I have successfully cultured MSCs from the bone marrow by 
isolating them with plastic adherence and culturing them in medium supplemented 
with bFGF. This resulted in a population of PαS cells which comprised about 65% of the 
total population. In contrast, I was not able to use this same protocol to isolate lung 
MSCs due to the high level of contaminating fibroblasts that outgrew the PαS cells. I 
used FACS to attempt to purify PαS cells prior to tissue culture and to extract mRNA for 
qRT-PCR, however this was unsuccessful due to inadequate cell yield and the failure of 
these cells to expand in culture. This therefore meant that I was only able to examine 
the differentiation potential of bone marrow PαS cells. Passage 2 bone marrow PαS cells 
grown in specific culture conditions to induce differentiation were shown to 
differentiate into all three cell lineages, confirming the results of Morikawa et al. and 
that they are indeed MSCs (Figure 4.8) [86]. 
 
The ability of MSCs to migrate into tissues from the circulation is likely to be dependent 
on chemokines and their receptors. Indeed, chemokines have been shown to be 
important in the migration of other subsets of bone marrow progenitor cells [67, 259]. 
A number of studies have been carried out investigating the expression of chemokine 
receptors on human MSCs, although studies have produced conflicting results [135, 
276]. To date, very little work has been done to establish the chemokine receptor 
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expression profile of murine MSCs [134]. In addition, although lung-derived MSCs have 
been increasingly studied, no work has been carried out to characterise the chemokine 
receptors expressed by these cells in either humans or mice.  
 
Chamberlain et al. [134] screened cultured murine bone marrow MSCs for a range of 
chemokine receptors and showed these cells to express a more restricted repertoire of 
chemokine receptors than human MSCs (Table 1.1). The study conducted by 
Chamberlain et al. showed murine bone marrow MSCs to be positive for CCR6, CXCR3, 
CXCR6 and CCR9, while human MSCs were positive for these chemokine receptors, 
along with CCR1, CCR2, CCR3, CCR5, CCR7, CCR10, CXCR1, CXCR4 and CXCR5 [134]. 
Furthermore, recent work in our laboratory has shown in vitro expanded murine bone 
marrow MSCs to express CXCR3, CXCR4, CXCR6, CCR6, CCR7, CCR9 and CCR10 (M. 
Hahnel, personal communication). The discrepancies between this work and that of 
Chamberlain et al. [134], and the conflicting data from the human MSC studies is 
potentially a reflection of different isolation methods and culture conditions. It is also 
worth noting that previous work in our laboratory has demonstrated that chemokine 
receptor expression is reduced with multiple passages, especially with respect to CXCR4 
expression (M. Hahnel, personal communication), which may in part account for 
discrepancies in data from different groups. These problems associated with in vitro 
expanded MSCs, highlight the need to study uncultured MSCs, in order to gain an 
understanding of the biology of the endogenous cells, unperturbed by culture 
conditions. 
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Importantly, the work presented here is the first to investigate the profile of chemokine 
receptors expressed by freshly isolated murine bone marrow MSCs, as opposed to 
culture expanded MSCs. In addition, I have compared lung and bone marrow MSCs in 
vivo. The repertoire of chemokine receptors expressed by PαS cells from the bone 
marrow and lungs was very similar, with the majority of both cell populations 
expressing CXCR3, CCR9 and CCR10 (Figure 4.9 and 4.10). Two of these chemokine 
receptors, CXCR3 and CCR9, have been previously shown to be expressed on murine 
cultured bone marrow MSCs [134]. A proportion of bone marrow and lung PαS cells 
were shown to express CXCR4, but in both strains of mice the percentage and level of 
CXCR4 expression by PαS cells was higher in the bone marrow than in the lungs (Figure 
9 and 10). As previously mentioned, the CXCL12/CXCR4 chemokine axis is important in 
retaining cells in the bone marrow and in the trafficking of cells into tissues [190, 259]. 
It is possible that the differences in expression of CXCR4 between the two cellular 
sources reflect the different microenvironments in which these cells reside and may 
indicate functional differences in the cell populations. These results indicate that a 
proportion of bone marrow MSCs do express CXCR4 in vivo, and suggest that the lack of 
expression of CXCR4 on bone marrow MSCs in the previous study [134] may be a 
consequence of passaging the cells.  
 
The functional relevance of expression of these chemokine receptors is currently 
unknown, in particular with respect to lung MSCs. The fact that PαS cells from both the 
bone marrow and lungs express a range a chemokine receptors, suggests that these 
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cells have the potential to home to different tissues, and that this might be enhanced in 
certain inflammatory settings where greater concentrations of chemokines are 
produced. Future work to investigate whether these chemokine receptors are functional 
will be important to establish which of these chemokine receptors might be most 
important in regulating the trafficking of MSCs in vivo. 
 
Although PαS cells in the lungs and bone marrow appear to be largely similar in terms 
of antigen and chemokine receptor expression, they do differ in their levels of Sca-1 
expression. In the bone marrow, only one population of Sca-1low cells could be observed, 
while in the lungs, two populations were apparent, one Sca-1low, the other Sca-1high 
(Figure 4.11). The other striking difference was that a large percentage (70%) of lung 
PαS cells expressed EpCAM, while very few bone marrow PαS cells were positive for 
this antigen. It is well known in the literature that there is a population of CD45- CD31- 
Sca-1+ cells in the lungs, but in recent years there has been much debate about what 
these cells are [218, 219, 221, 222, 228]. Further two populations of Sca-1pos cells were 
observed, Sca1low and Sca1high, in agreement with the findings presented here. In a 
recent study, EpCAM expression was investigated on these cells and it was found that 
the Sca-1low population were positive for EpCAM, and these cells were considered to be 
epithelial progenitor cells, while the Sca-1high population were negative for EpCAM, and 
these were considered to be mesenchymal stem cells [220, 234]. In contrast my studies 
indicate that EpCAMpos cells were evident in both the Sca-1low and Sca-1high population, 
both when examining the total CD45- Ter119- CD31- Sca-1+, disregarding PDGFRα 
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expression, as McQualter et al. did, and when considering just the PαS cell population 
(Figure 4.11). These discrepancies are likely the result of experimental differences and 
in particular, different flow cytometry gating strategies. My work suggests that using 
levels of expression of Sca-1 does not effectively discriminate between the 
subpopulations of lung PαS cells. However, it is clear that expression of EpCAM 
indicates that lung PαS cells can be divided into EpCAMpos and EpCAMneg cells, while 
virtually all bone marrow PαS cells do not express EpCAM. This suggests that EpCAMpos 
and EpCAMneg PαS cells may be functionally distinct. 
 
Based on previous studies it is tempting to speculate that PαS cells in the bone marrow 
constitute a largely homogenous population of MSCs, while lung PαS cells represent a 
mixture of mesenchymal and epithelial progenitors and that EpCAM may distinguish 
these cell types. In the future it would be interesting to investigate the genome and 
secretome of these cells in order to gain more insight into the different properties of 
PαS cells in the bone marrow and lungs and in particular to further characterise the 
subpopulation of PαS cells in the lungs.  
 
The work presented here has highlighted the phenotypic differences and similarities 
between PαS cells in the bone marrow and lungs, however, functional assays would 
need to be conducted to establish the fundamental differences between these cell 
populations, and in addition, in the lungs, between the EpCAMpos and EpCAMneg 
populations. In order to conduct these sorts of studies, it is necessary to isolate these 
 ~ 151 ~ 
 
cell populations and to grow them in culture. As mentioned above, I have cultured PαS 
cells from the bone marrow, however I have not been able to isolate lung PαS cells by 
either using the same protocol as for the bone marrow or by FACS. This inability to 
grow lung PαS cells in culture has significantly limited the possibility of conducting 
functional assays. Although this has been unsuccessful to date, FACS still seems to be the 
most appropriate method to isolate these cells, given the lack of a single marker to 
identify this population, and further optimisation of a FACS protocol to isolate PαS cells 
from the lungs will be important in the future. This would enable functional 
experiments to be carried out which will provide more insight into the physiological 
roles of bone marrow and lung PαS cells.   
 
It was also be important to identify the localisation of EpCAMpos and EpCAMneg PαS cells 
in the lungs, to give further insights into their physiological roles. Morikawa et al. 
showed that PαS cells were localised close to the vasculature in the bone marrow [86], 
while studies in the lungs have shown CD45neg CD31neg Sca-1pos cells to localise to the 
bronchoalveolar duct junction, the branch point between a terminal bronchiole and the 
alveolar space [218].  In preliminary experiments, sections from PDGFRα-GFP reporter 
mice were stained with antibodies against Sca-1 and EpCAM so that PDGFRαpos Sca-1pos 
EpCAMpos cells, along with PDGFRαpos Sca-1pos EpCAMneg cells could be visualised (Figure 
4.12). Staining for Sca-1 was diffuse and it was therefore not possible to use this to 
identify PαS cells, however PDGFRαpos and EpCAMpos cells were visible. PDGFRαpos 
EpCAMpos cells were shown to be located throughout the distal lungs, however, no 
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obvious differences could be observed in the localisation of EpCAMneg and EpCAMpos 
PDGFRαpos cells. Further optimisation of Sca-1 staining was not practical within the time 
constraints of this project; however, it would be important in the future in order to 
quantify the localisation of PαS cells within the lungs and to further our understanding 
of these populations of cells. 
 
In recent years there has been much interest in changes to the HSC population of the 
bone marrow with age, however very little work has been carried out with respect to 
changes in either the bone marrow or lung MSC populations. The literature suggests 
that ageing causes a decrease in the homing and engraftment potential of HSCs, and that 
the frequency of these cells increase with age [264-266]. In order to investigate whether 
ageing causes changes in MSC populations I examined PαS cells in the bone marrow and 
lungs of 2.5 week old mice and 34 week old middle-aged mice as a comparison. A 
significant decrease in the percentage of PαS cells was observed in both the bone 
marrow and lungs of the older mice compared with the younger ones. Notably the 
percentage of PαS cells in the bone marrow and lungs of the older mice was comparable 
to percentages in the 8-10 week old mice used in other experiments (Figure 4.13C). It 
appears therefore, that at these time points the numbers of MSCs are not decreasing 
with age, but rather young mice have significantly higher numbers of them. This is 
consistent with young mice having a greater capacity for tissue regeneration than older 
ones [277]. Further analysis into the proliferative capacity and function of PαS cell 
populations with age would be important to give more insight into how these cell 
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populations change with age, since changes in their properties may be more significant 
than changes in their number. 
 
In this work, a population of CD45neg Ter119neg Sca-1pos PDGFRαpos (PαS) cells has been 
identified in the murine bone marrow and importantly, in the lungs. These cells have 
been shown to exhibit MSC-like characteristics in terms of expression of cell surface 
antigens. Interestingly, PαS cells from both tissues express a range of chemokine 
receptors, suggesting that these cells might be able to be recruited into tissues in 
response to injury. The data demonstrate that PαS cells in the lungs can be further 
subdivided into EpCAMpos and EpCAMneg cells, possibly indicating a way to distinguish 
between MSCs and epithelial progenitor cells in the lungs. However, using the current 
markers, it is still not possible to distinguish between MSCs in the bone marrow and 
lungs. 
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CHAPTER 5 
Characterisation of PαS cells in disease 
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5.1 Introduction 
As previously described, MSCs are multipotent cells that can differentiate into 
specialised cells, such as chondrocytes, osteoblasts and adipocytes [278] and as such 
have been considered to hold great promise for regenerative medicine. More recently, it 
has been recognised that these cells possess another important feature which makes 
their therapeutic potential even greater; that is their ability to modulate the immune 
response and to promote tissue repair through paracrine effects on other cells. In 2002, 
Batholomew et al. showed that baboon MSCs could reduce T cell proliferation in a 
mixed lymphocyte reaction in vitro and importantly, protect against rejection of 
allogeneic skin grafts in vivo [89]. Since this original observation, much work has been 
carried out and has confirmed the immunosuppressive capacity of MSCs in vitro and in 
vivo in a number of animal models and human studies [90, 279]. 
 
Given these unique features of MSCs, it is not surprising that their reparative potential 
has been investigated in a number of animal models and human diseases [276]. Barbash 
et al. investigated whether systemically administered MSCs could migrate to the heart 
after myocardial infarction (MI) and found that MSC migration into the heart was 
significantly higher in MI rats than in sham-MI rats [128]. Interestingly, they found that 
MSCs were preferentially retained in the ischemic tissue as opposed to the uninjured 
tissue, suggesting that injury might upregulate expression of specific receptors or 
ligands on cells within the tissue which enhances the infiltration of MSCs [128]. Work 
since has shown that systemically administered MSCs can enhance repair in cardiac 
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disease [141, 151], kidney disease [280], and diabetes [281], as well as reducing graft 
versus host disease [147], to name but a few. Systemically administered MSCs have also 
been shown to reduce inflammation and fibrosis in the bleomycin model of pulmonary 
fibrosis [129, 143]. Similar to the study carried out by Barbash et al. [128], in these two 
studies MSCs were preferentially localised to areas of tissue damage and in one study 
the authors observed a 23-fold increase in engraftment of donor-derived MSCs into the 
injured lungs, compared to control mice not exposed to bleomycin [129]. In a 
subsequent study, Ortiz et al. suggested that MSCs protect the lungs from bleomycin-
induced injury by reducing the pro-inflammatory cytokines TNF-α and IL-1 in the lungs 
[142]. Although these studies confirm the ability of MSCs to migrate into tissue from the 
circulation, they fail to address the mechanism by which this migration occurs and 
whether endogenous MSCs will naturally migrate into tissue in injury or disease. 
 
Importantly, in a number of these studies, engraftment of MSCs into tissue was very low 
or transient, despite the evident reparative effects of the administered MSCs [151-154]. 
This suggests that it is soluble factors secreted by MSCs that are essential for their 
reparative capacity and not their ability to differentiate into different cell types. Indeed, 
in a number of animal models, MSC-conditioned medium has been shown to enhance 
wound healing [91] and to improve repair after MI [92, 93]. MSCs have been shown to 
produce a range of growth factors, cytokines and chemokines and it is likely that it is the 
MSC secretome that is important in conditions of injury in modulating the immune 
response and enhancing repair [282, 283].   
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Given that exogenously administered MSCs have been shown to possess the capacity to 
ameliorate tissue damage in models of injury and disease, it seems logical to speculate 
that this process occurs naturally and that endogenous MSCs can act in a similar way. 
Indeed we hypothesise that MSCs are mobilised from the bone marrow into the 
circulation, from where they are recruited into tissues in response to injury and disease. 
Once in the tissue, the disease-specific microenvironment would cause the recruited 
MSCs to secrete an array of growth factors, cytokines and chemokines, which would act 
to modulate the immune response and the reparative process. Despite the significant 
therapeutic potential of exogenously administered MSCs, no work has been published to 
date, exploring the role of endogenous MSCs in the context of injury or inflammatory 
disease. This is largely due to the lack of reliable markers to identify these cells in vivo. 
As described in the previous chapter, there are significant limitations to using ex vivo 
expanded MSCs, as well as regulatory and practical hurdles which impact on the cost of 
using these cells therapeutically. If this hypothesis holds true and MSCs are naturally 
recruited into damaged tissue to enhance repair, understanding the mechanisms by 
which this occurs could prove crucial in developing a therapeutic strategy to enhance 
this process as an alternative to administering exogenous MSCs. I sought to explore the 
role of MSCs, identified as PαS (CD45neg Ter119neg PDGFRαpos Sca-1pos) cells [86], in lung 
disease and to address the question of whether MSCs could be mobilised from the bone 
marrow and recruited into the lungs in response to injury.  
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The bleomycin model of pulmonary fibrosis was chosen as a model in which to study 
the role of PαS cells in disease. In this model, intratracheal administration of bleomycin, 
a chemotherapy drug, causes DNA damage, which results in apoptosis of alveolar 
epithelial cells [284]. This initial toxicity elicits an infiltration of inflammatory cells into 
the lungs which release a range of chemokines and cytokines, such as TGF-β and TNF-α, 
and promote the development of fibrosis [208, 285]. In the later phase of this model 
collagen deposition occurs in the lung tissue, accompanied by a proliferation of lung 
fibroblasts and smooth muscle cells and fibrotic foci are evident [206]. As mentioned 
above, a number of studies have investigated the effects of exogenously administered 
MSCs on the progression of disease in the bleomycin model [129, 142, 143], however 
the role of endogenous MSCs in this model remains to be established. Administration of 
bleomycin has been shown to be associated with increased levels of a number of 
chemokines in the lungs, including CCL2 [212], CXCL12 [164] and CXCL10 [210] and it 
is therefore possible that in this inflammatory milieu, endogenous bone marrow-
derived MSCs that are known to express the appropriate chemokine receptors for these 
chemokines are recruited into the lungs.      
 
5.2 Aims 
 To set up the bleomycin model of pulmonary fibrosis  to use in subsequent 
studies  
 To investigate whether PαS cells increase in number in the lungs in response to 
injury 
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 To investigate whether PαS cells are being mobilised from the bone marrow into 
the circulation and recruited to the lungs in response to injury 
 To investigate the mechanism by which PαS cells are recruited into the injured 
lungs 
 To establish the role of PαS cells in the bleomycin model of pulmonary fibrosis 
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5.3 Results 
5.3.1 Setting up the bleomycin model of pulmonary fibrosis 
In an initial optimisation experiment C57BL/6 mice were given either 1.25 U/kg 
bleomycin, 2.5 U/kg bleomycin or PBS intratracheally at day 0 and culled 7 days later 
(Figure 5.1A). Bronchoalveolar (BAL) fluid, lung cells and lung sections were taken for 
analysis. It is important to note that from preliminary experiments that proved 
unsuccessful (data not shown), the intratracheal method of administration of bleomycin 
was crucial. The optimal method was to intubate the mice using a gavage needle, 
confirming entry into the trachea by the presence of collagen rings, and injecting the 
bleomycin directly into the lungs (Figure 5.1A). Once this technique was established, the 
model worked consistently, with mice losing weight in the first few days after 
administration (Figure 5.1B).  The weight loss was not significantly different between 
the group that was dosed with 1.25 U/kg bleomycin and those that received 2.5 U/kg 
bleomycin (Figure 5.1B).  
 ~ 161 ~ 
 
 
 
 
Figure 5.1 Setting up bleomycin model of pulmonary fibrosis 
PBS, 1.25 U/kg bleomycin or 2.5 U/kg bleomycin was administered intratracheally to C57BL/6 mice. Mice 
were intubated with a gavage needle and bleomycin administered directly into the lungs (A). Mice were 
culled 7 days after bleomycin instillation. Mice were weighed daily for 7 days and culled on day 7. Graph 
represents mean percentage of original weight on day 0 for each group. * denotes statistical difference 
between the PBS and 2.5 U/kg bleomycin groups (B). Lung sections were prepared and stained with 
haematoxylin and eosin (H&E) (C) or picrosirius red (D), 20x magnification. Total cell numbers were 
enumerated for the BAL fluid (E) and CD45-positive cells were enumerated by flow cytometry for the large 
lobe of the lungs (F). Bars represent mean ± SEM. n=4, * p < 0.05. 
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Haematoxylin and eosin staining of lung sections showed there to be an inflammatory 
infiltrate in both groups of mice 7 days after bleomycin treatment compared to PBS 
controls, although this was higher in the group that received 2.5 U/kg than those that 
received 1.25 U/kg bleomycin (Figure 5.1C). Indeed, there was a dose dependent 
increase in total cell numbers in the BAL fluid and CD45 positive cells in the lungs 7 
days after bleomycin treatment (Figure 5.1E and 5.1F). No collagen deposition was 
detected by picrosirius red staining at either dose of bleomycin, consistent with what 
has previously been published about the time-course of this disease model (Figure 
5.1D). From these results, 2.5 U/kg bleomycin was chosen as an optimal dose to use in 
future experiments as it resulted in a robust inflammatory response 7 days after 
administration and would therefore provide the most useful tool to study MSCs in this 
model. 
 
5.3.2 Time-course of the bleomycin model of pulmonary fibrosis 
Mice were weighed daily for up to 21 days after 2.5 U/kg bleomycin was given 
intratracheally. Mice began to lose weight in the first few days after administration of 
bleomycin and this continued for the first 7 days, after which time the weight loss 
ceased but the mice did not regain weight (Figure 5.2A). Over the 21 day time-course an 
infiltration of inflammatory cells was apparent when looking at the total number of cells 
in the BAL fluid (Figure 5.2B). There was a significant increase in the total number of 
cells just 2 days after administration of bleomycin, and this continued to increase at day 
4, reaching a peak at day 7. The total number of cells in the BAL was comparable to 
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control animals by day 21, when the inflammatory phase of the bleomycin model is 
thought to have passed (Figure 5.2B). In the lungs there was no increase in the number 
of CD45-positive cells until day 7, and lung CD45-positive cell numbers were 
comparable to control mice by day 21 (Figure 5.2C). These experiments confirm that the 
peak of the inflammatory response at the time points investigated in this model is at day 
7 and has subsided by day 21. 
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Figure 5.2 Time-course of the bleomycin model of pulmonary fibrosis 
2.5 U/kg bleomycin was administered intratracheally to C57BL/6 mice. Mice were weighed daily for up to 
21 days. Graph represents mean percentage of original weight on day 0 for each group (A). Groups of mice 
were culled at day 2, 4, 7 and 21. Total cell numbers were enumerated for the BAL fluid (B) and CD45-
positive cells were enumerated for the large left lobe of the lungs by flow cytometry (C). Control mice were 
analysed at each time point and the data pooled. Bars represent mean ± SEM. n=4-5 (day 2), n=4-6 (day 4), 
n=12-14 (day 7), n=7 (day 21) in 7 independent experiments. ** p < 0.01; *** p < 0.001.  
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5.3.3 Inflammatory infiltrate and collagen deposition in the bleomycin model of 
pulmonary fibrosis 
Haematoxylin and eosin (H&E) staining of lung sections at days 4, 7 and 21 after 
bleomycin treatment showed inflammation in the lung tissue after 7 days (Figure 5.3A). 
More detailed analysis of the lungs at the peak of inflammation, 7 days after bleomycin 
administration, showed there to be an infiltration of T cells, neutrophils, eosinophils 
and macrophages into the lungs in response to injury (Figure 5.3C).  Having established 
that the inflammatory phase of the model is early on, peaking at day 7, it was important 
to investigate the other important phase of this model, which is the onset and 
development of fibrosis. Collagen deposition in the lungs was studied as a measure of 
this. Picrosirius red staining of lung sections showed there to be no evidence of collagen 
deposition at either 4 or 7 days after bleomycin injury, however, after 21 days 
significant collagen deposition in the lung parenchyma was apparent (Figure 5.3B). 
Quantification of collagen content in the lungs 21 days after bleomycin administration 
showed there to be an increase in collagen deposition when compared to control mice 
(Figure 5.3D). 
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Figure 5.3 Inflammatory infiltrate and collagen deposition in the bleomycin model of pulmonary fibrosis 
C57BL/6 mice were given 2.5 U/kg bleomycin intratracheally at day 0 and groups were culled at days 4, 7 
and 21. Lung sections were prepared and stained with haematoxylin and eosin (H&E) (A) or picrosirius red 
(B), 20x magnification. At the 7 day time point the large left lobe of the lungs was analysed by flow 
cytometry for B cells (B220
+
 CD19
+
), T cells (CD3
+
), Neutrophils (Ly6G
+
), Eosinophils (Siglec F
+
 CD11c
low
) and 
macrophages (CD68
+
 CD11c
+
) (C). At the 21 day time point collagen content in the lungs was quantified by 
Sircol assay (D). Bars represent mean ± SEM. n=4-6 (day 4), n=12-14 (day 7), n=6 (day 21) in 7 independent 
experiments, * p < 0.05; ** p < 0.01.  
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5.3.4 PαS cell staining over the time-course of the bleomycin model 
Having set up the bleomycin model in the laboratory and studied the progression of 
disease in this model, the role of MSCs could be investigated. C57BL/6 mice were dosed 
with 2.5 U/kg bleomycin and PαS cell numbers were investigated in the bone marrow 
and lung tissue at 2, 4, 7 and 21 days after bleomycin instillation. In the bone marrow 
there was no significant change in the absolute number of PαS cells per femur at any of 
the time points investigated after bleomycin treatment compared to control animals 
(Figure 5.4A). In the lungs there was no change in the absolute number of PαS cells up 
to 4 days after bleomycin administration compared with controls; however, a significant 
increase in the number of PαS cells could be observed in the lungs 7 days after 
bleomycin treatment, with numbers remaining elevated 21 days after bleomycin 
treatment (Figure 5.4B).  
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Figure 5.4 PαS cell numbers over the time-course of the bleomycin model 
C57BL/6 mice were given 2.5 U/kg bleomycin intratracheally at day 0 and groups were culled at days 2, 4, 7 and 
21 after injury. Bone marrow and lung cells were stained with antibodies to identify PαS cells and analysed by 
flow cytometry. CD45
neg
 Ter119
neg
 cells were selected and PDGFRα
pos
 Sca-1
pos 
cells were calculated as a 
percentage of this population. Total numbers of PαS cells were enumerated per femur in the bone marrow (A) 
and per large left lobe of the lungs (B). Control mice were analysed at each time point and the data pooled. Bars 
represent mean ± SEM. n=4-5 (day 2), n=4-6 (day 4), n=12-14 (day 7), n=7 (day 21) in 7 independent experiments, 
* p < 0.05; *** p < 0.001.   
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Analysing the blood for PαS cells showed there to be no change in numbers 2 days after 
administration of bleomycin but a significant increase in numbers was observed in the 
circulation 4 and 7 days after bleomycin injury (Figure 5.5A). Furthermore, PαS cells in 
the blood of control animals and mice 7 days after bleomycin injury were shown to be 
almost entirely negative for EpCAM, a cell surface antigen that was shown in the 
previous chapter to be present on approximately 70% of lung PαS cells, but absent on 
virtually all those in the bone marrow (Figure 5.5B). 
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Figure 5.5 PαS cell staining in blood of bleomycin-treated mice 
C57BL/6 mice were given 2.5U/kg bleomycin intratracheally at day 0 and culled 2, 4 and 7 days later. Blood was 
stained with antibodies to identify PαS cells and analysed by flow cytometry. CD45
neg
 Ter119
neg
 cells were 
selected and PDGFRα
pos
 Sca-1
pos 
cells were calculated as a percentage of this population in the blood. Total PαS 
cell numbers were enumerated per ml blood (A). At the 7 day time point, EpCAM
neg 
and EpCAM
pos 
percentage of 
the PαS cell population was examined by flow cytometry (B). Bars represent mean ± SEM. n=2-3 (day 2), n=4-5 
(day 4), n=20-24 (day 7) in 7 independent experiments, ** p < 0.01. 
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5.3.5 EpCAM-positive and -negative PαS cells in the lungs after bleomycin injury 
C57BL/6 mice were dosed with either 2.5 U/kg bleomycin or PBS, and culled 7 days 
later, at the time point at which an increase in the number of PαS cells in the lungs could 
first be observed. As described in the previous chapter EpCAM is an epithelial cell 
marker recently suggested to distinguish between mesenchymal and epithelial 
progenitor cells in the lungs [220]. By analysing the expression of EpCAM on PαS cells a 
shift in the relative proportions of the EpCAMneg and EpCAMpos populations was shown 
to occur after bleomycin injury. In a naïve animal, approximately 70% of lung PαS cells 
were EpCAMpos, while the remaining 30% were negative for EpCAM (Figure 5.6A).  In 
terms of absolute numbers of PαS cells in the lungs, there was a significant increase in 
EpCAMneg PαS cells 7 days after bleomycin treatment, compared to PBS-treated control 
mice, while there was a slight decrease in EpCAMpos PαS cells, although this decrease 
was not statistically significant (Figure 5.6B). These changes in absolute numbers 
resulted in a change in the relative percentage of EpCAMpos/EpCAMneg PαS cells, with the 
percentage of EpCAM-negative PαS cells increasing to 46%, while the percentage of 
EpCAM-positive PαS cells decreased to 54% 7 days after bleomycin injury (Figure 5.6A). 
These results demonstrate that it is that EpCAMneg population of PαS cells in the lungs 
that is increased in number in response to bleomycin injury. 
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Figure 5.6 EpCAM-positive and -negative PαS cells in the lungs after bleomycin injury 
C57BL/6 mice were given 2.5 U/kg bleomycin intratracheally and culled at day 7. Lung cells were stained with 
antibodies to identify PαS cells and were analysed by flow cytometry. EpCAM expression was analysed on the 
PαS cell population. The EpCAM-negative and -positive percentage of PαS cells in the lungs was calculated for 
bleomycin-treated mice and PBS controls (A). Absolute numbers of EpCAM-negative and -positive PαS cells in 
the large left lobe of the lungs of bleomycin and PBS-treated mice is also shown (B). Bars represent mean ± 
SEM. n=8-11, 2 independent experiments, * p < 0.05; *** p < 0.001. 
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5.3.6 Proliferation of PαS cells after bleomycin instillation 
Having established that PαS cell numbers were increased in the lungs 7 days after 
bleomycin administration compared with PBS-treated control mice, it was necessary to 
investigate whether this was the result of a recruitment of cells from the bone marrow 
into the lungs, or whether it was an expansion of lung-resident MSCs in response to 
injury. Initially, to address this question, BrdU incorporation into the DNA of PαS cells 
was investigated after bleomycin treatment to establish whether MSCs were induced to 
proliferate in response to injury. This was investigated 4 days after bleomycin 
treatment, before the increase in the number of PαS cells in the lungs was observed, and 
7 days after bleomycin treatment, when the number of PαS cells in the lungs was 
increased. The proliferation of PαS cells in the bone marrow was also investigated as a 
comparison. A large proportion of PαS cells in the bone marrow were observed to be 
proliferating even in naïve animals, and no change in this percentage was observed in 
the bone marrow either 4 or 7 days after administration of bleomycin (Figure 5.7A and 
5.7C). In comparison, only a relatively small population of lung PαS cells (1%) were 
observed to be proliferating in the naïve lungs (Figure 5.7B and 5.7C). No change was 
observed in the proliferation of PαS cells in the lungs 4 days after bleomycin 
administration, however a small but significant increase in the proliferation of PαS cells 
in the lungs could be observed 7 days after bleomycin injury, with the percentage of 
proliferating PαS cells increasing from 1% to 4% (Figure 5.7B and 5.7C). Ki67 staining 
on lung and bone marrow PαS cells confirmed these results (Appendix Figure 9.1). 
Furthermore, analysis of the proliferation of the EpCAM-positive and -negative 
subpopulations of PαS cells in the lungs showed there to be a significant increase in the 
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proliferation of both subpopulations (Figure 5.7D). It is therefore, not possible to 
exclude the possibility that lung-resident PαS cells are induced to proliferate in 
response to bleomycin injury and that this is responsible for the observed increase in 
the number of these cells in the lungs. 
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Figure 5.7 Proliferation of PαS cells after bleomycin instillation 
2.5 U/kg bleomycin was administered intratracheally to C57BL/6 mice. 1 mg BrdU was administered 
intraperitoneally 3 days later for 1 set of mice and 6 days later for another. Mice were culled 24 hours after BrdU 
injection, at days 4 and 7, respectively, after bleomycin injury. Bone marrow and lung cells were stained with 
antibodies to identify PαS cells and were analysed by flow cytometry. BrdU incorporation into PαS cells was 
detected using an antibody against BrdU, and compared to mice not injected with BrdU, in the bone marrow (A) 
and lungs (B). Percentage of PαS cells positive for BrdU in the bone marrow and lungs was represented as a bar 
graph where bars represent mean ± SEM (C). The percentage EpCAM
neg
 and EpCAM
pos
 PαS cells in the lungs 
positive for Ki67 were examined at the 7 day time point by flow cytometry. (D) Bars represent mean ± SEM. n=4-
12, 3 independent experiments, ** p < 0.01; *** p < 0.001. 
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5.3.7 PαS cell staining in BAL fluid of bleomycin-treated mice 
BAL fluid was analysed for the presence of PαS cells 4 and 7 days after bleomycin injury. 
A population of PαS cells could be identified in the BAL fluid of both naïve and 
bleomycin-treated animals, along with populations of PDGFRαneg Sca-1pos cells, 
PDGFRαpos Sca-1neg cells, and PDGFRαneg Sca-1neg cells (Figure 5.8A). When considering 
absolute numbers of cells in the BAL fluid, an increase in numbers of both CD45neg 
Ter119neg Sca-1pos and PαS cells was observed at both 4 and 7 days after bleomycin 
injury, although the greatest increase was seen in the CD45neg Ter119neg Sca-1pos 
population (Figure 5.8B and C). Further analysis of EpCAM expression on these 
populations in the BAL fluid showed both the CD45neg Ter119neg Sca-1pos and the PαS cell 
population to be comprised of mostly EpCAMpos cells (Figure 5.8D). As in the lungs, an 
increase in the percentage of EpCAMneg cells was evident in both the CD45neg Ter119neg 
Sca-1pos and the PαS cell population in the BAL fluid 7 days after bleomycin injury when 
compared to PBS controls, along with a significant increase in the EpCAMpos fraction of  
CD45neg Ter119neg Sca-1pos cells (Figure 5.8D and 5.8E). 
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Figure 5.8 PαS cell staining in BAL of the bleomycin-treated mice 
C57BL/6 mice were given 2.5U/kg bleomycin intratracheally at day 0 and culled 4 and 7 days later. Lungs were 
lavaged and BAL cells were stained with antibodies to identify PαS cells and analysed by flow cytometry. CD45
neg
 
Ter119
neg
 cells were selected and PDGFRα and Sca-1
 
expression was analysed on this population of cells in the BAL. 
Representative FACS plots shown (A). Total CD45
neg 
Ter119
neg 
Sca-1
pos
 (B) and PαS (C) cell numbers were 
enumerated per lavage. The EpCAM-negative and -positive percentage of CD45
neg 
Ter119
neg 
Sca-1
pos
 (D) and PαS (E) 
cells was examined at the 7 day time point. Bars represent mean ± SEM. n=4-6, * p < 0.05.
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5.3.8 Effect of blocking CXCR3 on PαS cell recruitment to the lungs in the 
bleomycin model 
Given that PαS cells were shown in the previous chapter to express high levels of CXCR3 
and the ligand for this receptor, CXCL10, has been shown to be increased in the lungs in 
the bleomycin model, I sought to investigate whether the recruitment of PαS cells to the 
lungs could be prevented by using a CXCR3 blocking antibody in the bleomycin model. 
Here mice were given PBS or 2.5 U/kg bleomycin intratracheally as previously 
described, followed by either 100 µg anti-CXCR3 antibody or control antibody 
intraperitoneally at days 1 and 4 after bleomycin administration (Figure 5.9A). Mice 
receiving either the anti-CXCR3 antibody or the control antibody lost similar amounts of 
weight in the 7 days they were monitored (Figure 5.9B). CD45-positive cell numbers 
were increased in the lungs of mice that had been treated with bleomycin and control 
antibody, as has been shown previously in this chapter (Figure 5.9C). The anti-CXCR3 
antibody had no effect on the number of CD45-positive cells in the lungs, with mice 
receiving the anti-CXCR3 antibody showing a similar increase in the number of cells in 
the lungs in response to bleomycin injury compared to those receiving the control 
antibody (Figure 5.9C). Analysis of CD8+ and CD4+ T cells showed an increase in the 
percentage of both populations of cells in the lungs 7 days after bleomycin treatment 
(Figure 5.9D). Mice treated with bleomycin and the anti-CXCR3 antibody also showed 
an increase in the percentage of CD8+ and CD4+ T cells in the lungs with no significant 
difference between the percentage in the lungs of the mice treated with anti-CXCR3 
antibody and those that were given the control antibody (Figure 5.9D). This same result 
was observed when looking at absolute numbers of CD8+ and CD4+ T cells in the lungs, 
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as well as the percentage and absolute numbers of these populations of cells in the BAL 
fluid (data not shown). PαS cell numbers in the bone marrow were shown to be 
unchanged after bleomycin treatment in either the group that were treated with control 
antibody or those that were given the anti-CXCR3 antibody (Figure 5.9E). In the lungs, 
PαS cell numbers were not significantly changed by treatment with the anti-CXCR3 
antibody (Figure 5.9F), suggesting that in this study blocking CXCR3 had no effect on the 
recruitment of PαS cells into the lungs in response to bleomycin injury. 
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Figure 5.9 Effect of blocking CXCR3 on PαS cell recruitment to the lungs in the bleomycin model 
C57BL/6 mice were given 2.5 U/kg bleomycin intratracheally at day 0 and then given 100 μg anti-CXCR3 mAb 
(Clone CXCR3-173) or control antibody intraperitoneally on days 1 and 4. Mice were culled on day 7 (A). Weight 
loss was monitored daily over this period. * denotes statistically significant difference between PBS and 
bleomycin + control antibody groups (B). CD45-positive lung cells were enumerated for each group of mice by 
flow cytometry (C). CD4- and CD8-positive T cells were analysed in the lung by flow cytometry and expressed as 
a percentage of the total lung (D). Bone marrow and lung cells were stained with antibodies to identify PαS cells 
and analysed by flow cytometry. CD45
neg
 Ter119
neg
 cells were selected and PDGFRα
pos
 Sca-1
pos 
cells were 
calculated as a percentage of this population. Total numbers of PαS cells were enumerated per femur in the 
bone marrow (E) and per large lobe of the lung (F). Bars represent mean ±SEM. n=4-5, * p < 0.05. 
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5.3.9 Recruitment of exogenously administered BM-PαS cells to the BAL fluid 
and lungs after bleomycin treatment  
In the laboratory, we can culture PαS cells from the bone marrow by isolating cells using 
plastic adherence and culturing cells in medium supplemented with bFGF. At passage 2 
the resulting cells are about 65% CD45-negative and of those cells, all are positive for 
PDGFRα and Sca-1 (Figure 5.10A). We sought to investigate whether these cells would 
be recruited to the lungs in response to bleomycin injury and what effect these cells 
would have on inflammation in the lungs. 
 
One million fluorescently labelled MSCs, cultured in this way, were injected 
intravenously 3 days after administration of bleomycin and the BAL fluid, lung tissue 
and spleen were harvested 4 days later (Figure 5.10B). We analysed the population of 
CD45-negative DiD-positive cells as this should represent recruited exogenous MSCs. 
Recruitment of CD45neg DiDpos MSCs to the lungs, BAL and spleen was observed in 
control mice and those treated with bleomycin (Figure 5.10C). Furthermore, a 
significantly greater recruitment of CD45neg DiDpos MSCs was observed in the BAL and 
lungs of bleomycin-treated mice, while no difference was observed in the recruitment of 
cells to the spleen (Figure 5.10D). 
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Figure 5.10 Exogenously administered BM-PαS cells are recruited to the BAL fluid and lungs after bleomycin 
treatment 
PαS cells were isolated from C57BL/6 mice bone marrow by plastic adherence, and grown in medium 
supplemented with 10% FBS, 1 U/ml heparin and 5 ng/ml bFGF. Passage 2 cells were stained with antibodies to 
PDGFRα and Sca-1 and analysed by flow cytometry (A). PBS or 2.5U/kg bleomycin was administered 
intratracheally to C57BL/6 mice. 10
6
 DiD-labelled passage 2 PαS cells were administered intravenously 3 days 
later and mice were culled at day 7 (B). BAL fluid, lung and spleen cells were analysed by flow cytometry to 
detect CD45
neg
 DiD-labelled cells (C). The percentage of CD45
neg
 DiD
pos
 cells in the BAL, lungs and spleen is 
shown (D). Bars represent mean ± SEM. n=4-6, * p < 0.05; ** p < 0.01. 
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Injection of MSCs did not appear to affect the weight lost by animals treated with 
bleomycin, with similar weight loss in both groups (Figure 5.11A). Administration of 
MSCs resulted in a trend towards a reduction in the total number of cells in the BAL 
(Figure 5.11B) and a significant decrease in the number of cells in the lungs (Figure 
5.11C) when compared to bleomycin-treated mice that did not receive MSCs, suggesting 
that the recruited MSCs may be having an anti-inflammatory effect.  
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Figure 5.11 The effect of administration of BM-PαS cells in the bleomycin model on weight loss and total 
inflammation  
2.5 U/kg bleomycin was administered intratracheally to C57BL/6 mice. 10
6
 DiD-labelled PαS were administered 
intravenously 3 days later and mice were culled at day 7. Mice were weighed daily and graph represents mean 
percentage of original weight on day 0 for each group (A). Total BAL (B) and lung (C) cells were enumerated. 
Bars represent mean ±SEM. n=4-6, * p < 0.05; ** p < 0.01. 
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5.5 Discussion 
In order to investigate whether endogenous MSCs can be mobilised from the bone 
marrow and recruited to a tissue in response to injury it was necessary to set up a 
model to study this hypothesis. The bleomycin model of pulmonary fibrosis represents 
a severe, progressive injury in which initial DNA damage triggers an inflammatory 
response early in the model, followed by collagen deposition and proliferation of 
fibroblasts. Finally fibrotic plaques form and fibrosis develops. The different stages of 
this model make it a useful tool to study the role of endogenous MSCs in both the initial 
inflammatory response, and then later in remodelling, in the fibrotic phase of the 
disease. To date the potential involvement of endogenous bone marrow-derived MSCs 
has not been studied in the bleomycin model, or indeed any model of respiratory 
disease.  
 
It has previously been reported that the peak of inflammation in this model occurs 7 
days after bleomycin injury and therefore this time point was selected at which to 
optimise the dose of bleomycin [206]. An initial optimisation experiment showed 
intratracheal administration of both 1.25 U/kg and 2.5 U/kg bleomycin to elicit an influx 
of inflammatory cells into the BAL and lungs, with 2.5 U/kg giving the more robust 
response (Figure 5.1). This dose was therefore chosen to use in future experiments.  
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Having established the optimal dose of bleomycin to use in these studies, it was 
necessary to investigate the course of this model over time to establish the best time 
point at which to study the recruitment of MSCs. Previous studies have reported that 
the peak of inflammation in this model is 7 days after bleomycin injury, after which time 
collagen deposition in the lung parenchyma begins and by day 21 fibrosis is fully 
established [206]. The time points that were investigated were therefore chosen as they 
represent different stages of the model: days 2 and 4 were selected as early time points 
at the onset of the disease, day 7 at the peak of inflammation and day 21 as a later time 
point when fibrosis should be established. Results show intratracheal administration of 
2.5 U/kg bleomycin to cause an influx of inflammatory cells into the lungs and BAL, 
peaking at day 7 and returning to baseline level by day 21 (Figure 5.2). More detailed 
analysis showed there to be an influx of neutrophils, eosinophils, macrophages and T 
cells (Figure 5.3). Picrosirius red staining of lung sections and quantification of lung 
collagen content by Sircol assay showed there to be greater amounts of collagen in the 
lungs 21 days after bleomycin treatment when compared with PBS controls, indicating 
the development of lung fibrosis (Figure 5.3). This pattern of inflammation, resolution 
and fibrosis is consistent with what has previously been published about the course of 
this model [206]. 
 
Having set up and characterised the bleomycin model of pulmonary fibrosis it was then 
possible to go on to study the MSC populations in the bone marrow and lungs in disease. 
As shown in the previous chapter, there is a population of resident MSCs in the lungs of 
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naïve animals and I sought to investigate whether this population changed in number 
after bleomycin treatment and, if so, at which time point in the disease model this 
change occurred. Analysis of PαS cells in the bone marrow showed no change in the 
absolute number of PαS cells per femur, however in the lungs a significant increase in 
the absolute number of PαS cells was observed 7 days after bleomycin injury and this 
number remained significantly elevated at day 21 (Figure 5.4).  
 
In a recent study it was suggested that administration of hyaluronidase into the lungs of 
bleomycin-treated mice could recruit a population of MSC-like cells, however this study 
failed to convincingly establish that these cells were actually recruited from outside the 
lungs or that they were indeed MSCs, as cells were only analysed for expression of 
single MSC markers and no co-expression analysis was performed [286]. Indeed, the 
authors only refer to these cells as MSC-like and it is possible they may in fact represent 
a different cell type. In addition, the authors did not assess whether there was any 
increase in this MSC-like population in response to bleomycin injury in the absence of 
intervention with hyaluronidase [286]. In another recent study, it was suggested that 
contrary to what I have shown, bleomycin injury resulted in a loss of endogenous lung 
MSCs [243]. In this study, lung MSCs were defined as Hoechstdim CD45neg; characteristics 
which have been suggested to define the lung-resident MSC [221, 227]. This study was 
therefore based on different criteria to what I have used here and it is therefore possible 
that this represents a different population of cells to the one I am investigating. Indeed, 
since I showed a significant decrease in the percentage of EpCAMpos PαS cells (Figure 
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5.6), it is possible that it is this population of cells that is equivalent to those 
investigated in the previous study [243], and that my observations are therefore 
consistent with this study. 
 
Given the increase in PαS cells in the lungs it was important to establish where these 
MSCs originated from. The observed increase in the number of PαS cells in the lungs of 
bleomycin-treated mice could be the result of an expansion of the population of PαS 
cells resident in the lungs of naïve mice, or it could be due to recruitment of PαS cells 
from the bone marrow into the lungs in response to injury. For PαS cells to be recruited 
into the lungs, they must first be mobilised from the bone marrow into the blood. This is 
a dynamic process and it is therefore a challenge to actually analyse levels of these cells 
in the blood. Identification of an increased number of PαS cells in the blood 4 and 7 days 
after bleomycin injury compared to control mice (Figure 5.5) suggests that PαS cells are 
mobilised from the bone marrow into the blood in response to injury. This therefore 
indicates that the increase in PαS cell numbers observed in the lungs after bleomycin 
injury may be the result of increased mobilisation of these cells from the bone marrow 
into the blood, from where they are recruited into the lungs. Furthermore, lack of 
expression of EpCAM on PαS cells identified in the circulation adds weight to the 
hypothesis that these cells are being mobilised from the bone marrow (Figure 5.5).  
 
Phenotypic characterisation of PαS cells in the bone marrow and lungs, as presented in 
the previous chapter, revealed that the PαS cell population in the lungs consists of at 
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least two subpopulations: EpCAMneg and EpCAMpos PαS cells. The work presented here 
has demonstrated an increase in the number of PαS cells in the lungs in response to 
bleomycin injury, taking into account both of these subpopulations. Given that these 
subpopulations may represent cell types with different functions it was of interest to 
investigate how these subpopulations changed in this model and whether the observed 
increase in total PαS cells in the lungs represented an increase in both subpopulations, 
or just one of them. Interestingly, 7 days after bleomycin injury, a change in the 
proportion of EpCAMneg and EpCAMpos PαS cells in the lungs was observed, with the 
EpCAMneg population increasing both in percentage and absolute number (Figure 5.6). 
As described in the previous chapter, in naïve mice PαS cells in the bone marrow 
differed from PαS cells in the lungs in terms of their lack of expression of EpCAM, which 
70% of lung PαS cells were shown to express, compared to virtually no expression on 
bone  marrow PαS cells. It is therefore possible that the increase in EpCAMneg PαS cells 
in the lungs 7 days after bleomycin injury signifies a recruitment of EpCAMneg PαS cells 
from the bone marrow. This would support the hypothesis that PαS cells are mobilised 
from the bone marrow and recruited to the lungs in response to injury. However, it is 
also possible that this result could simply highlight functional differences that exist 
between the EpCAMneg and EpCAMpos PαS cell populations. Indeed it is possible that 
these subpopulations of PαS cells represent different cell types with different functions 
and that one population increases in number in response to injury to perform some as 
yet unknown function, while the other population remains unchanged. As previously 
discussed, the EpCAMpos PαS cell population may represent epithelial progenitor cells, 
while the EpCAMneg PαS cell population may represent MSCs; in which case, these data 
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would suggest that it is the MSC population that is increasing in number in response to 
bleomycin injury, supporting our original hypothesis. 
 
In order to investigate whether the increase in PαS cells in the lungs in response to 
bleomycin injury was the result of an expansion of lung-resident PαS cells, the 
proliferation of PαS cells was examined. Analysis of BrdU incorporation into the DNA of 
PαS cells revealed that very few of the PαS cells in the lungs were proliferating under 
normal conditions (Figure 5.7). No change could be seen in the percentage of BrdU-
positive PαS cells 4 days after bleomycin treatment, however a small but significant 
increase in the percentage of proliferating PαS cells was observed 7 days after 
bleomycin treatment, compared to PBS-treated control mice (Figure 5.7). These data 
were confirmed by examination of Ki67 staining in PαS cells 7 days after bleomycin 
treatment. This increase in proliferation was small and it is possible that the time point 
at which these cells are proliferating most has been missed, however, it was not feasible 
within the scope of this project to exhaustively analyse cells at every time point. These 
results indicate that there is an expansion of the lung-resident PαS cell population; 
however, further studies would be required to definitively prove this.  
 
Further investigation of proliferation of the EpCAM-positive and -negative 
subpopulations of PαS cells in the lungs showed there to be increased proliferation of 
both populations of cells in response to bleomycin injury (Figure 5.7). This is surprising 
since there was in fact a reduction in the number of EpCAMpos PαS cells in the lungs at 
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this time point after bleomycin injury (Figure 5.6). If, as discussed in the previous 
chapter, EpCAMneg PαS cells represent MSCs, while EpCAMpos PαS cells actually 
represent epithelial progenitor cells, then it is possible that the epithelial progenitor 
cells are proliferating in response to injury, as has been previously suggested to occur 
and are differentiating into epithelial cells in order to promote repair of the lungs [218]. 
The increase in number as well as proliferation of the EpCAMneg PαS cell population, the 
putative MSCs, in the lungs in response to injury may indicate that these cells are having 
a paracrine effect rather than differentiating into other cells types. Indeed it has been 
suggested that MSCs are necessary to support bronchiolar epithelial progenitor cell 
proliferation and differentiation in vitro [220]. 
 
Interestingly, although there is no change in the percentage of PαS cells proliferating in 
the bone marrow either 4 or 7 days after bleomycin treatment, the percentage of cells 
proliferating in naïve animals is much greater than the percentage proliferating in the 
lungs of naïve mice (36% in the bone marrow, compared to 1% in the lungs) (Figure 
5.7). This suggests that a significant proportion of PαS cells in the bone marrow are 
continually dividing, possibly to provide cells to be mobilised into the circulation from 
where they can be recruited to sites of injury or simply to contribute to day-to-day 
repair. These data are consistent with that of Morikawa et al. who showed 
approximately 30% of PαS cells in the bone marrow to be in the cell cycle in a naïve 
mouse [86]. This proliferation is unusual as HSCs and stem cells in the bone marrow are 
normally quiescent.  
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Analysis of PαS cells in the blood suggests that these cells may be recruited into the 
lungs from the bone marrow in response to injury, however the increased proliferation 
of this cell population in the bleomycin-exposed lungs also suggests there may be an 
expansion of lung-resident PαS cells in response to injury. At this stage, it is still not 
possible to say for certain which of these processes is responsible for the increase in the 
number of PαS cells in the lungs of bleomycin-treated mice.  Indeed the question of 
whether MSCs are being mobilised from the bone marrow in this, or any model is a very 
difficult one to answer and at present no completely satisfactory method exists to 
address it. One option would be to create a chimeric mouse, in which the bone marrow 
is GFP-labelled, by irradiating the bone marrow of one mouse and reconstituting it with 
the bone marrow of a GFP-labelled mouse. These mice could then be treated with 
bleomycin and the lungs analysed for presence of GFP-positive PαS cells, which would 
confirm the bone marrow origin of these cells. This method would be useful and would 
certainly provide complimentary data to what has been presented here, but limitations 
still remain. Indeed, the concept of using bone marrow chimeric mice to investigate 
MSCs is a contentious subject since it is debatable as to whether MSCs are actually 
destroyed by irradiation, since, as stromal cells, it is possible that they resist irradiation. 
Indeed, in some studies bone marrow chimeric mice are used assuming resistance of 
MSCs to irradiation, and therefore considering the GFP-negative fraction of bone 
marrow cells to contain host-derived MSCs [287], while in others, bone marrow 
chimeric mice have been used assuming that MSCs are killed by irradiation, and 
therefore considering the GFP-positive fraction of the bone marrow to contain MSCs 
[288]. Furthermore, studies conducted by Morikawa et al. demonstrated that PαS cells 
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were largely resistant to irradiation [86]. Given this, it would not be possible to 
unequivocally conclude that a lack of GFP-positive PαS cells in the lungs after bleomycin 
treatment means that these cells do not have a bone marrow origin since there could 
still be recruitment of MSCs from the recipient mouse that resisted initial irradiation.  
 
Given that an increase in the number of PαS cells was observed in the lungs 7 days after 
bleomycin treatment, it was of interest to investigate whether this population of cells 
could be identified in the airways and whether it changed after injury. Although there 
was an evident population of PαS cells in the BAL fluid, and there was an increase in the 
number of these cells both 4 and 7 days after bleomycin injury compared to control 
mice, the most notable increase was in the total CD45neg Ter119neg Sca-1pos population 
(Figure 5.8). As in the lung tissue, there was a significant increase in the number of the 
EpCAMneg population of CD45neg Ter119neg Sca-1pos and PαS cells 7 days after bleomycin 
injury, but again, most notably in the CD45neg Ter119neg Sca-1pos population (Figure 5.8). 
There was also a significant increase in the EpCAMpos CD45neg Ter119neg Sca-1pos 
population, but not in the EpCAMpos PαS cell population. Further phenotypic and 
functional analysis of the CD45neg Ter119neg Sca-1pos population of cells will be 
necessary to ascertain what these cells are and the importance of this population of cells 
in the airways of the injured lungs. 
 
Although not conclusive, the data is consistent with the idea that PαS cells are being 
recruited from the bone marrow into the lungs in response to bleomycin injury. Indeed 
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it is well known that exogenously administered MSCs can migrate into tissue from the 
bloodstream, although the mechanisms by which this migration occurs remain unclear. 
As described in the previous chapter, chemokines and their receptors are known to be 
important in the migration of cells into tissue and it is therefore likely that they are 
playing a role here. As demonstrated in the previous chapter, PαS cells express a 
number of chemokine receptors, including CXCR3, CCR9 and CCR10 and therefore it is 
reasonable to hypothesise that the ligands for one or more of these receptors are 
upregulated in response to bleomycin injury, causing PαS cells to migrate into the lungs.  
 
Interestingly, CXCL10/IP-10, and its receptor CXCR3, have been previously shown to be 
important in the bleomycin model of pulmonary fibrosis [210, 289, 290], along with 
fibrosis of the heart [291], liver [292] and kidney [293]. Work published in 2004 
showed CXCL10 expression to be induced in the lung tissue and BAL fluid of bleomycin-
treated mice, and bleomycin-induced fibrosis has been shown to be increased in 
CXCL10-knockout mice [210]. It is worth noting that no difference in recruitment of T 
cells, NK cells or NKT cells, cells known to be chemotactic to CXCL10, was observed in 
CXCL10-deficient mice [210], suggesting that the detrimental effect of blocking CXCL10 
in this model is not the result of changes in numbers of these cells recruited to the lungs. 
In fact, no convincing data has yet been published to explain the role of CXCL10 in 
reducing fibrosis in the bleomycin model of pulmonary fibrosis. Given these results and 
the data presented in the previous chapter showing high levels of expression of CXCR3 
on PαS cells, we hypothesised that CXCL10 produced in the lungs after bleomycin injury 
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results in the recruitment of PαS cells into the lungs where their anti-inflammatory 
effects would decrease the fibrosis that would otherwise occur. If this hypothesis were 
correct, blocking either CXCL10 or CXCR3 would prevent the recruitment of PαS cells to 
the lungs in response to bleomycin injury, which would prevent them from suppressing 
the immune response and would exacerbate the fibrotic response, as is seen in CXCL10-
knockout mice [210].   This would not only confirm the importance of CXCR3 in the 
recruitment of MSCs in response to injury, but would also confirm that PαS cells are 
indeed being recruited from the bone marrow. 
 
It is interesting to note that in this study blocking CXCR3 had no effect on the 
recruitment of PαS cells into the lungs 7 days after bleomycin injury, as well as having 
no effect on the increase in number of CD45-positive lung cells or on the infiltration of T 
cells into the lungs (Figure 5.9). This would suggest that contrary to the original 
hypothesis, CXCR3 and CXCL10 are not involved in the recruitment of PαS cells into the 
lungs in response to injury, or at least if they are, other chemokines and receptors are 
also involved which compensate for the loss of CXCR3. It is worth noting that in most of 
the previous studies mentioned above, CXCL10 knockout mice were used instead of 
blocking CXCR3. This is a better tool to use to investigate the involvement of CXCL10 
and CXCR3 as it ensures the complete blockade of this interaction, while using an 
antibody to block CXCR3 is unlikely to inactivate this interaction to the same level, and 
therefore some residual signalling may remain. The time constraints of this project, 
however, did not allow for the use of CXCL10-knockout mice. It is also possible that the 
 ~ 196 ~ 
 
blocking regime used here is not optimal for this model and that use of a higher dose of 
the CXCR3-blocking antibody or its administration at different time points in the model 
may still block the increase in the number of PαS cells in the lungs that is observed in 
response to bleomycin injury. 
 
 In addition, it would be worthwhile investigating the role of other chemokines and 
their receptors in the recruitment of PαS cells into the lungs in response to injury. Since 
CXCL12 and CXCR4 have been shown to be involved in the recruitment of fibrocytes 
into the bleomycin-injured lungs [164], it is possible that this chemokine axis may also 
be involved in the migration of PαS cells. Indeed, in a recent study, it was suggested that 
inhibition of CXCR4 decreased the in vitro migration of MSCs towards bleomycin-
treated lung lysates [294]; however, whether this chemokine axis is important in vivo 
remains to be established.  
 
Given that there is an increase in PαS cells in the lungs 7 days after bleomycin injury, the 
next question that was important to address was what role these cells are playing in the 
diseased lungs. One approach we took to addressing this question was to isolate PαS 
cells from the bone marrow and to inject them into bleomycin-treated mice. Although 
culture expanded MSCs have been injected into mice treated with bleomycin in previous 
studies and shown to be immunosuppressive [129, 142, 143], this is the first study to 
inject PαS cells, which have been previously shown to be enriched for cells with 
phenotypic and functional characteristics of MSCs [86], into mice in this disease model. 
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A robust recruitment of PαS cells could be seen in the BAL, lung tissue and spleen in 
both control and bleomycin-treated mice (Figure 5.10), confirming the ability of these 
cells to migrate into tissue.  Furthermore, there was a significantly greater recruitment 
of CD45neg DiDpos MSCs in the lung tissue and BAL in mice that had been treated with 
bleomycin, while there was no difference in the recruitment of CD45neg DiDpos cells to 
the spleen (Figure 5.10). This demonstrates that MSCs can be specifically recruited into 
tissues from the circulation in response to injury and suggests that the increased 
number of endogenous PαS cells that we have observed in the bleomycin-treated lungs 
may be at least in part the result of recruitment from the circulation. These data are 
consistent with the results of Ortiz et al. who showed significantly greater recruitment 
of exogenous MSCs into the bleomycin-injured lungs compared to controls [129]. 
Although at this time point injection of PαS cells had no beneficial effect on weight-loss 
there was a trend towards a reduced total number of cells in the BAL and a significant 
decrease in the total number of lung cells compared to bleomycin-treated control mice, 
suggesting that injection of MSCs may have some anti-inflammatory effect. In future, 
examination of leukocyte populations and cytokine production in the lungs and BAL 
following MSC injection will be necessary to gain further insights into the possible anti-
inflammatory effects of MSCs in the diseased lungs. It would be interesting in the future 
to investigate the effect of injecting PαS cells on the development of fibrosis at a later 
time point, although previous studies suggest it is likely that administration of these 
cells would reduce fibrosis [129, 142, 143]. It is also possible, that the protocol used 
here was not optimal and that a more dramatic effect may have been observed had 
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more PαS  cells been injected, multiple injections been performed or the timing of the 
injection changed.  
 
Furthermore, this model provides a unique tool to dissect the mechanisms of trafficking 
and recruitment of bone marrow MSCs into the lungs in response to injury as well as to 
examine the role MSCs are playing in the diseased lungs.  Indeed by pre-treating MSCs 
with pertussis toxin prior to injection it would be possible to establish whether 
recruitment of MSCs into tissues is dependent on chemokines and their receptors. 
Studies following on from this blocking specific chemokine receptors would increase 
our understanding of which chemokines in particular are important in the migration of 
MSCs into tissues. Following on from this, it would be possible to use this knowledge to 
block or enhance the recruitment of endogenous PαS cells to the lungs in response to 
bleomycin injury.  
 
It would also be interesting to investigate whether enhancing mobilisation of 
endogenous PαS cells using an established method in the laboratory, by pre-treating 
mice with VEGF before administration of a CXCR4 antagonist, AMD3100, would enhance 
recruitment of PαS cells to the bleomycin-injured lungs, and whether this would result 
in a shift in the inflammatory profile of the lungs to a more anti-inflammatory and anti-
fibrotic phenotype. 
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In summary, PαS cells have been studied in the lungs after bleomycin treatment and 
have been shown to increase in number 7 days after injury. Analysing expression of 
EpCAM on PαS cells in the lungs demonstrated that it was the EpCAMneg population of 
PαS cells that increased in number in response to injury. At this time point an increased 
number of EpCAMneg PαS cells was observed in the circulation and a small but 
significant increase in the percentage of PαS cells proliferating in the lung could be 
detected, suggesting both a mobilisation of PαS cells from the bone marrow and 
recruitment to the lungs, as well as an expansion of lung-resident PαS cells, in response 
to injury.  Administration of exogenous PαS cells resulted in a significantly greater 
recruitment of PαS cells to the BAL and lungs in mice treated with bleomycin, further 
confirming the ability of these cells to be recruited from the circulation into the lungs in 
response to injury. Further experiments will be required to confirm the recruitment of 
endogenous PαS cells from the bone marrow into the lungs in response to injury and to 
establish the role of these cells in the injured lungs.  
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CHAPTER 6 
Characterisation of the composition and 
functionality of the bone marrow in the HDM 
model of allergic airways disease 
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6.1 Introduction 
The bone marrow is the primary site of haematopoiesis during adult life, and also 
serves as a reservoir for mature leukocytes and stem cells. Although cells are mobilised 
from the bone marrow under homeostatic conditions, a much higher mobilisation of 
certain subsets of these cells occurs under inflammatory conditions.  
 
The chemokine CXCL12 is constitutively produced within the bone marrow, and via its 
interaction with CXCR4, has been shown to be important in retaining leukocytes and 
stem cells within the bone marrow [190]. Indeed, antagonism of CXCR4 has been shown 
to mobilise HSPCs and EPCs into the blood [191, 192, 194]. In addition, granulocyte-
colony stimulating factor (G-CSF), which is known to mobilise HSPCs from the bone 
marrow, has been shown to disrupt this CXCL12/CXCR4 retention axis by reducing both 
the concentration of CXCL12 in the bone marrow and the expression of CXCR4 on HSPCs 
[190]. Moreover, blood-borne factors such as cytokines, chemokines and growth factors 
have previously been shown to stimulate mobilisation of cells from the bone marrow 
into the circulation [23-25, 189]. In 1999, Asahara et al. showed that intraperitoneal 
administration of vascular endothelial growth factor (VEGF) over 4 days caused an 
increase in mobilisation of EPCs from the bone marrow into the circulation [295]. 
Furthermore, previous work in our laboratory has shown that cytokine pre-
conditioning of the bone marrow can modulate the profile of progenitor cells and 
leukocytes that can be mobilised from the bone marrow into the circulation in response 
to CXCR4 antagonism by affecting their cell cycle status and retention in the bone 
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marrow [196]. Intraperitoneal administration of VEGF was shown to increase the 
mobilisation of EPCs and MSCs from the bone marrow into the blood, while it had an 
inhibitory effect on the mobilisation of HPCs and neutrophils in response to AMD3100 
administration [196]. In contrast to G-CSF induced mobilisation, VEGF did not disrupt 
the CXCR4/CXCL12 retention axis, but instead stimulated HPCs to enter the cell cycle by 
signalling through VEGFR1, thereby reducing their capacity to migrate and be mobilised 
from the bone marrow. Conversely, VEGF signalled through VEGFR2 on EPCs, 
stimulating their mobilisation from the bone marrow in response to CXCR4 antagonism 
with AMD3100 [196]. Importantly, pre-treatment with VEGF induced the mobilisation 
of significant numbers of MSCs from the bone marrow in contrast with all other 
treatment combinations tested, where no mobilisation was observed [67]. Following on 
from this, work in our laboratory has shown VEGF to signal through VEGFR2 expressed 
on MSCs to induce their mobilisation, and that this is dependent on membrane 
metalloproteinase (MMP) activity (Hahnel, M., personal communication). It is important 
to note that mobilisation of MSCs in response to AMD3100 was critically dependent on a 
4-day pre-treatment with VEGF. Furthermore, changes in the mobilisation of progenitor 
cells from the bone marrow occurred in the absence of changes in the number of cells in 
the bone marrow. These results demonstrate that the mobilisation of subsets of 
progenitor cells and leukocytes from the bone marrow into the circulation is regulated 
by distinct factors and mechanisms, which may be important in inflammatory disease 
where levels of circulating cytokines, chemokines and growth factors change. However, 
the mechanisms involved in regulating the mobilisation of progenitor cells and 
leukocytes in inflammatory disease are still largely unknown and whether the bone 
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marrow is functionally altered in inflammation in terms of its potential for mobilisation 
remains to be established. 
 
To date, there has been only limited investigation into the impact of inflammation on 
the bone marrow and whether the bone marrow changes in terms of its composition. 
One inflammatory state in which the bone marrow has been investigated is in 
hypercholesterolemia, where increased numbers of monocytes are observed in the bone 
marrow, accompanied by an increased mobilisation of these cells into the circulation 
[296]. Another example of inflammatory disease is allergic asthma, where respiratory 
allergen exposure elicits Th2-polarised airway inflammation, along with airway 
hyperreactivity and structural remodelling of the lungs [297]. One of the hallmarks of 
human asthma is an accumulation of eosinophils in the lungs; this is associated with 
eosinophilia in the blood, and, in the OVA model of murine allergic airways disease, in 
the bone marrow [200-202, 298-301]. Furthermore, previous work in our laboratory 
has demonstrated an increased release of eosinophils from the bone marrow into the 
circulation in response to OVA sensitisation and challenge and that this is the result of 
IL-5, generated during the allergic response, acting systemically to mobilise eosinophils 
[26]. Following on from this, studies in vitro suggested that IL-5 stimulated 
chemokinesis of bone marrow-derived eosinophils and that this was responsible for 
their release from the bone marrow in vivo [25]. Further analysis in vivo suggested that 
the process of mobilisation of eosinophils was regulated by integrin α4 acting to retain 
eosinophils in the bone marrow, and integrin β2 acting in the opposite direction [25]. In 
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addition, a number of studies have shown there to be increased eosinopoeisis in the 
bone marrow, associated with increased CD34+ IL-5+ eosinophil progenitor cells in the 
bone marrow and lungs in asthmatic patients and OVA-challenged mice [302-304]. 
Furthermore, studies have shown there to be an increased mobilisation of these cells 
from the bone marrow into the circulation, which is mediated by increased expression 
of CCR3, along with decreased expression of CXCR4 on CD34+ progenitor cells [305-
307]. These studies suggest that the bone marrow is activated by allergen exposure to 
increase production of IL-5, which drives increases eosinopoeisis and mobilisation of 
eosinophils from the bone marrow. These studies show that inflammation can change 
the composition of the bone marrow in terms of mature leukocytes and HPCs and 
suggest that the functionality of the bone marrow may also be altered in terms of the 
potential for mobilisation of cells into the circulation. However, the effect of 
inflammation on other populations of progenitor cells within the bone marrow and 
whether their mobilisation into the bloodstream in inflammatory disease is altered 
remains unclear.  
 
Previous work in our laboratory, working with the OVA model of allergic airways 
disease, has shown increased recruitment of late outgrowth EPCs to the lungs of 
allergen-challenged mice compared with PBS-treated controls at days 24 and 35, during 
the early stages of tissue remodelling, which correlated with an increased number of 
blood vessels present in the lungs [67].  At day 55, once tissue remodelling and 
angiogenesis were fully established, numbers of EPCs in the lungs of allergen-
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challenged mice were comparable to control mice [67]. In addition, an elevation of EPCs 
in the blood could be detected at day 24 in mice challenged with OVA, compared to 
control mice [67]. EPCs have been shown to express the chemokine receptor CXCR2 
[68] and their recruitment to the lungs in response to sensitisation and challenge with 
OVA has been shown to be dependent on the CXCL1/2-CXCR2 chemokine axis [67]. The 
concentration of the chemokines CXCL1 and CXCL2 were shown to be elevated in the 
lungs following allergen challenge and blockade of CXCR2 reduced numbers of late 
outgrowth EPCs in the lungs of OVA sensitised mice back to basal levels [67]. VEGF-A is 
a potent pro-angiogenic factor, stimulating survival and proliferation of endothelial 
cells, and has been previously implicated in asthma, where levels in the BAL fluid have 
been shown to correlate with the degree of angiogenesis observed in the lungs [295, 
308-310]. Furthermore, in the OVA model of allergic airways disease, VEGF-A was 
shown to be elevated in the lung tissue at days 24 and 35 of the model, at the onset of 
tissue remodelling [67]. Indeed, Lee et al. demonstrated that overexpression of VEGF-A 
in the murine lungs resulted in increased blood vessels in the lungs and increased 
airway remodelling [311]. Studies in our laboratory showed that although intranasal 
administration of CXCL1/2 in combination with OVA sensitisation resulted in a 
significant recruitment of late outgrowth EPCs to the lungs, no such effect was observed 
with VEGF-A [67], suggesting that recruitment from the blood to the lungs is not 
dependent on VEGF. Critically, recruitment of EPCs to the lungs in response to CXCL1/2 
administration was dependent on prior sensitisation with OVA, suggesting that there 
may be changes that occur in the bone marrow as a result of allergen sensitisation, such 
as changes in numbers of EPCs, or their capacity to be mobilised. In subsequent 
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experiments where CXCR2 was blocked and recruitment of EPCs to the lungs was 
abrogated, levels of EPCs in the blood were unchanged [67], suggesting that although 
CXCL1/2 may be critical for the recruitment of EPCs to the lungs, another distinct 
mechanism is involved in the mobilisation of EPCs from the bone marrow into the blood 
from where they can be recruited to the lungs; however, this remains unclear. Since 
VEGF has been shown previously to mobilise EPCs from the bone marrow [295], it is 
possible that in addition to driving angiogenesis in the lungs, VEGF acts systemically to 
regulate EPC mobilisation in models of allergic airways disease.  
 
Historically, chicken egg ovalbumin (OVA) sensitisation of mice has been used in the 
laboratory to model asthma; however, it has some limitations.  OVA is an innocuous 
protein, which when administered intranasally causes inhalation tolerance rather than 
sensitisation. In order to elicit an immune response to inhaled OVA, the mouse must 
first be sensitised by administration of OVA in combination with a strong Th2-polarising 
adjuvant such as aluminium hydroxide into the peritoneal cavity. Subsequent airway 
challenge with OVA then elicits an asthma-like phenotype. The differences between OVA 
and an aeroallergen inhaled by humans are likely to affect not only the allergic 
response, but also the mechanisms which bring about this response, and therefore it is 
not the most appropriate model to use to attempt to recapitulate the human asthmatic 
phenotype and to dissect the mechanisms underlying disease progression. In more 
recent years, the house dust mite (HDM) model has been thought to be more 
representative of asthma in humans. HDM is a common environmental aeroallergen and 
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has clinical relevance with respect to asthma given that sensitisation to HDM allergens 
in humans has been strongly associated with allergic asthma [312]. HDM has been 
shown to have an intrinsic ability to elicit an immune response when administered 
intranasally. Indeed, repeated intranasal administration of HDM has been shown to 
elicit an asthma-like phenotype in the absence of adjuvant, unlike the surrogate allergen 
OVA [313]. For these reasons, the studies described in this thesis have been carried out 
in the HDM model of allergic airways disease. 
 
Given the role of the bone marrow as a reservoir for leukocytes and progenitor cells, it 
seems likely that its composition and functionality is altered in inflammatory disease, 
with changes in cytokines, chemokines and growth factors in the serum impacting on 
the bone marrow to mobilise subsets of cells into the circulation. Data from the OVA 
model of allergic airways disease has demonstrated a role for EPCs in the development 
of pathological angiogenesis in the lungs and has shown CXCL1/2 to be critical in their 
recruitment to the lungs in response to allergen sensitisation [67]; however the 
question of how these cells are mobilised from the bone marrow still remains. We 
sought to investigate this process in more detail, to gain a better understanding of the 
role of the bone marrow in allergic airways disease and to determine the mechanism by 
which EPCs are mobilised from the bone marrow to be recruited to the lungs in 
response to allergen challenge.  
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6.2 Aims 
 To characterise the composition and functionality of the bone marrow in terms of 
progenitor cell numbers in the HDM model of allergic airways disease 
 To investigate whether progenitor cells are recruited to the lungs in the HDM model 
of allergic airways disease 
 To investigate the effect of blocking VEGF on the recruitment of EPCs to the lungs in 
response to HDM 
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6.3 Results 
6.3.1 Progenitor cells and angiogenesis in the lungs in the HDM model 
In initial experiments, Balb/c mice were intranasally exposed to either 15 μg HDM or 
PBS 3 times a week for 1 or 3 weeks (Figure 6.1A). Progenitor cells were enumerated in 
the lungs of HDM-challenged mice to ascertain whether similar changes could be 
observed in this model compared with the OVA model of allergic airways disease [67]. 
In the lungs, an increase in numbers of late outgrowth EPCs could be observed during 
the acute inflammatory phase of the HDM model, after only 1 week of HDM exposure, 
with late outgrowth EPC levels returning to baseline after 3 weeks of HDM treatment 
(Figure 6.1B). In contrast, no increase in numbers of early outgrowth EPCs could be 
observed after 1 week of HDM treatment, but a significant elevation was shown 
following 3 weeks of HDM exposure (Figure 6.1C), demonstrating different recruitment 
kinetics for each cell population. In contrast, no change in the number of PαS cells was 
observed in the lungs after 1 week of HDM challenge, compared with control PBS-
treated mice (Figure 6.1D). This is in contrast with the bleomycin model of pulmonary 
fibrosis, where an increase in the number of PαS cells was observed in the lungs 7 days 
after bleomycin instillation (Figure 5.4B). Total numbers of cells in the BAL fluid are 
shown to indicate the level of inflammation at both time points. After 1 week of HDM 
exposure, a trend towards an increase in cell numbers could be observed in the BAL 
fluid, however this was not significant (Figure 6.1E). After 3 weeks of HDM exposure, a 
significant increase in numbers of cells in the BAL was observed, indicating a greater 
degree of inflammation at this time point (Figure 6.1E). 
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Figure 6.1 Progenitor cells in the lungs in the HDM model 
8-10 week old female Balb/c mice were challenged intranasally with 15 μg HDM or PBS 3 times a week for 1 
or 3 weeks (A). 24 hours after the last challenge, mice were culled and lungs were harvested.  Lung 
mononuclear cells were plated into EPC colony assays and LOG (B) and EOG (C) EPCs were enumerated. 
Total lung cells were analysed for PαS cell numbers (D). Total cell numbers in the BAL fluid are shown for 
each time point (E). Bars represent mean ± SEM. n=4-6, 3 independent experiments, * p < 0.05, p < 0.01. 
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Increased peribronchial blood vessels were observed in the lungs of mice treated with 
HDM for 3 and 5 weeks (Figure 6.2A and 6.2B) consistent with what has been 
previously shown in the OVA model of allergic airways disease, albeit with a different 
time-course [67] and in asthmatic patients [314, 315]. Furthermore, a significant 
increase was seen in levels of VEGF in the lung tissue of mice treated with HDM for 1 
week compared with PBS control mice (Figure 6.2C). 
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Figure 6.2 Angiogenesis in the lungs in the HDM model 
8-10 week old mice were challenged intranasally with 15 μg HDM or PBS 3 times a week for 1, 3 or 5 weeks. 24 
hours after the last challenge, mice were culled. Lungs were paraffin-embedded and sections were stained for 
vWF to label blood vessels (brown) (A). The number of peribronchial blood vessels was quantified per mm
2
 (B). 
VEGF levels in the lung homogenate of mice treated with HDM for 1 week were measured (C). Bars represent 
mean ± SEM. n=4-6, * p < 0.05. 
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6.3.2 Effect of blocking VEGF on recruitment of EPCs to the lungs 
VEGF is a potent pro-angiogenic factor [295] and has been shown to regulate EPC 
mobilisation from the bone marrow [295]; therefore, the effect of blocking VEGF 
signalling on the recruitment of EPCs into the lungs in response to allergen was 
investigated. In order to investigate whether VEGF acts systemically in the HDM model 
of allergic airways disease to regulate the mobilisation of EPCs from the bone marrow 
into the circulation, experiments to block VEGF signalling were carried out. Balb/c mice 
were exposed to either PBS or HDM for 1 or 5 weeks, with SU5416, a VEGF receptor 1/2 
inhibitor, administered intraperitoneally 20 minutes prior to airway allergen challenge. 
As previously observed, 1 week of HDM exposure resulted in a significant elevation in 
late outgrowth EPCs in the lungs, while this effect was abrogated by the blockade of 
VEGF (Figure 6.3A). Furthermore, after 5 weeks of HDM exposure, blockade of VEGF 
reduced the number of peribronchial blood vessels in the lungs of HDM-challenged mice 
back to baseline levels (Figure 6.3B). 
 
 
 
 
 ~ 214 ~ 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Effect of blocking VEGF on recruitment of EPCs to the lungs 
8-10 week old mice were challenged intranasally with 15 μg HDM or PBS 3 times a week for 1 or 5 weeks. Mice 
were intraperitoneally administered SU5416 or PBS 20 minutes prior to challenge. 24 hours after the last 
challenge, mice were culled. LOG EPC colonies were enumerated in the lungs of mice treated with HDM and 
SU5416 for 1 week (A). Lung sections from mice treated with HDM and SU5416 for 5 weeks were stained with an 
antibody to vWF and peribronchial blood vessels within 10 μm of a medium sized airway (30 μm in diameter) 
were quantified. Numbers expressed as vessels per airway (B). Bars represent mean ± SEM. n=4-8, 2 independent 
experiments, ** p < 0.01, *** p < 0.001. 
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6.3.3 Changes in the composition of the bone marrow in the HDM model of 
allergic airways disease 
Having observed the same pattern of recruitment of EPCs to the lungs in response to 
allergen challenge along with increased peribronchial angiogenesis in the HDM model 
compared with the OVA model, the next step was to investigate whether this was 
associated with any changes in the bone marrow. The bone marrow of Balb/c mice 
treated intranasally for 1 week with either PBS or HDM, the time point at which an 
increase in EPCs in the lungs was observed, was analysed for progenitor cell 
populations, to determine whether the composition of the bone marrow was changed 
during inflammation. Colony assays were used to determine the proportion of HPCs and 
MSCs, along with further quantification of MSCs by flow cytometry to measure PαS cells 
in the bone marrow of HDM-treated mice, compared with controls (Figure 6.4A-C). No 
significant differences were observed in either the HPC or MSC populations, measured 
either by colony assays or flow cytometry (Figure 6.4A-C). 
 
Numbers of early outgrowth and late outgrowth EPCs were measured in the bone 
marrow of mice treated with HDM for 1 week, as well as in mice challenged for 5 weeks 
as a comparison since numbers of late outgrowth EPCs in the lungs were shown to be 
comparable to control mice by this time point (Figure 6.4A). Investigating the numbers 
of EPCs showed there to be no significant difference in the proportion of early 
outgrowth EPCs in the bone marrow in mice treated with HDM for either 1 or 5 weeks 
(Figure 6.4D). However, in terms of late outgrowth EPCs, a trend towards an increase in 
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this population of progenitor cells was observed after 1 week of HDM treatment 
compared to PBS-treated controls, and this population remained increased after 5 
weeks of HDM treatment (Figure 6.4E). 
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Figure 6.4 Changes in the composition of the bone marrow in the HDM model of allergic airways disease 
8-10 week old mice were challenged intranasally with 15 μg HDM or PBS 3 times a week for 1 week. 24 hours 
after the last challenge, mice were culled and the bone marrow isolated for analysis. Bone marrow cells were 
put in colony assays to evaluate numbers of HPCs (A) and MSCs (B). Bone marrow cells were also analysed by 
flow cytometry to identify PαS cells as another measure of MSCs (C). Total bone marrow cells were put into 
EPC colony assays and early outgrowth EPCs (D) were enumerated by morphology after 7 days, while late 
outgrowth EPCs (E) were enumerated by morphology after 21 days in culture. Bars represent mean ± SEM. 
n=4-12, 2 independent experiments. 
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6.3.4 Mobilisation of cells into the blood in response to AMD3100 in the HDM 
model 
To investigate whether changes in the cytokine milieu associated with allergen 
challenge alters the functionality of the bone marrow, the mobilisation of cells from the 
bone marrow into the circulation in response to the CXCR4 antagonist AMD3100 was 
investigated. Balb/c mice were exposed to HDM for 1 week before AMD3100 was 
administered intraperitoneally, and 1 hour later, mice were sacrificed. In both naïve and 
HDM-exposed mice, a significant increase was observed in both the total white blood 
cells and HPCs in the blood in mice that were administered AMD3100 (Figure 6.5A and 
6.5B). Although there may have been a trend towards increased mobilisation of total 
white blood cells in response to AMD3100 in the HDM-treated mice compared to the 
PBS-treated controls, this was not statistically significant. No difference in mobilisation 
of HPCs in response to AMD3100 was observed between control mice treated with PBS 
and those exposed to HDM (Figure 6.5B). Differential counts of eosinophil and 
neutrophil numbers in the blood in response to AMD3100 administration showed no 
difference between HDM- and PBS-treated mice (data not shown). At this time point, no 
measurable levels of EPCs could be detected in the blood in mice either with or without 
administration of AMD3100. Due to low cell numbers, mobilisation of other cell 
populations could not be measured; however, this would be important to investigate in 
future studies. 
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Figure 6.5 Mobilisation of cells into the blood in response to AMD3100 in the HDM model 
8-10 week old mice were challenged intranasally with 15 μg HDM or PBS 3 times a week for 1 week. 23 hours 
after the last challenge, mice were administered either PBS or 5 mg/kg AMD3100 intraperitoneally and 1 hour 
later mice were culled. Total white blood cells were enumerated (A) and HPCs were quantified per ml blood by 
colony assay (B). Bars represent mean ± SEM. n=4-7, 2 independent experiments, * p < 0.05, ** p < 0.01. 
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6.4 Discussion 
While the bone marrow is an important reservoir for leukocytes and progenitor cells 
that contribute to inflammatory disease, to date, very few studies have examined the 
functional changes in the bone marrow associated with inflammatory disease. Given its 
function in haematopoiesis and its role as a reservoir for leukocytes and progenitor 
cells, it is logical to hypothesise that it may be altered in terms of its composition and 
functionality in inflammatory disease. Furthermore, previous work in the laboratory 
has demonstrated increased recruitment of late outgrowth EPCs to the lungs in the OVA 
model of allergic airways disease, which correlated with increased peribronchial 
angiogenesis, but had failed to establish a mechanism for the mobilisation of these cells 
from the bone marrow in response to OVA sensitisation [67]. In order to further 
investigate the role of the bone marrow in allergic airways disease, the HDM model was 
chosen as it is thought to be a more relevant allergen to study asthma in humans as it 
does not require peripheral sensitisation and is a common environmental allergen 
[313]. This model has been shown to recapitulate the characteristic features of asthma, 
including inflammation, increased mucus production and collagen deposition, along 
with increased airway smooth muscle cell mass [313]. 
 
Here, we show increased peribronchial angiogenesis in the HDM model of allergic 
airways disease, after 3 and 5 weeks of allergen challenge (Figure 6.2), consistent with 
previous data published using the OVA model [67] and that observed in asthmatic 
patients [198, 199]. Furthermore, in the HDM model of allergic airways disease, an 
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increase in the number of late outgrowth EPCs in the allergen-challenged lungs was 
observed after 1 week of HDM treatment, at the onset of tissue remodelling; this had 
returned to basal levels after 3 weeks of HDM treatment when the early stages of tissue 
remodelling, epithelial changes and mucus cell hyperplasia, should have been 
established (C. Jones, personal communication) (Figure 6.1B). The recruitment of EPCs 
to the allergen-challenged lungs and the kinetics of their recruitment is consistent 
between models, suggesting that the CXCL1/2-CXCR2 chemokine axis, which was shown 
to be critical for the recruitment of EPCs to the lungs in the OVA model, is most likely 
important in the HDM model as well. Furthermore, although no increase was observed 
in the number of early outgrowth EPCs in the lungs after 1 week of allergen challenge, a 
significant increase was observed after 3 weeks, when increased angiogenesis can 
already be observed (Figure 6.1C). This early recruitment of late outgrowth EPCs 
followed by the recruitment of early outgrowth EPCs later in the model is consistent 
with what was previously observed in the OVA model (C. Jones, personal 
communication). The differing kinetics of recruitment of these two subpopulations of 
EPCs gives weight to the argument that they represent distinct populations of cells, with 
late outgrowth EPCs being independently recruited and not derived from the early 
outgrowth EPCs. It also highlights the different roles these populations of cells are 
thought to have, since late outgrowth EPCs are thought to integrate into blood vessels 
and in this way directly contribute to angiogenesis [46, 49], and are recruited early at 
the onset of vascular remodelling, while early outgrowth EPCs, which are thought to 
support angiogenesis in a paracrine manner through the secretion of cytokines and 
growth factors [43], are recruited later when vascular remodelling is already underway. 
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These results support the idea that EPCs can contribute to the pathogenesis of 
inflammatory lung disease. In agreement with this idea, in an recent study, EPC 
numbers in the lungs were shown to be increased in lung diseases associated with high 
pulmonary arterial pressure and were suggested to contribute to vascular remodelling 
in pulmonary disease [316]. 
 
In contrast to the data presented in the previous chapter showing an increased number 
of PαS cells in the lungs of bleomycin-injured mice compared with controls, after 1 week 
of HDM exposure, no difference was observed in the number of PαS cells in the lungs of 
allergen-challenged mice compared to control mice (Figure 6.1D). This suggests that the 
recruitment of populations of progenitor cells into the lungs is dependent on the 
inflammatory milieu and that different populations of progenitor cells will be involved 
in different diseases. 
 
In the OVA model of allergic airways disease, VEGF was shown to be elevated in the 
lungs at the onset of vascular remodelling, however it did not appear to be involved in 
the recruitment of EPCs to the lungs [67]. In agreement with these results, levels of 
VEGF in the lungs were shown to be elevated in mice challenged with HDM for 1 week 
compared to control mice (Figure 6.2C). Data from the OVA model suggested that 
although CXCL1/2 was critical for the recruitment of EPCs to the lungs in response to 
allergen sensitisation, another mechanism was involved in their mobilisation from the 
bone marrow into the blood. Since VEGF has been previously shown to mobilise EPCs 
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from the bone marrow into the circulation [295], we sought to investigate whether it 
might be involved in the mobilisation of EPCs in the HDM model.  
 
In the OVA model of allergic airways disease, a significant increase in the number of 
EPCs could be observed in the blood [67]; however, in my experiments in the HDM 
model, EPCs were never detected in the circulation. In this study, EPCs were measured 
in the blood at weeks 1, 3 and 5, but since the mobilisation of EPCs from the bone 
marrow into the blood and their subsequent recruitment into the tissue is a transient 
process, it is possible that the time point at which they are significantly elevated in the 
blood was simply missed in this model. Since we could not detect EPCs in the blood, we 
investigated the effect of blocking VEGF on the recruitment of EPCs to the lungs in 
response to allergen challenge with the assumption that blocking the mobilisation of 
EPCs from the bone marrow would consequently block their recruitment to the lungs. 
Balb/c mice were given HDM or PBS intranasally for 1 week as previously described, 
accompanied by intraperitoneal administration of SU5416, 20 minutes prior to allergen 
challenge. 1 week of HDM exposure resulted in an increase in numbers of late 
outgrowth EPCs in the lungs which was completely abrogated by blocking VEGF (Figure 
6.3A). In another experiment, the increased peribronchial angiogenesis which was 
observed after 5 weeks of HDM exposure was also shown to be reduced when VEGF was 
blocked (Figure 6.3B). Since it has previously been shown that VEGF is not involved in 
the recruitment of EPCs to the allergen-challenged lungs [67], this blockade of 
recruitment of EPCs would suggest that VEGF is involved in their mobilisation from the 
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bone marrow into the blood from where they can be recruited into the lungs. Further 
analysis of the blood at different time points in this model would be necessary to detect 
significant increases in EPCs in the blood and confirm that blocking VEGF prevents their 
mobilisation from the bone marrow into the blood. Taken together with data from the 
OVA model, it appears that VEGF is important in the mobilisation of EPCs from the bone 
marrow into the blood in allergic airways disease and that their subsequent recruitment 
into the lungs is dependent on CXCL1/2 [196]. In agreement with this data, Lee et al. 
showed that overexpression of VEGF-A in the lungs led to an increased Th2-polarised 
immune response even in the absence of allergen, increased blood vessel numbers in 
the lungs and increased airway remodelling [311]. Furthermore, VEGF is a well-known 
growth and survival factor for endothelial cells [252, 253]. This again supports the 
hypothesis that VEGF has an important role in the allergic response and is important for 
promoting angiogenesis in the allergic lungs.  
 
This investigation into the recruitment of EPCs into the lungs in response to HDM 
challenge was continued by a post-doctoral researcher, C. Jones, in our laboratory. She 
went on to demonstrate that HDM exposure directly stimulates lung macrophages to 
produce significant amounts of the pro-angiogenic proteins VEGF-A and CXCL1 in a HIF-
1α dependent fashion. She showed that blockade of HIF-1α reduced the recruitment of 
cells, particularly eosinophils, to the lungs and airways, along with reducing the 
accumulation of EPCs and the production of CXCL1 and VEGF-A in the lungs after 
allergen exposure (C. Jones, personal communication). These data demonstrate that 
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HDM upregulates HIF-1α in lung macrophages, stimulating the production of cytokines 
and chemokines required for recruitment of EPCs, suggesting that HIF-1α may have a 
regulatory role in the angiogenic switch observed in the lungs in allergy.  
 
To investigate whether changes occur in the bone marrow in response to allergen 
challenge, Balb/c mice were challenged with HDM for 1 week and the bone marrow 
analysed in terms of its composition of progenitor cells compared to PBS-treated 
control mice (Figure 6.4). No significant difference was seen in the proportion of HPCs 
and MSCs, either measured by colony assays or by flow cytometry, in the bone marrow 
of HDM-exposed mice compared with PBS-treated controls. Previous studies have 
shown increased levels of eosinophils in the circulation and lungs in human asthmatics 
and murine models of allergic airways disease [200-202, 298-301]. In addition, a 
number of studies have demonstrated increased eosinopoeisis and increased numbers 
of CD34+ IL-5R+ eosinophil progenitor cells in the bone marrow and lungs in both 
human asthmatics and in OVA-challenged mice [302, 304]. My data is therefore not 
consistent with these studies; however it is possible that had the sub-types of HPCs 
been individually quantified, a difference may have been observed in the number of 
eosinophil progenitor cells that was lost when considering all HPCs together.  
 
Given the role of EPCs in vascular remodelling in the lungs of OVA sensitised mice [67] 
and the results presented here showing an increase in EPCs in the lungs in response to 1 
week of HDM challenge, I investigated how numbers of these cells changed in the bone 
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marrow in the HDM model. In these experiments, two time points of the model were 
investigated: after 1 week of HDM exposure during the initial stages of angiogenesis, 
and after 5 weeks of HDM exposure when angiogenesis was established (Figure 6.4D). 
EPCs were quantified by colony assays, differentiating between early and late 
outgrowth. No changes were observed in the number of early outgrowth EPCs in the 
bone marrow of HDM-challenged mice compared to PBS-treated controls at either of the 
time points investigated (Figure 6.4E). However, after both 1 and 5 weeks of HDM 
treatment, a trend towards a greater number of late outgrowth EPCs could be observed 
in the bone marrow compared to mice treated with PBS, suggesting that HDM challenge 
initiates an expansion of this pool of progenitor cells which can then be mobilised into 
the circulation (Figure 6.4D).  
 
VEGF has been previously shown to be elevated in the peripheral blood of asthma 
patients [317]. Furthermore, our data show that VEGF is elevated in the lungs of HDM-
challenged mice and that it plays a role in EPC mobilisation and angiogenesis. It has 
previously been shown that pre-treatment of mice with VEGF for 4 days alters the 
profile of leukocytes and progenitor cells mobilised from the bone marrow in response 
to CXCR4 antagonism with AMD3100. Given this, we sought to investigate whether 
changes in the cytokine milieu in the HDM model altered the functionality of the bone 
marrow in terms of the mobilisation of cells into the circulation in response to the 
CXCR4 antagonist, AMD3100. The elevated levels of circulating VEGF in asthmatic 
patients [317] and previous work in the laboratory showing pre-conditioning of the 
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bone marrow to inhibit the mobilisation of HPCs and neutrophils from the bone marrow 
in response to AMD3100 administration [196], led us to hypothesise that we would 
observe reduced numbers of these populations of cells in the circulation of HDM-treated 
mice administered AMD3100 compared to PBS controls. As has been previously shown, 
administration of AMD3100 resulted in a significant increase in the total number of 
white blood cells and HPCs in the blood in naïve animals (Figure 6.5) [192, 196]. 
Similarly in mice exposed to HDM for 1 week, AMD3100 resulted in a significant 
increase in white blood cells and HPCs in the circulation compared to those 
administered PBS (Figure 6.5). Numbers of total white blood cells and HPCs in the blood 
were comparable between control and HDM-exposed mice both in the groups that were 
given PBS and those that were administered AMD3100, suggesting that the bone 
marrow is not functionally altered in terms of the mobilisation of neutrophils and HPCs 
into the circulation in response to AMD3100, as was hypothesised. This is most likely 
due to the production of a range of other cytokines and chemokines in this model in 
addition to VEGF and it may be that the combination of these factors together affects the 
mobilisation of cells from the bone marrow.  
 
Here, these results demonstrate increased recruitment of EPCs to the lungs after HDM 
exposure, accompanied by an increase in peribronchial angiogenesis and an increase in 
the proportion of late outgrowth EPCs in the bone marrow. Furthermore, we 
demonstrate a critical role for VEGF in this process, with blockade of VEGF preventing 
the recruitment of EPCs to the lungs and the subsequent peribronchial angiogenesis. 
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Viewed in the context of previous work in the OVA model of allergic airways disease, 
these data suggest that VEGF is involved in the mobilisation of EPCs from the bone 
marrow, from where they are subsequently recruited to the lungs in response to 
chemokines following HDM exposure.  
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CHAPTER 7 
General Discussion 
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The bone marrow serves as a reservoir for a number of different populations of cells 
including mature leukocytes, as well as stem and progenitor cells. Two notable 
populations of these are the endothelial progenitor cells (EPCs), which have been shown 
to contribute to angiogenesis, and the mesenchymal stem cells (MSCs), which can 
differentiate into adipocytes, chondrocytes and osteocytes, as well as having the 
capacity to promote tissue repair and to modulate the immune response. Given these 
important features we have been interested in whether endogenous bone marrow-
derived progenitor cells can modulate disease. There has been much interest in the 
characteristics and functions of bone marrow progenitor cells, however, to date, no 
studies have conclusively established whether MSCs or EPCs are mobilised from the 
bone marrow into the circulation and subsequently recruited to the lungs in the context 
of inflammatory lung disease. We were therefore interested in investigating whether 
mobilisation of bone marrow progenitor cells does occur in disease, as well as 
understanding the mechanisms of mobilisation and subsequent recruitment to sites of 
inflammation, and finally, establishing whether bone marrow progenitor cells were 
contributing to or ameliorating lung disease. 
 
If progenitor cells are mobilised from the bone marrow and recruited to the lungs in 
inflammatory disease, then mechanisms to release these cells into the circulation and 
direct their migration to areas of injury must exist. In the case of mature leukocytes, 
these mechanisms have been well studied and are known to involve cytokines and 
chemokines. In contrast, the mechanisms of mobilisation and recruitment of progenitor 
 ~ 231 ~ 
 
cells remain largely unclear. It is possible that the recruitment of progenitor cells into 
inflamed tissue is dependent on chemokines, as is the case for mature leukocytes. 
However, to date, the chemokine receptors expressed by bone marrow progenitor cells 
have been poorly characterised and whether trafficking involves chemokines and their 
receptors remains to be established. 
 
Studies show that systemic and chronic administration of cytokines can induce the 
mobilisation of populations of progenitor cells from the bone marrow into the blood. G-
CSF has long been known to mobilise HSCs and HPCs from the bone marrow into the 
blood and has more recently been shown to act synergistically with a CXCR4 antagonist 
[190, 193]. Consequently, G-CSF is now used in combination with a CXCR4 antagonist in 
peripheral blood haematopoietic stem cell transplantation. In addition, administration 
of VEGF for 4 days, was shown by Asahara et al. to mobilise EPCs from the bone marrow 
into the circulation [295] and our studies have shown enhanced mobilisation when 
administered in combination with a CXCR4 antagonist [196]. Furthermore, work in our 
laboratory has shown that 4 day pre-treatment with VEGF could mobilise MSCs from 
the bone marrow into the blood in response to CXCR4 antagonism [196]. This is the first 
demonstration that MSCs can be mobilised into the blood. In addition, in a recent study, 
pre-treatment with IGF-1 in combination with a CXCR4 antagonist was suggested to 
induce mobilisation of MSCs from the bone marrow into the circulation [197]. Despite 
these studies, pathophysiological mechanisms of mobilisation of progenitor cell 
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populations from the bone marrow into the blood in inflammatory disease remain to be 
established.   
 
7.1 Molecular mechanisms of transcellular migration in the bone 
marrow 
The molecular mechanisms regulating leukocyte migration from the blood across 
inflamed endothelium into tissues has been elucidated using in vitro models of 
transmigration [247, 248]. Despite this, at present the molecular mechanisms regulating 
stem cell egress from the bone marrow are poorly characterised and therefore the first 
aim of this project was to set up an in vitro system in which to dissect these 
mechanisms. Although the lumen of the entire vasculature is lined by endothelial cells, it 
has been shown that there is a high degree of heterogeneity amongst endothelial cells 
from different tissues [9, 10]. Indeed, bone marrow sinusoidal endothelium in particular 
has been shown to have a distinct phenotype, constitutively expressing E-selectin, P-
selectin and VCAM-1 [12-14], usually only expressed by endothelial cells under 
inflammatory conditions. In addition, bone marrow sinusoidal endothelium has been 
shown to express VEGFR3, as well as VEGFR1 and VEGFR2, which has been shown to be 
absent on bone marrow vascular endothelium [18]. Furthermore, mobilisation of cells 
from the bone marrow requires apical to luminal transmigration, unlike in the context 
of migration of leukocytes into tissues, which occurs in the luminal to apical direction. 
In addition, it is thought that transcellular migration happens rarely and only in 
inflamed endothelium, however it is believed to be the usual method of transmigration 
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across the bone marrow endothelium [11, 22]. This may reflect the high level of traffic 
that occurs across the bone marrow endothelium, permitting egress of mature 
leukocytes produced in the bone marrow into the blood. Given that  bone marrow 
endothelial cells are unique compared to endothelial cells from other vascular beds, 
there was little value in using endothelial cells isolated from another tissue to 
investigate mechanisms of transendothelial migration in the bone marrow and it was 
therefore important to develop a system using bone marrow endothelium. 
 
The initial aim of this project was therefore to develop a system to enable the 
underlying molecular mechanisms of cellular transmigration across bone marrow 
sinusoidal endothelium to be studied in more detail. In order to do this, a method first 
needed to be established to isolate murine bone marrow sinusoidal endothelial cells 
and to grow them in vitro. Lack of availability of murine bone marrow endothelial cell 
lines prevented the use of these as an alternative to primary cultures. Various 
purification techniques were attempted with limited success, however eventually a 
protocol was developed based on a study published in 2009 [246], which yielded a 
culture of endothelial cells that were greater than 80% pure. Unfortunately it was not 
possible to expand these cells in culture and further attempts at isolation of bone 
marrow endothelial cells using this protocol were unsuccessful. Although the optimised 
protocol generated a highly pure culture of bone marrow endothelial cells, the lack of 
reproducibility of this protocol meant that there were significant limitations to using 
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this approach to study mobilisation of cells from the bone marrow at a cellular or 
molecular level. 
 
7.2 Can endogenous progenitor cells be mobilised from the bone marrow 
and contribute to lung disease? 
In a number of studies in animal models and clinical trials, administration of exogenous 
bone marrow progenitor cells has been shown to elicit beneficial effects. EPCs, for 
example, have been shown to contribute to neoangiogenesis in a hind limb ischemia 
murine model [45, 51]. Furthermore, MSCs have been shown to possess potent 
immunoregulatory properties and as such have been used in a number of animal 
models and human diseases to investigate their therapeutic potential [276]. These 
studies show that exogenously administered EPCs and MSCs can traffic to sites of 
inflammation and raise the question of whether endogenous bone marrow progenitor 
cells traffic from the bone marrow to sites of inflammation and if so whether they 
contribute to disease progression or repair. Results showing that mobilisation of 
progenitor cells from the bone marrow can be artificially induced by changing the 
cytokine milieu suggest that this mobilisation may occur physiologically in 
inflammatory disease when levels of systemic cytokines are altered. To investigate 
whether progenitor cell populations are mobilised from the bone marrow into the blood 
from where they can be recruited to sites of inflammation, I utilised two contrasting 
models of inflammatory lung disease: the bleomycin model of pulmonary fibrosis and 
the house dust mite (HDM) model of allergic airways disease. Both of these models have 
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an early inflammatory phase, however they differ in disease pathology: the HDM model 
leads to airway remodelling and airway hyperreactivity (AHR), while the bleomycin 
model leads to collagen deposition and the development of fibrosis [206, 207].  
 
Although the role of bone marrow progenitor cells in inflammatory lung disease 
remains largely unknown, previous studies investigating the role of fibrocytes have 
shown that bone marrow-derived cells can contribute to lung disease. Studies have 
shown that this population of bone marrow progenitor cells can be recruited into the 
lungs in the bleomycin model of pulmonary fibrosis [164-166, 318] and in a model of 
asthma [167], where they have been suggested to differentiate into myofibroblasts and 
contribute to disease pathology. In human studies it has been shown that circulating 
fibrocytes are increased in patients suffering from idiopathic pulmonary fibrosis (IPF) 
[319], suggesting that mobilisation of these cells is increased in this disease. 
Accumulation of fibrocytes in the lungs is thought to be dependent on chemokines and 
their receptors, with studies in animal models of pulmonary fibrosis showing 
recruitment to involve CCR2, CCR7 and CXCR4 [164, 170]. In the bleomycin model of 
pulmonary fibrosis, fibrocytes were shown to be increased in the lungs during the early 
inflammatory phase, just 7 days after bleomycin injury [164]. These data suggest that at 
this time point in the bleomycin model there is an alteration in the cytokine milieu, 
causing mobilisation of fibrocytes from the bone marrow into the blood. This in turn 
suggests that other populations of progenitor cells may also be mobilised from the bone 
marrow into the circulation in this model. Of note, factors regulating fibrocyte 
 ~ 236 ~ 
 
mobilisation from the bone marrow into the blood have yet to be identified and may 
represent a target for therapeutic intervention. 
 
There is some suggestion in the literature that bone marrow MSCs may be mobilised in 
bleomycin-treated mice, however the study in question is far from conclusive. The 
authors show that CXCR4 expression is reduced on bone marrow MSCs and that there is 
a decrease in the number of MSCs in the bone marrow after bleomycin injury [320]. The 
authors suggest that this shows mobilisation of MSCs in response to injury, however, 
the MSCs were characterised only as CD45- CD105+ CD44+ [320] and therefore may in 
fact represent a different cell type, for example EPCs. In addition no increase in numbers 
of MSCs was observed in either the blood or lungs, and therefore it is difficult to 
conclude that these results demonstrate mobilisation of MSCs in response to injury. 
 
In pulmonary fibrosis, systemic administration of exogenous MSCs has been shown to 
reduce inflammation and fibrosis [129, 143], and a clinical trial to evaluate the 
therapeutic potential of MSCs in IPF is now registered on www.clinicaltrials.gov. In the 
bleomycin model of pulmonary fibrosis administered MSCs were shown to be 
preferentially localised to areas of tissue damage and recruitment to the injured lungs 
was shown to be significantly higher than to the lungs of control mice [129, 143]. These 
studies confirm the capacity of MSCs to migrate into tissue in response to injury; 
however they fail to establish the mechanisms by which they do this. In addition, the 
role of endogenous bone marrow MSCs has not been conclusively addressed in this 
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model. Given that exogenous MSCs can migrate into tissue in response to injury and the 
suggestion from the fibrocyte studies that the cytokine milieu in the inflammatory 
phase of the bleomycin model is altered facilitating mobilisation of progenitor cells, we 
hypothesised that endogenous MSCs are mobilised from the bone marrow and recruited 
to the lungs in response to injury. 
 
7.3 Investigation of differences between bone marrow and lung MSC 
populations 
In recent years, MSCs have been extensively studied, however, due to a lack of specific 
markers to identify these cells in vivo, the majority of studies have relied on the use of in 
vitro expanded cells. In 2009, Morikawa et al. proposed a combination of cell surface 
markers which identified a population of bone marrow cells in vivo that were enriched 
for cells with MSC-like properties, as well as being capable of repopulating the 
haematopoietic niche and adipose tissue following irradiation and transplantation [86].  
The authors defined this population of cells as CD45neg Ter119neg PDGFRαpos Sca-1pos 
(PαS cells) and suggested that this population defines MSCs in vivo [86]. This population 
of PαS cells was initially identified in the murine bone marrow. In the current study 
presented here I have confirmed the presence of this population of PαS cells in the bone 
marrow, as well as identifying a similar, more abundant population in the murine lungs.  
 
One notable feature of bone marrow PαS cells is their small size in comparison to bone 
marrow leukocytes. This is consistent with the literature which suggests that stem cells 
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are small in size in comparison to other cell types [269]. Indeed, recently a population of 
bone marrow progenitor cells, very small embryonic-like stem cells (VSELs), was 
identified and noted for their small size compared to bone marrow leukocytes [268, 
269]. VSELs are classified as CD45- Lin- Sca-1+ and express markers of pluripotent stem 
cells such as Oct-4 and Nanog [268]. Of note, these cells have been shown to be 
mobilised into the circulation early after myocardial infarction [321]. Given the similar 
size and antigen expression of bone marrow VSELs and PαS cells, it is possible that 
there is an overlap in the characteristics of these cells and that PαS cells may represent 
a subset of VSELs or that the two populations may in fact be the same.  
 
Initial studies of bone marrow and lungs from naïve mice revealed a large population of 
PαS cells in the lungs. In terms of the pattern of expression of cell surface markers, PαS 
cells from the bone marrow and lungs appear to be largely similar. However, there was 
one notable difference in cell surface expression between the two populations: 
approximately 70% of lung PαS cells were shown to express EpCAM, while virtually no 
expression of this marker was detected on bone marrow PαS cells. EpCAM is considered 
to be an epithelial marker, however, it has also been shown to be expressed on 
embryonic stem cells [322]. Although the literature regarding the identity of CD45neg 
Sca-1pos cells within the lungs is complex and as yet has not been conclusively 
established, the current consensus is that CD45neg Sca-1low EpCAMpos cells represent 
epithelial progenitor cells, of which there are several subsets, while CD45neg Sca-1high 
EpCAMneg cells represent mesenchymal stem cells [220, 323, 324]. My results are 
somewhat at odds with these results, demonstrating EpCAMpos populations in both the 
 ~ 239 ~ 
 
Sca-1low and Sca-1high populations of the lungs. Interestingly, looking in detail at a 
subsequent study examining the subpopulations of EpCAMpos epithelial progenitor cells 
within the lungs, it is possible to observe in one of the figures a population of Sca-1pos 
EpCAMpos cells in the lungs [236]. These discrepancies are most likely the result of 
experimental differences and highlight the need for more rigorous studies to be 
conducted to gain a better understanding of these different populations of cells. 
However, until this is done, my results suggest that using levels of expression of Sca-1 
alone is not an effective way to discriminate between the subpopulations of PαS cells in 
the lungs. It is apparent, however, that lung PαS cells can be further divided into 
EpCAMpos and EpCAMneg cells, while bone marrow PαS cells are virtually all EpCAMneg. 
This suggests that expression of EpCAM may signify some functional distinction 
between these two subpopulations of PαS cells and it is possible that EpCAMneg PαS cells 
represent MSCs, while EpCAMpos PαS cells represent epithelial progenitor cells. In 
future, functional assays including investigation of differentiation capacity in vitro and 
in vivo using lineage tracing experiments will be essential to better understand these 
lung progenitor cell populations. 
 
7.4 Contribution of bone marrow MSCs in the bleomycin-injured lungs 
In a number of recent studies the effects of bleomycin on epithelial progenitor cells in 
the lung have been examined. In one study bleomycin was shown to increase the 
proliferation of lung BASCs [218], while in another, it was shown to significantly reduce 
the frequency of the CD24low SFTPC-GFPpos subset of EpCAMpos epithelial progenitor 
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cells [236]. In the latter study, Chen et al. suggest that there may be region specific 
airway epithelial progenitor cells within the lungs which differentially respond to 
bleomycin injury [236]. In addition, β4 integrinpos alveolar epithelial progenitor cells 
have recently been shown to increase in response to bleomycin injury [237]. In contrast, 
there have been very few studies examining the effect of bleomycin injury on either 
bone marrow or lung MSCs. One study suggested that lung-resident MSCs are reduced 
following bleomycin injury, however, the authors only define MSCs as Hoechstdim 
CD45neg [325], and therefore it is not possible to conclude that this population 
represents only MSCs.  Furthermore, whether bone marrow MSCs traffic to the lungs in 
response to bleomycin injury remains to be established.  
 
My analysis of PαS cell numbers in the bleomycin model shows an increase in absolute 
numbers of PαS cells in the lungs 7 days after bleomycin injury. Although exogenous 
MSCs have been shown to migrate into the lungs in response to injury, this is the first 
demonstration of an increase in endogenous MSCs in the lungs in the bleomycin model 
of pulmonary fibrosis, or indeed in any other model of inflammatory lung disease. The 
increased numbers of circulating PαS cells 4 and 7 days after bleomycin injury suggests 
that this population of cells can be mobilised from the bone marrow into the blood in 
inflammatory disease and that they may traffic to the lungs in response to injury. It is 
worth noting that this is the same time point after bleomycin injury at which increased 
numbers of fibrocytes have been observed in the lungs, implying that the conditions of 
the inflammatory milieu that mobilise and recruit fibrocytes in this model, may have a 
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similar effect on bone marrow MSCs. In addition, I observed a small but significant 
increase in proliferation of the PαS cell population in the lungs following bleomycin 
injury, suggesting some expansion of lung-resident PαS cells. Therefore, the increase in 
PαS cell numbers in the lungs may be accounted for by either expansion of lung-resident 
PαS cells or by recruitment of endogenous bone marrow PαS cells and at this stage my 
results do not distinguish between these two processes.  
 
In line with the hypothesis that bone marrow MSCs can be recruited to the lungs in 
response to injury, previous in vitro studies have shown lung cells from bleomycin-
injured mice to produce soluble factors which are chemotactic for bone marrow MSCs 
[320, 326]. Furthermore, in the study presented here, systemic injection of exogenous 
PαS cells in the bleomycin model resulted in recruitment of significantly higher 
numbers of PαS cells to the injured lungs compared to control lungs. This recruitment of 
MSCs to the injured lungs is consistent with previous studies using MSCs therapeutically 
in animal models of disease [116, 117, 129, 141-143]. It also confirms that circulating 
MSCs can traffic to the lungs in response to injury and in light of these results and the 
presence of PαS cells in the blood 4 and 7 days after bleomycin administration, it is 
tempting to hypothesise that the increase in endogenous PαS cells that I have observed 
in the lungs 7 days after bleomycin injury is, at least in part, the result of recruitment of 
PαS cells from outside of the lungs in response to the inflammatory milieu induced by 
injury.  
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Having established that systemically administered bone marrow PαS cells can traffic to 
the lungs in response to injury, it would now be possible to use this as a model to dissect 
the roles of specific chemokines in this process and to gain a better understanding of the 
underlying mechanisms of recruitment of endogenous MSCs to the lungs in disease. To 
this end I have profiled the chemokine receptors expressed on PαS cells both in the 
bone marrow and lungs. I observed that bone marrow and lung PαS cells express a 
range of chemokine receptors (CXCR3, CCR9 and CCR10) consistent with them having 
the capacity to home to different tissues. Indeed changes in levels of chemokines in the 
lungs and BAL fluid are known to occur in inflammatory lung disease. Of note, the 
bleomycin model has been shown to be associated with increased levels of CCL2, CCL3, 
CCL12, CCL17, CXCL2, CXCL10 and CXCL12 in the lungs [164, 206, 210-214]. 
Furthermore, the increase in levels of CXCL12 in particular in the lungs has been shown 
to be involved in the recruitment of fibrocytes from the bone marrow into the lungs in 
this model [164]. Given that PαS cells express a range of chemokine receptors, it is 
therefore possible, that the higher concentrations of chemokines in the lungs in this 
inflammatory setting might recruit MSCs from the bone marrow into the lungs in a 
manner similar to fibrocytes. Notably, my results demonstrate PαS cells to show robust 
expression of CXCR3, the cognate receptor for CXCL10, which is known to be increased 
in the lungs of bleomycin-treated mice and has been shown to be important in the 
bleomycin model [210, 289, 290], therefore suggesting that the CXCR3/CXCL10 
chemokine axis may be involved in the migration of PαS cells into the bleomycin-injured 
lungs.  Although in my study blocking CXCR3 failed to block the accumulation of PαS 
cells in the bleomycin-injured lungs, it is difficult to establish whether this experimental 
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protocol was optimal and it remains possible that the CXCR3/CXCL10 axis is important 
in recruiting PαS cells into the lungs in the bleomycin model. In future experiments, 
investigating the effect of blocking CXCR3 on the recruitment of exogenous PαS cells to 
the bleomycin-injured lungs would give a clearer indication of whether this chemokine 
is important in the recruitment of PαS cells into the lungs in the bleomycin model. 
Having used this model to further dissect the roles of specific chemokines in the 
trafficking of MSCs into the injured lungs, it would then be possible to apply this 
knowledge to attempt to either block or enhance the number of PαS cells in the lungs in 
response to bleomycin injury. This would not only increase our understanding of the 
mechanisms of recruitment of MSCs into tissue in disease, but would also provide more 
evidence that MSCs are being mobilised from the bone marrow and recruited to the 
lungs in this model and provide insight into their role in disease pathology. 
 
My results show that within the lung PαS cell population, it is the EpCAMneg PαS cells 
that are increased in the lungs in response to bleomycin injury. It is possible that this 
increase in EpCAMneg PαS cells could indicate a recruitment of EpCAMneg PαS cells from 
the bone marrow, which would be in line with the idea that cells from the bone marrow 
can be recruited into the lungs in response to injury. However, this result could also 
highlight functional differences between EpCAMneg and EpCAMpos PαS cells in the lungs. 
Indeed, if these do represent different cell types with different functions then it is 
possible that they would respond differently in disease. If the suggestion that the 
EpCAMpos PαS cell population represents epithelial progenitor cells, while the EpCAMneg 
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PαS cell population represents MSCs holds true [220], then these results would suggest 
that it is the MSC population that is increasing in number in the lungs in response to 
bleomycin injury. This is consistent with our hypothesis that MSC numbers increase in 
the lungs after injury in order to regulate inflammation.  
 
7.5 Functional significance of the accumulation of MSCs in the bleomycin-
injured lungs 
The increase in PαS cells and exogenous MSCs that we have observed in the lungs 
following bleomycin injury suggests that these cells have some functional relevance in 
the bleomycin model of pulmonary fibrosis. It was initially believed that exogenous 
MSCs contributed to repair after injury by adopting an epithelial-like phenotype [129], 
however the consensus now is that MSCs have paracrine effects and that it is the soluble 
factors these cells secrete that are responsible for their reparative properties. MSCs 
have been shown to produce a range of growth factors, cytokines and chemokines 
which could act in a paracrine manner to modulate the immune response and enhance 
repair in the bleomycin-injured lungs. For example, MSCs have been shown to produce 
IL-10, PGE2, VEGF and SDF-1 [90]. Furthermore, my data demonstrating that lung PαS 
cells are more granular than those from the bone marrow suggests that in the lung 
environment they may be secreting a multitude of soluble factors.  Indeed, studies using 
systemically administered exogenous MSCs in animal models of disease and in clinical 
trials suggest that engraftment into tissue is low or transient despite the observed 
beneficial effects [151-154].  Furthermore, MSC-conditioned medium has been shown in 
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a number of animal models to enhance wound healing [91] and repair after myocardial 
infarction [92, 93].  
 
It is possible that the increased numbers of PαS cells in the lungs are secreting 
immunomodulatory factors which impact on the immune response in the lungs, for 
example by suppressing the proliferation of pro-inflammatory T cells, enhancing the 
development of T regulatory cells and modifying macrophage polarisation. Indeed, in an 
endotoxin model of lung injury, administration of exogenous murine bone marrow 
MSCs was shown to increase the secretion of IL-10 by alveolar macrophages [109] and 
in a model of sepsis, the protective effect observed on administration of exogenous bone 
marrow MSCs was shown to be dependent on this increased IL-10 macrophage 
production [108]. Furthermore, the presence of these cells in the BAL fluid further 
supports the concept that MSCs may be interacting with immune cells to modulate the 
inflammatory response.  
 
It is well known that interactions between the epithelium and mesenchyme are 
required for normal lung development, with mesenchymal stromal cells determining 
epithelial morphogenesis, as well as playing a role in inducing specific epithelial 
phenotypes during development [327]. In a recent study McQualter et al. demonstrated 
that lung MSCs could support the proliferation of bronchiolar stem cells in vitro and 
postulated that this modulation of epithelial cell growth is dependent on the secretion 
of fibroblast growth factor-10 (FGF-10) by mesenchymal stem cells [220]. Indeed, 
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during development mesenchymal stromal cells at the distal tip of the embryonic lungs 
have been shown to possess the capacity to modulate epithelial development, by 
secreting FGF-10 which is involved in determining the proliferation and differentiation 
of epithelial progenitor cells [328, 329]. Furthermore in another study using a mouse 
model of bronchopulmonary dysplasia (BPD), it was shown that systemic treatment of 
hypoxia-injured neonatal mice with either MSCs or MSC-conditioned medium led to a 
significant increase in numbers of bronchioalveolar stem cells (BASCs) in the lungs 
compared to control mice [323]. Taken together these results suggest that MSCs may act 
as part of the epithelial progenitor cell niche in the adult lungs and that they may 
secrete factors which stimulate lung epithelial progenitor cells to contribute to 
epithelial repair after injury. Indeed in the bleomycin model of pulmonary fibrosis, it is 
possible that MSCs accumulate in the lungs and promote repair after injury by 
activating the lung-resident population of epithelial progenitor cells.  
 
In future experiments it would be interesting to investigate whether fibrosis could be 
reduced if recruitment of PαS cells was increased and in turn, whether blocking the 
recruitment of PαS cells to the lungs would enhance fibrosis following bleomycin injury. 
In addition it would be important to examine the PαS cell transcriptome, as well as what 
these cells secrete, in the lungs of bleomycin-treated mice compared to control mice. It 
is possible that it is not a change in the number of MSCs in the lungs that is important in 
the bleomycin model, but rather what they are secreting. The inflammatory milieu of 
the injured lungs may ‘switch on’ the immunosuppressive capacity of either recruited 
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bone marrow MSCs or lung-resident MSCs, by inducing them to produce different 
cytokines and growth factors which may modulate the inflammatory response and 
promote repair in response to injury. Indeed, production of cytokines and growth 
factors by MSCs has been shown in vitro to be stimulated by IFN-γ and TNF-α amongst 
other things [95], two cytokines known to be elevated in the bleomycin-injured lungs 
[206, 216]. 
 
Although the majority of studies examining the effects of administration of exogenous 
MSCs suggest them to be therapeutically beneficial, there is some data to suggest this 
may not always be the case [330]. Indeed although Ortiz et al. demonstrated a reduction 
in fibrosis in bleomycin-treated mice when MSCs were administered immediately after 
injury, no effect was observed when MSCs were administered 7 days after injury [129]. 
Furthermore there is also some evidence to suggest MSCs may actually have a 
detrimental effect in lung disease. In a murine model of radiation-induced pneumonitis 
in which exogenous MSCs were administered during the fibrotic phase of the model, a 
subpopulation of VEGFR2-positive MSCs were found to be located in the interstitial area 
of the lungs and appeared to have a myofibroblast-like phenotype [331]. These studies 
suggest that the injured lung microenvironment may direct both the phenotype of 
recruited bone marrow MSCs, as well as the effects they elicit, and suggest that the time 
of recruitment may be crucial.  
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7.6 Contribution of bone marrow EPCs in the HDM-challenged lungs 
 My results investigating changes in progenitor cell populations in the lungs of a 
contrasting model of inflammatory lung disease, the HDM model of allergic airways 
disease provide an interesting comparison to the data obtained from the bleomycin 
model of pulmonary fibrosis. The HDM model represents a less severe injury than that 
caused by administration of bleomycin, with disease progression primarily 
characterised by airway remodelling rather than the development of fibrosis. In this 
model no changes were observed in the number of PαS cells in the lungs after 1 week of 
HDM exposure, although an increased number of late outgrowth EPCs could be 
observed in the lungs at this time point. Recruitment of EPCs to the lungs in response to 
allergen challenge could be abrogated by blockade of VEGF signalling, implicating VEGF 
in the mobilisation of EPCs from the bone marrow into the circulation in the allergic 
response. Notably, blocking mobilisation of EPCs from the bone marrow reduced the 
increased peribronchial angiogenesis observed in the allergen-challenged lungs. This 
suggests that recruitment of EPCs to the lungs in response to allergen challenge 
contributes to vascular remodelling in the lungs. The data from the HDM model not only 
implicates VEGF in the mobilisation of endogenous EPCs from the bone marrow into the 
circulation from where they can be recruited to the lungs in response to allergen 
challenge, but also demonstrates that bone marrow progenitor cells can play a role in 
inflammatory lung disease and, in this context at least, can contribute to disease 
pathology. 
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It is interesting to note that in these two contrasting models of inflammatory lung 
disease, distinct populations of progenitor cells appear to be involved in the different 
disease models. This suggests that recruitment of bone marrow progenitor cells may be 
disease dependent, with distinct progenitor cell populations either modulating repair or 
contributing to disease pathology in different models.  
 
7.7 Summary 
The aim of the work presented in this thesis was to gain a better understanding of the 
involvement of endogenous bone marrow progenitor cells in inflammatory lung disease. 
My work demonstrates involvement of EPCs in the HDM model of allergic airways 
disease, as well as MSCs in the bleomycin model of pulmonary fibrosis. In the HDM 
model, increased numbers of EPCs were observed in the lungs after 1 week of allergen 
challenge, along with increased peribronchial angiogenesis. This recruitment and 
increased angiogenesis could be inhibited by the blockade of VEGF signalling, 
implicating VEGF in the mobilisation of EPCs from the bone marrow in allergic airways 
disease and EPCs in the pathological vascular remodelling associated with this disease. 
In the bleomycin model, increased numbers of endogenous PαS cells were observed in 
the lungs, BAL and blood 1 week after bleomycin injury, in addition to increased 
recruitment of exogenous PαS cells to the bleomycin-injured lungs compared to 
controls. The demonstration that exogenous bone marrow PαS cells can be recruited 
into the bleomycin-injured lungs, along with the presence of endogenous PαS cells in 
the blood of bleomycin-treated mice suggest that the increased numbers of endogenous 
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PαS cells in the injured lungs may be a result of recruitment of endogenous bone 
marrow PαS cells in response to injury. However, increased proliferation of lung PαS 
cells was also observed in the bleomycin-injured lungs and therefore it is possible that 
an expansion of lung-resident PαS cells may also be responsible for the increased 
numbers I have observed in the lungs in this model. Importantly, this work shows that 
bone marrow progenitor cells can contribute to inflammatory lung disease and that this 
may be disease dependent. Indeed, the involvement of different progenitor cell 
populations in the two disease models investigated suggests that differential 
mobilisation and recruitment of bone marrow progenitor cells may occur in 
inflammatory disease. Although much work still remains to be done to dissect the 
mechanisms of mobilisation and recruitment and to establish the contribution of these 
populations of cells to disease, this work has important implications for human 
inflammatory lung disease and manipulation of these populations of cells could 
eventually be used in developing therapies to enhance lung repair and regeneration. 
 
7.8 Future Work 
 It would be important to examine the localisation of EpCAMpos and EpCAMneg PαS 
cells in the bleomycin-injured lungs compared to controls to establish whether PαS 
cells are found in close proximity to areas of injury. In addition, it would also be 
interesting to examine where the proliferating PαS cells are localised after 
bleomycin injury. This would give more information about the progenitor cell 
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response after bleomycin injury, as well as further insight into the MSC niche in the 
adult lungs. 
 
 In future studies, genomic analysis of PαS cells from the bone marrow, as well as the 
EpCAMpos and EpCAMneg  populations of PαS cells from the lung would be important 
in order to gain more understanding about the differences between these 
populations in naïve mice and disease models. 
 
 Optimisation of a technique to successfully isolate EpCAMpos and EpCAMneg PαS cells 
from the murine lungs and to grow them in culture will be crucial to enable 
functional assays to be performed, including examination of their differentiation 
potential in epithelial- and mesenchymal-inductive conditions.  
 
 Analysis of the secretome of EpCAMpos and EpCAMneg PαS cells from the naïve lungs 
compared to the bleomycin-injured lungs would also be important. This would 
provide further understanding as to whether these cells are being ‘switched on’ by 
the inflamed lung microenvironment, as well as giving more insight into the 
mechanism of action of these populations of cells in the injured lungs. 
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 Using the model of administration of exogenous bone marrow PαS cells it would be 
possible to dissect the mechanisms underlying recruitment of PαS cells into the 
lungs in response to injury. Using pertussis toxin I would be able to determine 
whether this migration is chemokine receptor dependent and following on from this, 
experiments blocking specific chemokines would provide greater understanding 
about the involvement of particular chemokines and their receptors. 
 
 Following on from examination of recruitment of exogenous bone marrow PαS cells 
in the bleomycin model it would be possible to apply this knowledge and attempt to 
block or enhance the recruitment of endogenous PαS cells into the lungs in response 
to injury and to investigate the effect of this on the injured lungs. 
 
 It would be interesting to attempt to enhance recruitment of PαS cells into the lungs 
in the bleomycin model by using the VEGF-A + AMD3100 mobilisation regime 
established in our laboratory to mobilise MSCs from the bone marrow into the blood 
[196]. Examining the effect of enhanced mobilisation on the inflammatory response 
and the development of fibrosis would be informative in understanding the role of 
MSCs in this disease context.  
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Figure 9.1 Proliferation of PαS cells after bleomycin instillation 
2.5 U/kg bleomycin was administered intratracheally to C57BL/6 mice. Mice were culled 7 days later. Bone 
marrow and lung cells were stained with antibodies to visualise Ki67 in PαS cells and analysed by flow 
cytometry. Percentage of PαS cells positive for Ki67 in the bone marrow and lungs is represented as a bar 
graph where bars represent mean ± SEM. n=4-8, ** p < 0.01. 
 
 
